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Stephen Bela Kovacs: Inflammasomes and gasdermins in immune defense and pathology 
(Under the direction of Edward Miao) 
 Pyroptosis is a form of programmed cell death that effectively defends against 
intracellular pathogens by lysing an infected cell, thereby removing the pathogens’ replicative 
niche, and by releasing danger-associated molecular patterns and the pro-inflammatory cytokines 
interleukin (IL)-1b and IL-18, thereby promoting an immune response. However, when activated 
at the incorrect time or in excess, pyroptosis can cause significant pathology.  
 Pyroptosis was traditionally considered to primarily occur in monocytes and 
macrophages and, as a result, most studies of pyroptosis to date utilized monocytes and 
macrophages. Recently, the role of pyroptosis in defending non-immune cells, most notably 
intestinal epithelial cells, has been appreciated. Furthermore, with the recent discovery that 
gasdermin D was the direct mediator of pyroptosis in macrophages and monocytes, we now 
know that there is an entire gasdermin family with similar pore-forming and lytic capabilities, 
each with a specific expression pattern in different tissue compartments. Consequently, it is 
essential to improve our understanding about how inflammasomes and various members of the 
gasdermin family trigger pyroptosis and interface with immune responses not just in 
macrophages, but also in other cell types and tissues as well. 
 To explore this concept, we first compared the role of inflammasomes and gasdermin D 
in neutrophils versus macrophages during infection with the environmental pathogen 
 iv 
Burkholderia thailandensis. Second, we completed the first steps for generating a cell-specific 
knockout line of gasdermin D. Third, we explored the gasdermin family by specifically focusing 
on the keratinocyte-specific gasdermin A, and by performing a molecular evolutionary analysis 
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CHAPTER 1: INTRODUCTION1 
 
Intrinsic and extrinsic cell death pathways defend against pathogens 
The immune system actively surveys the extracellular space with phagocytes, including 
macrophages and neutrophils, that phagocytose bacteria, fungi, and parasites. Many pathogens 
invade host cells and, consequently, avoid phagocytes. The host engages cell intrinsic defenses to 
kill intracellular pathogens, such as autophagy to return cytosolic pathogens into lysosomes 
where they can be degraded. Having evolved in this context, successful intracellular pathogens 
evade these defenses. The continued existence of the infected host cell as a permissive niche 
threatens the host. The solution is that this infected cell must be killed.  
Killing of infected cells can be accomplished through either cell-intrinsic or cell-extrinsic 
mechanisms. If the cell itself can identify its compromised state, it will activate cell-intrinsic 
death mechanisms that include cell-intrinsic apoptosis, necroptosis, and pyroptosis. However, 
many intracellular pathogens evade or inhibit cell-intrinsic programmed cell death. Our last lines 
of defense are cytotoxic cells in the innate and adaptive immune systems, including natural killer 
cells and cytotoxic T lymphocytes, that can induce cell-extrinsic apoptosis of infected cells. Our 
laboratory compared these forms of cell death in a recent review1. Recently, gasdermin D was 
discovered to form a pore and act as the effector for pyroptosis, (cell-intrinsic programmed 
 
1This chapter was adapted from a review published in Trends in Cell Biology. The original citation is as follows: 
Kovacs SB, Miao EA. Gasdermins: Effectors of Pyroptosis. Trends Cell Biol. 2017 Sep;27(9):673-684. SBK wrote 
and edited this review under the guidance of EAM. 
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lysis). Gasdermin D is one of six gasdermin proteins, most of which have now been shown to 
have pore-forming activity.  
 
Inflammasomes survey the cytosol for contamination or perturbation 
Inflammasomes are innate immune sensors that survey the cytosol for contamination or 
cellular perturbation, and in response they trigger pyroptosis. For example, the NAIP/NLRC4 
inflammasome detects bacterial type III and type IV secretion systems when they aberrantly 
inject rod, needle, or flagellin protein into the cytosol2. Once activated, the NAIP/NLRC4 
inflammasome activates the protease caspase-1, which in turn cleaves the inflammatory 
cytokines pro-IL-1b and pro-IL-18 to their mature forms and also triggers pyroptotic membrane 
rupture. Other caspase-1-activating inflammasomes respond to cytosolic contamination by DNA 
(AIM2) or proteases (NLRP1), to perturbations within the Rho GTPases (Pyrin), or to 
catastrophic disruption of cellular physiology (NLRP3)2.  
In parallel, murine caspase-11, and its humans orthologs caspase-4 and -5, independently 
activate pyroptosis but cannot directly cleave pro-IL-1b and pro-IL-18. Unlike all other caspases, 
caspase-11/4/5 are activated by direct interaction with cytosolic LPS2.  
Inflammasomes defend against numerous pathogens, although many pathogens evade 
detection. However, when aberrantly activated, inflammasomes drive immunopathology and 
sepsis. 
 
Pyroptosis defends against intracellular infection 
Pyroptosis can defend against intracellular infection by eliminating the compromised cell, 
thereby removing the pathogen’s protective niche, and simultaneously eliciting an inflammatory 
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response. The utility of pyroptosis against intracellular pathogens can be studied by engineering 
normally evasive bacteria to be detected by inflammasomes. For example, Salmonella 
Typhimurium and Listeria monocytogenes, which evade inflammasomes during systemic 
infection by repressing flagellin, among other strategies1, have been engineered to force flagellin 
expression during the intracellular phase of infection. These modified bacteria reveal that 
pyroptosis kills the compromised host cell but does not kill the intracellular bacteria1. These 
bacteria remain trapped within the corpse of the pyroptotic cell in a structure we term the pore-
induced intracellular trap (PIT)3 (Figure 1). The PIT holds the bacteria in place and 
simultaneously elaborates neutrophil chemoattractants3,4 including DAMPs and eicosanoids5. 
Neutrophils, or perhaps ROS-producing macrophages6, then engulf and kill the trapped bacteria 
when they efferocytose the PIT3,4.  
Pyroptosis is perhaps most effective in defense against bacteria that never evolved in the 
context of hosts with inflammasomes. Chromobacterium violaceum and Burkholderia 
thailandensis are two environmental bacteria with the strongest known phenotypes of infection 
in inflammasome-deficient mice7,8 (reviewed further in 9). Pyroptosis is implicated as a major 
defense mechanism against these ubiquitous environmental pathogens. 
 
Gasdermin D pores are the effectors of pyroptosis 
Cleaved gasdermin D oligomerizes to form the pyroptotic pore 
Cleavage of gasdermin D was recently discovered to be the mechanism by which 
Caspase-1 and -11 trigger pyroptosis10-12. Gasdermin D is expressed in immune cells and in 
intestinal epithelial cells13,14. In humans, gasdermin D is composed of a 242 amino acid (aa) 
amino-terminal domain (also called N-domain, NT, or gasdermin domain) connected by a 43 aa 
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linker to a 199 aa carboxy-terminal domain (also called C-domain or CT) (Figure 2). The amino-
terminal domain forms a gasdermin pore15,16, and thus we propose to term it the “pore-forming 
domain” (PFD). This pyroptotic pore forming activity has been demonstrated for most 
gasdermins10,15. However, this activity is held in check by the carboxy-terminal domain10, which 
we propose to term as the “repressor domain” (RD). After the linker is cleaved, the RD separates 
from the PFD. The liberated PFD then integrates into the cell membrane, where an estimated 16 
PFD monomers oligomerize to form a large 10-15 nm diameter pore15-17; another group suggests 
21 nm18. 
The predicted structure of gasdermin D, based on the crystal structure of full length 
gasdermin A3 (discussed below) and more recently supported by the crystal structure of the C-
terminal domain of gasdermin D, reveals an interesting mechanism of autoinhibition. The PFD 
and RD interact by a large surface area between these domains. The linker domain ties the two 
domains together at one end of the structure, while the a4 helix of the PFD extends far across the 
C-domain to the opposite end, where it binds to a pocket in the RD15,19. Upon activation, either 
caspase-1 or -11 cleaves the linker after amino acid 275 at a conserved (F/L)LTD motif10,11. Of 
note, the C-terminal domain contains an interface that interacts with caspase-1 (caspase-11 was 
not tested) to increase caspase-1- gasdermin D interactions and improve cleavage efficiency20. 
Presumably, when the linker is cleaved, the interface dissociates, the a4 helix is released from its 
pocket, and the PFD is released from the RD (Figure 2). Interestingly, gasdermin D can also be 
cleaved by caspase-3 within the PFD21, which should inactivate the PFD and thus prevent 
pyroptosis once caspase-3 initiates apoptosis. 
The gasdermin D pore has affinity for liposomes containing lipids with double 
phosphates on the glycerol scaffold (cardiolipin) or phosphorylated head groups 
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(phosphatidylinositol phosphate PIP1 and PIP2 species), and it may have a lower affinity for 
triple-phosphorylated PIP3 and the zwitterion head group phosphatidylserine (PS)15,16. 
Gasdermin D does not bind the non-charged head group lipid phosphatidylinositol (PI) or the 
positively charged head group lipids phosphatidylcholine (PC) or phosphatidylethanolamine 
(PE)15,16. Thus, gasdermin D has greatest affinity for lipid species whose head groups have 
negative charge. Since PIP species and PS are restricted to the cytosolic leaflet of the plasma 
membrane, gasdermin D can only form pores from the cytosolic face. Neighboring cells are thus 
protected from gasdermin D arising from adjacent cells16. Cardiolipin is a component of the 
inner mitochondrial membrane and bacterial membranes; it is unclear whether gasdermin D has 
access to the inner leaflet of the mitochondria.  
 
Gasdermin D pore formation mediates pyroptosis  
The open gasdermin D pore breaks the normal permeability barrier of the plasma 
membrane. The most catastrophic effect is disruption of the normal separation of sodium and 
potassium across the plasma membrane. Normally, the cytosol has a low concentration of 
sodium and a high concentration of potassium, which is reversed in extracellular fluid. This 
concentration gradient exists in the context of the electrical gradient across the plasma membrane 
that draws positive ions into the relatively negative cytosol. Consequently, when a pore opens in 
the plasma membrane, the forces created by the concentration gradient driving potassium out of 
the cell are roughly counterbalanced by the electrical forces that pull potassium into the cytosol, 
resulting in a minimal net potassium flux initially. In contrast, sodium is drawn into the cell by 
both its concentration gradient and the electrical gradient, resulting in a large inward sodium 
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flux. As sodium flows into the cytosol, it brings its hydrating water, causing the cell volume to 
increase.  
If few gasdermin pores are present, the cell should react by initiating compensatory 
mechanisms to decrease volume, called the regulatory volume decrease. Among these are 
swelling-activated K+, Cl-, and organic osmolyte (e.g. taurine) channels that export these solutes 
and their accompanying water22. If the number of pores in the plasma membrane remains small, 
normal emergency exocytic membrane fusion events can patch out the pore-containing 
membrane. Indeed, the ESCRT machinery has been shown to remove gasdermin D pores, as well 
as the MLKL pores that trigger necroptosis23-26. One can also imagine a hypothetical cell where 
the quantity of gasdermin D is pre-set to such a low concentration that it never exceeds the 
regulatory volume decrease capacity and therefore never undergoes pyroptosis. Indeed, instances 
of sub-lytic activation of gasdermin D have been described by others27. Lack of lysis does not 
mean lack of consequence, though, as sub-lytic pore formation could lead to extracellular release 
of activated IL-1b and IL-18, as well as leakage of mitochondrial DNA into the cytoplasm with 
subsequent activation of the cGAS pathway of immune activation27. 
On the other hand, if gasdermin pores are present in numbers exceeding the cell’s 
compensatory capabilities, cell volume inexorably increases. Once the volume exceeds 
membrane capacity, the plasma membrane separates from the cortical cytoskeleton in large fluid-
filled “balloons”. These “balloons” are distinct from apoptotic “blebs” by morphology and 
composition. Shortly thereafter, a membrane rupture event occurs that releases soluble cytosolic 
contents. This tear is large enough to immediately dissipate soluble proteins like LDH, but 
organelles are retained3. After the rupture event, we presume that osmotic pressure equalizes, 
stopping further volume increases.  
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In summary, two membrane-breaching events occur after caspase-1/11 activation: 1) the 
gasdermin D pore opens; and soon thereafter 2) the membrane ruptures (Figure 2). We use the 
term “pyroptosis” as synonymous with the membrane rupture event resulting from gasdermin 
pores10. Inflammasome activation has also been implicated in expulsion of intestinal epithelial 
cells (IECs) from the intestinal epithelium prior to pyroptosis in response to microbial infection. 
While gasdermin D is required for pyroptosis but dispensable for expulsion of IECs28, the 
possibility remains that other gasdermins  (discussed below) may play a role in IEC expulsion, 
either alone or with redundancy. 
 
Gasdermin D pore as the IL-1b and IL-18 release mechanism 
During pyroptosis, caspase-1 cleaves IL-1b and IL-18 to generate the mature cytokines 
prior to membrane rupture. As IL-1b and IL-18 lack a normal secretion signal, they are cytosol-
restricted proteins. The possibility that pyroptotic membrane rupture was the release mechanism 
was at odds with observations of IL-1b release in the absence of pyroptosis29-33. Thus, whether 
these cytokines were actively secreted from cells or whether they were instead released by 
pyroptotic membrane rupture had remained confusing. 
Remarkably, the 10-15 nm diameter of the gasdermin pore is large enough to allow 
passage of IL-1b (4.5 nm)15,16 and IL-18 (5.0 nm). This explains the mechanism by which these 
proteins are released from cells prior to lysis. Importantly, the gasdermin pore is small enough to 
restrict larger molecules; 25-30 nm diameter ribosomes and larger organelles will not pass 
through the pore3.  
How can a cell release IL-1b/IL-18 through a gasdermin pore without lysing soon after? 
Theoretically, a cell with few gasdermin pores could shut off the inflammasome34, remove the 
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pores through exocytic patching mechanisms23,24,26, and thus survive. This would release IL-1b 
and IL-18 though a transient gasdermin pore without killing the cell29-33. An additional layer of 
complexity arises from the membrane patching event itself, which should release a membrane-
bound exosome that contains not only the gasdermin pore, but also any processed IL-1b that is 
nearby, perhaps explaining IL-1b observed in microparticles35,36. 
 
Gasdermin pores may also target other membranes 
The gasdermin D pore can insert into the bacterial membranes, which are rich in 
cardiolipin, and kill the bacteria, at least in vitro16. However, since bacteria survive 
pyroptosis3,37, the physiologic relevance of bacterial membrane-targeting remains unclear. For 
vacuolar bacteria, the PFD would require passing through an existing gasdermin pore in the 
vacuole to oligomerize on the bacterial membrane; thus, vacuolar bacteria may have minimal 
exposure to the gasdermin pore. Indeed, we have shown that S. Typhimurium that has been 
engineered to trigger pyroptosis survives the pyroptotic event in vivo. Interestingly, while these 
bacteria survive, they are damaged during the process of pyroptosis3. This damage might be 
caused by the gasdermin D pore16, but equally valid hypotheses include damage from rapid 
volume (and presumably pressure) shifts during pyroptosis or from ROS generated from 
mitochondria during pyroptosis38. For cytosolic bacteria, the gasdermin D pore should have 
direct access to bacterial membranes. This has been suggested to be toxic to L. monocytogenes in 
vitro16, although L. monocytogenes and another cytosol-invasive bacterium survive pyroptosis in 
vitro in our hands3. Thus, bacteria remain alive in vivo after pyroptosis, but it remains unclear if 
pyroptosis damages bacteria to accelerate killing by secondary phagocytes that efferocytose 
these PIT-trapped bacteria. 
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Many organelles have cytosolic leaflets that are composed of lipids similar to the inner 
leaflet of the plasma membrane. If the gasdermin pore inserts into the endoplasmic reticulum, it 
would release calcium stores into the cytosol. This likely contributes to the calcium flux 
observed after caspase-1 activation but prior to pyroptosis5,39. The cytoplasmic leaflet of 
vacuoles also resembles the cytoplasmic leaflet of the plasma membrane. However, vacuolar 
fluid contents likely reflect the extracellular fluid. Therefore, insertion of the gasdermin pore into 
the vacuolar membrane would allow ionic flux that in theory should cause sodium to flow from 
the vacuole into the cytosol, thereby shrinking the vacuole. Thus, vacuolar bacteria may remain 
doubly trapped: first within the membrane-bound and compressed vacuole, and second within 
the PIT.   
 
Gasdermin family 
Gasdermin D is a member of a family of conserved proteins that includes gasdermin A, 
B, C, D, E, and DFNB5910,40 (Table 1). Previously, gasdermin E and DFNB59 were proposed to 
be excluded from the gasdermin family, and instead called gasdermin-related proteins14; 
however, we prefer to simplify the nomenclature by including all six genes in a single gasdermin 
family, given recent advances21,41. Most family members maintain the same domain structure 
with significant similarity between the PFD and RD, but divergent linkers10. DFNB59 is an 
exception with a divergent, shorter C-terminal domain. The PFD of most members can induce 
cell death10,11,15,21 (not yet examined for DFNB59). Whereas humans and most other mammals 
have one copy of each gasdermin, mice have triplicated gasdermin A (gasdermin A1-3), deleted 
gasdermin B, and quadruplicated gasdermin C (gasdermin C1-4). Each gasdermin member has a 
distinct and restricted pattern of expression as discussed below. 
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Gasdermin A 
Gasdermin A is expressed in epithelial cells of the skin, tongue, esophagus, stomach, 
mammary glands, and umbilical cord40,42,43. In mice, gasdermin A1 is expressed primarily in 
suprabasal epidermis, hair follicles, and forestomach14,43-45; gasdermin A2 is expressed primarily 
in glandular stomach40; and gasdermin A3 is expressed primarily in suprabasal 
epidermis14,43,44,46,47. Multiple spontaneous mutations in gasdermin A3 have been associated with 
spontaneous alopecia and hyperkeratosis44,46-50. Histologically, inflammation and a resulting 
depletion of skin bulge stem cells have been observed in mice with Gsdma3 mutations49,51. 
Additionally, one Gsdma3 mutation causes defective of mammary gland development52. In 
contrast, gasdermin A3 knockout mice are phenotypically normal43. The alopecia phenotypes 
therefore likely result from gain-of-function mutations. Indeed, in vitro, these disease-causing 
mutations in gasdermin A3 result in an inability of the RD to effectively inhibit the PFD, causing 
increased spontaneous pore formation in the absence of linker cleavage10. These mutations 
therefore suggest that gasdermin A may play a role in causing inflammation within the skin. In 
humans, single nucleotide polymorphisms (SNPs) in GSDMA have been associated with 
asthma53. Only one study has suggests gasdermin A expression in the lung54, consequently, the 
mechanism by which gasdermin A contributes to asthma remains unclear. 
 
Gasdermin B 
Like GSDMA, GSDMB SNPs are also associated with asthma in multiple populations53,55-
57. Gasdermin B expression has been detected in lymphocytes, esophagus, stomach, liver, and 
colon40,42. While one group did not observe significant expression of gasdermin B in the lung54, 
another group did observe gasdermin B in the lung and implicated it in influencing expression of 
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genes related to airway remodeling and hyper-responsiveness58. Furthermore, one disease-
associated SNP causes an alteration in the conformational flexibility and surface charge of a 
region in the RD59. The GSDMB SNPs and the GSDMB region of chromosome 17q21 have been 
associated with several other immune diseases as well60-67. Since GSDMA and GSDMB are 
genetically linked to each other as well as ORMDL3 (a gene encoding a sphingolipid 
biosynthesis regulator with SNPs also associated with asthma) within chromosome 17q12-21, it 
may be that the linkage with asthma is either due to one or some combination of these genes. The 
study of gasdermin B in vivo will be more difficult because mice naturally lack the gene. 
A recent report shows that gasdermin B can be cleaved by granzyme A68, suggesting that 
gasdermin B promotes pyroptotic cell death downstream of cytotoxic immune cells including 
NK cells and CD8+ cytotoxic T lymphocytes (CTLs). Therefore, NK or CTL attack can result in 
a cell dying by pyroptosis if granzyme A activates gasdermin B, or the cell may die by apoptosis 
if granzyme B activates caspase-8. It remains unclear how this decision is made, whether it is 
driven by the gasdermin expression in the target cell or the granzyme expression in the NK/CTL, 
and whether there is communication between the cells to change these expression patterns. This 
discovery suggests that gasdermin B may be particularly useful against viruses. However, mice 
lack gasdermin B, thereby limiting the ability to assess the function of gasdermin B using in vivo 
models. The physiologic relevance of this pathway during infections consequently remains 
unknown.   
Gasdermin B has also reported to be cleaved by caspase-3, -6, and -7, but within the 
PFD59, similar to PFD cleavage of gasdermin D21. Thus, both gasdermin B and gasdermin D may 
be inactivated during apoptosis to prevent pyroptosis after caspase-3 activates. However, this 
idea is must be reconciled with caspase-3 activating gasdermin E (see below), and with 
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Little is known about the function of gasdermin C. Gasdermin C is expressed in 
esophagus, stomach, trachea, spleen, intestines, bladder, and skin40,42. Gasdermin C expression is 
increased in metastatic melanoma69 but suppressed in esophageal and gastric cancer13. 
Furthermore, gasdermin C has recently been proposed to be activated by caspase-8 downstream 
of PD-L1 activation to promote pyroptosis of cancer cells. In mice, gasdermin C1, C2, and C4 
are expressed in stomach, large and small intestines, bladder, and prostate while C3 is restricted 
to bladder, prostate, and large intestines42.  
 
Gasdermin E (DFNA5) 
Mutations in GSDME are associated with development of heritable, nonsyndromal 
deafness (thus the original name: deafness autosomal dominant 5, DFNA5)70-72. GSDME is 
expressed in placenta, brain, heart, kidney, cochlea, intestines, and IgE-primed mast cells40,42. 
Deafness associated with GSDME is characterized by an autosomal dominant inheritance and 
gradual loss of hearing, typically starting at high frequency by age fifteen73. All known mutations 
in GSDME associated with deafness are characterized by skipping of exon 8, resulting in 
frameshifts and the formation of truncated gasdermin E protein70-72. The truncated RD fails to 
repress the PFD, resulting in a gain-of-function41. Knocking out GSDME in mice does not result 
in deafness74. 
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Caspase-3 was recently shown to specifically cleave gasdermin E, which then forms 
pores in the plasma membrane and triggers lytic cell death in response to caspase-3 activators 
such as chemotherapeutic drugs, TNF, and viral infection21,41. Rogers et al. proposed that 
gasdermin E is the effector of secondary necrosis21; that is lysis of apoptotic cells after prolonged 
time if apoptotic cells are not efferocytosed. On the other hand, Wang et al. demonstrated that 
only specific cells express gasdermin E, and proposed that in such cells, caspase-3 activation is 
switched from driving an apoptotic program to causing pyroptosis41. Thus, certain cells may be 
programmed to undergo pyroptosis instead of apoptosis, at least under certain circumstances. 
Gsdme-knockout mice were shown to be resistant to the toxicity of chemotherapy drugs such as 
cisplatin41.  
It is reasonable to expect that gain-of-function mutations in gasdermin E could lead to 
progressive deafness by increasing susceptibility for cells within the auditory system to undergo 
programmed cell death. However, why hair cells in the ear are uniquely susceptible to this is 
unclear. Transcription of GSDME increases in response to p53 activation, and its expression is 
silenced in colorectal, gastric, and breast cancer, suggesting a possible role of gasdermin E in 
suppressing cancer73. To date, most of the research into gasdermin E has focused on its role in 
tumor immunology and chemotherapy cytotoxicity. 
 
Pejvakin (DFNB59) 
 PJVK (also called DFNB59) encodes the protein pejvakin, which, like gasdermin E, is 
associated with deafness75,76. If pejvakin is later shown to form a pore, it may be appropriate to 
re-name it as “gasdermin F”. DFNB59 has been detected in hair cells of the inner ear and other 
cells of the auditory system, but it is also broadly expressed75. In humans, mutations in PJVK are 
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associated with autosomal recessive nonsyndromic sensorineural hearing loss with or without 
cochlear dysfunction75,76. Unlike GSDME mutations, PJVK mutations are heterogeneous, 
including both truncations and missense mutations (p.T54I or p.R183W). The Petit group 
observed that functional pejvakin in mice was necessary to allow existing peroxisomes to 
proliferate and protect cochlear sensory hair cells and auditory neurons from noise-induced 
generation of reactive oxidative species77. This same group later suggested that pejvakin is 
directly activated by the oxidation of cysteines on its C-terminal domain, thereby allowing 
pejvakin to detect ROS78. The ability of pejvakin to form pores and the possible role of pejvakin 
pore formation in mediating proliferation of peroxisomes remains unknown. One possibility is 
that pejvakin forms a pore to transport proteins into the peroxisomes necessary for peroxisome 
proliferation in response to increased ROS. Indeed, several PEX proteins are already known to 
mediate import of large proteins into peroxisomes through the formation of transient pores79. 
Alternatively, Defourney et al. suggest that pejvakin promotes peroxisome proliferation 
downstream of promoting autophagy of older peroxisomes78, though this could also plausibly 
reflect activation of autophagy machinery in response to leakage secondary to pore formation. 
Another group has suggested that pejvakin instead functions through interactions with 
cytoskeletal proteins or through a structural role in hair cells80. 
 
Cell-specific roles of inflammasomes and gasdermins 
Traditionally, pyroptosis was believed to occur predominantly in macrophages. As a 
result, most studies have been conducted using macrophages and most of our understanding of 
the pyroptotic pathways have thus been restricted to macrophages. However, it is now 
appreciated that pyroptosis does in fact occur not just in other immune cells, but even non-
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immune cells like intestinal epithelial cells28. Furthermore, this discovery that gasdermin D 
triggers pyroptosis is particularly remarkable because the human genome encodes six proteins 
with the potential to form pores in the membrane and cause lysis, each with their own specific 
expression pattern and most of which are in fact not expressed in immune cells. Thus, we need to 
improve our understanding of the function of pyroptotic pathways in the diverse array of cell-
types that we now know exhibit pyroptotic potential. The goal of my thesis was to expand our 
understanding of inflammasomes and gasdermins in various cell types, first by exploring the role 
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DFNA5 gasdermin E 
(GSDME) 
Dfna5 Placenta, brain, 
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Dfnb59 Inner ear hair cells, 
auditory system, 
broadly expressed in 
other tissues 
Unknown AR congenital 
deafness 
(LOF) 
Table 1. Gasdermin family nomenclature and expression pattern. 
aExpression data taken from 39-41 75 





Figure 1. Pyroptosis converts cells into pore-induced intracellular traps (PITs). Whereas 
apoptosis converts cells into apoptotic bodies, pyroptosis converts cells into PITs. The membrane 
rupture event that defines pyroptosis immediately disperses soluble cytosolic contents. However, 
although torn, the plasma membrane remains largely intact such that organelles and live 
intracellular bacteria remain trapped within. This is different from the image of cellular debris, 
where all cellular contents are dispersed. Efferocytosis is the process whereby one cell 
phagocytoses another. Apoptotic bodies are typically efferocytosed by macrophages. In contrast, 
PITs are efferocytosed by neutrophils. These neutrophils then kill the previously intracellular, 
now PIT-trapped, bacteria. Pictures of neutrophils (marked by Ly6G, white) that have 
efferocytosed macrophage PITs (marked by CD68, red) that entrap intracellular bacteria (GFP, 
green) after the engineered bacteria are prompted to express flagellin and trigger pyroptosis of 




Figure 2. Caspase-1/11 activate the gasdermin D pore to cause pyroptosis. Caspase-1 is 
activated by various inflammasomes in response to contamination of the cytosol or perturbation 
of basic cellular homeostasis. Caspase-11 (mice) and caspase-4 and -5 (humans) activate by 
direct sensing of cytosolic LPS. Upon activation, these caspases cleave pro-IL-1b, pro-IL-18, 
and gasdermin D. Gasdermin D is composed of an amino-terminal pore-forming domain (PFD, 
green), a linker (red), and a carboxy-terminal repression domain (RD). The amino-terminal pore-
forming domain (PFD) of gasdermin D then interacts with the plasma membrane and 
approximately 16 monomers oligomerize to form a gasdermin pore. The diameter of this pore is 
estimated in the range of 10-15 nm, which is large enough to release small proteins, including 
mature IL-1b (4.5 nm diameter), probably at a relatively slow rate. Simultaneously, sodium 
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enters the cell, bringing with it water that causes the cell volume to increase. This can rapidly 
exceed the volume capacity of the membrane, resulting in membrane rupture that is larger in size 
than the gasdermin pore, but smaller or on par with most organelles and intracellular bacteria. 
Upon membrane rupture, all remaining soluble cytosolic contents are released so rapidly as to be 
essentially instantaneous.
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CHAPTER 2: EVALUATING CYTOKINE PRODUCTION BY FLOW CYTOMETRY 
USING BREFELDIN A IN MICE2 
 
Introduction 
Activation of inflammasome pathways often requires two signals: a priming signal, and 
an activating signal. The priming signal is important for ensuring that an inflammasome is only 
activated in the context of infection, thereby reducing the risk of damage due to aberrant 
activation. Priming both promotes transcription of components of the inflammasome pathways 
and post-translational modifications of existing proteins to allow the inflammasomes to 
activate81. For example, signaling downstream of any TLR can prime the NLRP3 inflammasome 
for activation81. Caspase-11, on the other hand, has stricter priming requirements. In vivo 
defense against the cytosol invasive bacterium Burkholderia thailandensis requires priming by 
IFN-g8. This stricter priming may be due to the fact that the LPS sensed by caspase-11 is a 
ubiquitous molecule that can aberrantly be introduced into the cytosol even when the infecting 
pathogen lacks the virulence capacity to invade the cytosolic compartment. Therefore, 
identifying the source of IFN-g during infection is significant. 
During infection with Burkholderia thailandensis, IFN-g production is induced by IL-18 
within a day of infection to prime caspase-11, resulting in complete clearance of infection8. 
Given the swift kinetics of this IFN-g production, we wanted to identify which cells were 
 
2This chapter was adapted from a protocol previously published in STAR Protocols. The original citation is as 
follows: Kovacs, S. B., Oh, C., Aachoui, Y., & Miao, E. A. (2020). Evaluating cytokine production by flow 
cytometry using brefeldin A in mice. STAR Protocols, 2(1), 100244. SBK optimized the protocol and wrote this 
entire section himself under the guidance of EAM and YA. 
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responding to IL-18 to produce this IFN-g. Consequently, we needed to optimize a methodology 
to accurately identify cells producing IFN-g in situ in a mouse model of infection. Cytokine 
reporter mice are limited by the need to cross markers into various knockout backgrounds, and 
by availability of reporters of interest. To overcome this, we utilize injection of brefeldin A into 
mice to enable flow cytometric analysis of in situ cytokine production during a bacterial 
infection. While we evaluate IFN-g production during Burkholderia thailandensis infection, this 
protocol can be applied to other cytokines and other mouse models. 
For complete details on the use and execution of this protocol, please refer to Kovacs et al. 82, as 
well as Liu et al.83, the original publication from which we adapted this protocol. 
Before you Begin 
The investigator should be comfortable with any procedures involved with their 
particular in vivo model. Additionally, investigators should be proficient with injecting mice via 
the intravenous route, and the use of a flow cytometer with large multi-parameter capabilities 
(eg. LSR II). 
 
Table 2: Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Alexa Fluor (AF) 488 rat anti-mouse CD127 (clone A7R34) 
  
BioLegend Cat# 135017 
Brilliant Violet (BV) 570 rat anti-mouse CD3 (clone 17A2) BioLegend Cat# 100225 
APC-Cy7 rat anti-human/mouse CD45R (clone RA3-6B2) BioLegend Cat# 103223 
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APC-Cy7 rat anti-mouse Ly6G (clone 1A8) BioLegend Cat# 127623 
PE-Cy7 rat anti-mouse CD90.2 (clone 53-2.1) BioLegend Cat# 140309 
BV650 mouse anti-mouse NK1.1 (clone PK136) BioLegend Cat# 108735 
BV421 Armenian hamster anti-mouse TCRγδ (clone GL3) BioLegend Cat# 118119 
AF594 rat anti-mouse CD4 (clone GK1.5) BioLegend Cat# 100446 
PE rat anti-mouse CD8 (clone 53-6.7) BioLegend Cat# 100708 
APC rat anti-mouse IFN-γ (clone XMG1.2) BioLegend Cat# 505810 
Bacterial and Virus Strains 
Burkholderia thailandensis, strain E264-1 (ATCC® 
700388™ strain E264 that was previously passaged through 
Casp1–/–Casp11–/– mice) 
Aachoui et al., 
2015 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit ThermoFisher 
Scientific 
Cat# L23105 
Experimental Models: Organisms/Strains 




Software and Algorithms 
FlowJo (we used version 9.9.6 for all figures in this protocol 




Fixation/Permeabilization Solution kit BD Biosciences 554714 
Brilliant Stain Buffer BD Biosciences 563794 





Materials and Equipment 
Table 3: Extracellular antibody master mix  
Antibody Dilution factor  
BV650 anti-mouse NK1.1 1:80 
BV570 anti-mouse CD3 1:40 
BV421 anti-mouse TCRγδ 1:40 
AF488 anti-mouse CD127 1:320 
PE-Cy7 anti-mouse CD90 1:400 
APC-Cy7 anti-mouse Ly6G 1:1280 
APC-Cy7 anti-human/mouse CD45R 1:320 
AF594 anti-mouse CD4 (optional) 1:400 
PE anti-mouse CD8 (optional) 1:160 
Diluent Volume per sample 
Brilliant Stain Buffer 50 µL 
FACS Buffer Add until total volume is 100 µL 
 
Note 1: CD4 and CD8 antibodies are included as optional because while these antibodies did 
provide adequate delineation of CD4 and CD8 T cell populations, the fluorophore-marker 
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combinations were not optimized, resulting in minor compensation issues. See Expected 
Outcomes for more details. 
Note 2: All sample data included in figures in this protocol used FACS buffer as diluent without 
Brilliant Stain Buffer added. However, we recommend using Brilliant Stain Buffer in this panel 
or any other panel that utilizes multiple Brilliant Violet dyes to avoid potential nonspecific 
staining due to aggregation of these dyes that could affect your interpretation of your data. FACS 
buffer should be used when your panel includes one or fewer Brilliant Violet or other polymer-
based dyes. 
 
Table 4: Intracellular antibody master mix 
Antibody Dilution factor  
APC anti-mouse IFN-g  1:400 
Diluent BD Biosciences Perm/Wash buffer 
Total volume (per sample) 100 µL 
 
Table 5: ACK lysis buffer recipe  
Reagent Final Concentration Amount 
NH4Cl 150 mM 4.01 g 
KHCO3 10 mM 0.5 g 
Na2EDTA 0.1 mM 18.6 mg 
H2O N/A 500 mL 
Total N/A 500 mL 
Titrate pH to 7.2-7.4; Store at room temperature (25-27°C) 
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Table 6: FACS buffer 
Reagent Final Concentration Amount 
EDTA (0.5 M) 4 mM 4 mL 
Bovine Serum Albumin 
(BSA) 
0.5% 2.5g 
PBS N/A 496 mL 
Total N/A 500 mL 
Store at 4°C 
 
Step-by-Step Method Details 
Prepare bacterial inoculum 
For this protocol, we will describe staining for in situ cytokine production by 
lymphocytes during Burkholderia thailandensis infection. The inoculation protocol should be 
adjusted to fit the infection or treatment protocol of interest. Figure 3 summarizes the protocol. 
 
Timing: 2-3 days 
 
1. Grow a bacterial culture. 
a. Two to three days prior to infection, streak out Burkholderia thailandensis from 
frozen stock onto a Luria-Bertani (LB) plate, and grow for one to two days at 
37°C.  
Note: Plates of streaked B. thailandensis can be stored for up to a week at 4°C. 
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b. Inoculate a 1.5 mL liquid LB culture with a single colony and grow for 16 hours 
at 37°C in a shaking incubator to achieve stationary phase.  
Pause point: If mice will not be infected immediately at the end of this 16 hour 
incubation, place the bacteria on ice until ready to infect mice.  
2. Prepare the inoculum. 
a. Pellet the 1.5 mL liquid culture of bacteria by spinning in a microcentrifuge at 
3000xg for 1 minute. 
b. Remove the supernatant and resuspend in 1 mL PBS to wash the bacteria. Spin at 
3000xg for 1 minute. Repeat for a total of two PBS washes. Resuspend in 1 mL 
PBS. 
c. Estimate the concentration of bacteria using an OD600 as determined using a 
spectrometer. 
i An OD600 of 1.00 is approximately 1x109 CFU/mL of B. thailandensis. 
The relationship between OD600 and CFU is approximately linear below 
OD600 of 1.00. Dilute the bacteria until its OD600 is less than 1.00. 
ii Calculate concentration using the following equation: 
Concentration (in CFU/mL) = OD600 x 1x109 CFU/mL x dilution 
factor 
d. Dilute the inoculum with PBS to 2x107 CFU per 200 µL (the volume for each 
inoculum injection). 
e. Verify inoculum via spot dilution plating. 
i Create a total of eight (including undiluted) 1:10 serial dilutions of the 
inoculum in PBS. 
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ii Plate 10 µL of each dilution in triplicate on an LB plate using a spot 
plating method (or plate 100 µL if using a whole plate method). 
iii Incubate overnight (14-16hrs) at 37°C. 
iv Looking at the dilution which has approximately 10-50 colonies per spot, 
count and average the number of colonies per spot. 
v Calculate actual inoculum using the following formula: 
Inoculum (in CFU/mouse) = average # colonies x dilution factor x 20 
 
Infect and treat mice with brefeldin A  
We next infect the mice and, after waiting enough time to allow immune responses to 
establish, treat mice with the Golgi blocker brefeldin A (BFA). Since most cytokines are 
processed and secreted through the classical secretory pathway that passes through the Golgi 
apparatus, BFA prevents the secretion of cytokines, causing their accumulation within the 
immune cells for eventual detection by flow cytometry. Thus, treating mice with BFA allows for 
the evaluation of in situ cytokine production without requiring the use of reporter mice. 
Consequently, mice of any genetic background can be used, allowing the evaluation of the 
effects of knocking out genes on cytokine production without prior crossing of knockout mice 
onto a reporter background. For example, we successfully evaluated cytokine production in both 
wild type and Rag1–/– mice82.  
Our timings for this experiment were based on known kinetics of B. thailandensis infection 
in wild type mice. The time point in each mouse model will vary, but the timing of injecting 
BFA 6 hours prior to euthanizing the mice is important to allow for adequate accumulation of 
cytokines within cells. 
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Timing: 1 day 
3. Inject mice intraperitoneally with 200 µL of the inoculum created in step 2. Uninfected 
control mice should be injected with 200 µL of PBS as a mock infection. 
4. Twelve hours after infection, treat mice with BFA. 
a. Dilute BFA stock. 
i BFA stock should be reconstituted in DMSO to a concentration of 20 
mg/mL. 
Note: BFA stock can safely be stored at -20°C for at least a year. 
ii Further dilute working solution to 0.5 mg/mL in PBS. Keep this solution 
at room temperature (RT; 25-27°C) in order to avoid injecting a large 
volume of cold liquid into the mice. Do not reuse working solution. 
b. Inject 500 µL of working solution of BFA intravenously into the tail vein of both 
infected and uninfected mice. 
i Note: This volume was used in the original publication by Liu et al. 83. 
We did not attempt to optimize the injection volume, as this volume 
worked for our studies. Considerations include whether the volume used 
enhances BFA exposure throughout the body or reduces cytotoxic effects 
by dilution of BFA (Troubleshooting 2).  
5. Six hours after injecting BFA, euthanize mice and promptly harvest spleens per your 
institution’s animal guidelines. Keep spleens in PBS and on ice until all samples are 
ready to process. 
Alternative: While keeping the spleens in PBS is sufficient over a short duration when 
harvesting spleens and immediately proceeding to the next steps, consider keeping 
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spleens in serum-free media such as DMEM for longer durations to avoid loss of cell 
viability. Cells can be maintained in this media until RBC lysis.  
 
Note: Until cells have been fixed, cells are still alive and actively producing cytokines, albeit in a 
manner no longer reflective of the in situ setting. While the cell populations and their cytokine 
productions are likely stable at this point for a short period, it is advisable to proceed to the next 
steps through cell fixation (step 27) as soon as possible. 
 
CRITICAL: The exact timing of these injections will depend on the infection and model being 
tested. In this case, we have optimized the time points of our infection (18 hour total infection 
time) to view cytokine production during innate immune responses to B. thailandensis with a 
infective dose of 2x107 CFU. Indeed, if the inoculum of B. thailandensis is lowered to 1x104 
CFU in wild type mice, the infection is cleared faster and we think that cytokine production 
returns to baseline by 18 hours post-infection, resulting in a lack of staining (Figure 4, compared 
to robust IFN-g signal in Figure 5). Thus, it is important to optimize the timing of your BFA 
injections and tissue harvests for your specific model (Troubleshooting 1).  
 
Create a single cell suspension of splenocytes 
We next need to create a single cell suspension so that we can stain them for flow cytometry.  
Timing: 2 hours 
6. Place the spleen on a 70 micron cell strainer fitted on top of a 50 mL conical tube. 
7. Using the plunger of a 1 mL syringe, gently press the spleen against the strainer to 
mechanically disrupt the tissue. Continue until the only remaining tissue on the strainer is 
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white and fatty in texture, occasionally adding PBS to ensure that the tissue and cells do 
not dry out. 
8. Wash the remaining cells off the strainer and into the underlying 50 mL conical using 10 
mL of PBS. Dispose of the strainer and add PBS to the conical for a total volume of 30 
mL. 
Alternatives: If you are interested in immune cells present in other organs, the 
processing protocol may differ. Analogous procedures can be used for immune cell-dense 
organs like lymph nodes; however, more fibrous organs will likely require additional 
steps such as more intense physical manipulations and/or treatment with proteases like 
collagenase. For example, see the methods section of 84 for descriptions of how to process 
mouse liver and lungs. 
9. Spin the cells at 800xg, 4°C, for 10 minutes using a standard centrifuge 
10. Discard the supernatant and resuspend in 5 mL of ACK RBC lysis buffer. Incubate on ice 
for 5 minutes  
Critical: The timing of incubating your cells for five minutes is important to avoid 
potential loss of cell viability (Troubleshooting 1). 
11. Add 35 mL of PBS to stop lysis. Spin at 800xg, 4°C, for 10 minutes using a standard 
centrifuge. 
12. Discard the supernatant and resuspend in 5 mL of PBS. 
13. Filter through a new 70 micron cell strainer fitted on top of a new 50 mL conical to 
remove aggregates of dead cells that formed after lysis. 
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14. Key Step: Count cells using a cell counter or hemocytometer and record the data. These 
counts will be used to aliquot for staining in the next steps as well as for calculating 
absolute counts of subsets in the final analyses. 
Alternative: If you desire to localize the cells that are producing cytokine within the organ, you 
can instead fix the spleen in 4% PFA and perform immunofluorescent staining using an 
analogous protocol published by Mazet et al85. 
 
Stain splenocytes and perform flow cytometric analysis 
We next stain our cells for flow cytometry. Under normal circumstances (without BFA 
treatment), most cytokines are synthesized and promptly secreted by the cell. This causes the 
total pool of cytokine protein within the cell to be very low, despite high transcription and 
translation. Brefeldin A halts intracellular vesicle formation and transportation of proteins from 
the endoplasmic reticulum to the Golgi apparatus, inhibiting the secretory pathway and resulting 
in accumulation of translated proteins within the cell. This greatly increases the sensitivity of 
detection with antibodies specific for the cytokine of interest.   
Timing: 2 days 
15. Plate 1-2x106 cells in 200 µL PBS for each mouse into a well on a polypropylene, round-
bottom 96-well plate. 
16. Prepare a well for a live/dead (L/D) compensation tube.  
a. Take 1 to 2 million splenocytes and split into two Eppendorf tube. 
b. Heat shock one of the tubes by heating it at 55°C for 5 minutes followed by 2 
minutes on ice. The other tube should remain on ice the entire time. 
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c. Mix the cells from the two Eppendorf tubes together and plate onto the sample 
plate. This ensures that the compensation tube will have sizable populations of 
both live and dead cells to serve as positive and negative compensation controls. 
Alternative: Instead of using cells for L/D compensation, you can use amine reactive 
beads (for example, see ArcTM Amine Reactive Compensation Bead Kit (cat# A10628) 
from Thermo Fischer). If using these beads, you can make this compensation tube 
alongside the other compensation tubes in step 34. 
17. Centrifuge the plate at 450xg, RT, for 5 minutes. Discard supernatant. 
18. Resuspend each well with 200 µL of PBS. Centrifuge the plate at 450xg, RT, for 5 
minutes and discard supernatant. 
19. Resuspend each well with 100 µL of L/D stain in PBS for 20 minutes at RT in the dark 
a. To make L/D stain, add 1 µL of L/D stock per 1 mL of PBS 
20. Add 100 µL FACS buffer to each well. Centrifuge the plate at 450xg, RT, for 5 minutes 
and discard the supernatant. 
21. Resuspend each sample in 100 µL of extracellular staining master mix, and the L/D 
compensation well in 100 µL of PBS. Stain for 30 minutes at RT in the dark. 
22. Add 100 µL of FACS buffer to each well. Centrifuge the plate at 450xg, RT, for 5 
minutes and discard the supernatant. 
23. Resuspend each well with 200 µL of FBS buffer. Centrifuge the plate at 450xg, RT, for 5 
minutes and discard the supernatant. 
24. Add 100 µL of BD Biosciences Fix/Perm to each well. Incubate at 4°C for 20 minutes in 
the dark.  
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Note: Depending on the cytokine being stained, this fix/perm step may need to be 
extended to 45 minutes to an hour to get optimal intracellular staining of the cytokine. 
For IFN-g, we found that 20 minutes was sufficient (Troubleshooting 2). 
25. Add 100 µL of BD Biosciences Perm/Wash buffer to each well. Centrifuge the plate at 
1250xg, 4°C, for 5 minutes and discard the supernatant. 
26. Resuspend each well with 200 µL of BD Biosciences Perm/Wash buffer. Centrifuge the 
plate at 1250xg, 4°C, for 5 minutes and discard the supernatant. 
27. Resuspend each well with 200 µL of BD Biosciences Perm/Wash buffer. 
Pause Point: Once all cells have been fixed, samples can be stored at 4°C in the dark  
overnight in the Perm/Wash buffer. Intracellular staining can be resumed the following 
day with no significant change in staining.  
28. Centrifuge plate at 1250xg, 4°C, for 5 minutes and discard the supernatant. 
29. Resuspend each sample in 100 µL of intracellular staining master mix and the L/D 
compensation well in 100 µL of BD Biosciences Perm/Wash buffer. Stain for 1 hour at 
4°C in the dark. 
30. Resuspend each well with 100 µL of BD Biosciences Perm/Wash buffer. Centrifuge the 
plate at 1250xg, 4°C, for 5 minutes and discard the supernatant. 
31. Resuspend each well with 200 µL of FBS buffer. Centrifuge the plate at 1250xg, RT, for 
5 minutes and discard the supernatant.  
32. Resuspend in 200 µL of FACS buffer. Transfer to a flow tube with a filter.  
33. Prepare compensation tubes. 
a. Add 1 µL of antibody to 1 drop of UltraComp eBeads™ Compensation Beads.  
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Note: These beads can bind mouse, rat, and hamster-derived antibodies, which 
works with all antibodies used in the panel included in this protocol. However, if 
you use different antibodies in your panel, ensure that the beads are compatible 
with all antibodies being used. Beads compatible with antibodies derived from 
other species are also commercially available. Alternatively, if enough cells 
present the marker for the antibody, you can stain splenocytes with the antibody 
alone to use as a compensation tube.  
b. Vortex briefly. 
c. Incubate at RT in the dark for 15 minutes. 
d. Add 150 µL of FACS buffer and centrifuge at 450xg. 
e. Resuspend in 200 µL of FACS buffer and transfer to a flow tube. 
Note: For conventional flow cytometry (such as the flow we performed using an LSRII), 
beads offer an easy way to generate compensation samples that usually result in accurate 
compensation. However, if using a full spectrum flow cytometer, then the slight 
differences between fluorescent spectra of fluorophores on beads compared to cells could 
result in unmixing errors. Thus, these users will need to determine if there are any 
differences between single color controls using beads and cells, and they should use cells 
as compensations controls if there is a difference.  
34. Keep samples at 4°C in the dark until ready to run on a flow cytometer. 
35. Run samples through flow cytometer.  





If successful, using the gating schema displayed in Figure 5A, only minimal amounts of 
cytokine staining will be detected in uninfected controls, which represents the basal level of 
cytokine production (Troubleshooting 3). A robust signal should be detected from the infected 
mice where cells are strongly producing cytokine (Figure 5B). Frequency of cells can be 
determined directly from flow cytometry analyses. The gating schema used will enable analysis 
of T cells (CD3+), NK cells (CD3-NK1.1+CD127–), and ILC1s (CD3-NK1.1+CD127+CD90+ or 
CD3-NK1.1-CD127+CD90+) (Figure 5A-C). Gamma-delta T cells can also be identified within 
the CD3+ population (Figure 5D).  
 We have also expanded the panel with CD4 and CD8 (see optional antibodies), allowing 
the identification of CD4 and CD8 T cells within the CD3+ population. While compensation 
issues begin to appear since we did not optimize the fluorophore-marker combinations in the 
panel expanded to include CD4 and CD8, we include these antibodies in this protocol as an 
option since they were sufficient to delineate the CD4 and CD8 populations (Figure 5D). Further 
optimization of which fluorophore is assigned to each marker can be done to avoid these 
compensation issues.   
Quantification and Statistical Analysis 
Frequency is calculated using FlowJo analysis software. In addition to frequency, 
absolute counts for each population being examined should be calculated. This calculation is 
important because differences in frequency can result from either changes in that population of 
cells (eg. more NK cells are present in the spleen) or changes in the other populations (eg. fewer 
T cells will make NK cell frequency increase). Absolute counts allow determination of the 
causes of changes in frequencies. This can easily be performed by multiplying the total 
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splenocyte count determined immediately after forming the single cell suspension for each 
sample (see step 14) by the frequencies of each gate used to gate on the population. For example, 
to calculate absolute number of NK cells in the spleen that produce IFN-g using the gating from 
Figure 5A, we did the following: 
Absolute # of NK cells producing IFN-g in spleen = 
5.75𝑥10!	splenocytes	 × 	0.976	(singlet freq) 	× 	0.62	(lymphocyte freq)
× 	0.822	(live cell freq) 	× 	0.286	(non-excluded cell freq)
× 	0.0234	(IFN-g -producing cell freq) × 	0.618	(NK cell freq) 
= 1.18𝑥10"	NK cells 
 
Using the “Frequency of Total” statistic in FlowJo for a given population, this equation can be 
simplified to: 
 Absolute count = splenocyte count x Freq of Total (for given population) 
Limitations 
 BFA is a Golgi blocker that inhibits the secretory pathway. This has several implications. 
First, BFA only inhibits release of cytokines that go through the secretory pathway. Members of 
the IL-1 family (e.g. IL-1b, IL-18, IL-33) do not encode a secretion signal, are stored in the 
cytosol, and are released by cell lysis or membrane permeabilization rather than through the 
secretory pathway86.  Therefore, this methodology will not assess release of these cytokines. 
Indeed, it would give the opposite result: positive staining would indicate the lack of release of 
IL-1 family members. Similarly, some cell types contain pre-formed cytokine not intended for 
immediate release. Notably, this includes mast cells which store pre-formed TNF until another 
stimulus promotes its release87. Neither the methodology reported here nor the use of cytokine 
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reporter mice will be able to differentiate the pre-formed cytokine from cytokine that is created 
and immediately secreted on demand. 
Second, release of cytokines, chemokines, and other proteins is important for a diverse 
array of immune functions. Thus, adding BFA likely alters kinetics and dynamics of infections 
and immune responses. However, these effects of BFA could be minimized by only treating mice 
with BFA after the immune response to be studied has had time to establish and by limiting the 
treatment time with BFA to 6 hours.  
In addition, as a Golgi blocker, BFA can be toxic to cells. It is therefore important to 
monitor for cell death using live/dead markers. In our B. thailandensis infection model, BFA 
toxicity appears minimal. However, it is possible that some populations of cells may be more 
sensitive to BFA in other murine models, which could result in a selective loss in that population 
that may be difficult to detect unless that particular cell type was specifically examined. 
Finally, sensitivity for detecting a cytokine response will be limited by the robustness of 
the cytokine response, the size of the population being looked at, and the accessibility of the 
tissue to blood flow (and therefore to the BFA that is injected intravenously). Low prevalence of 
responding cells could be particularly apparent when examining non-lymphoid tissues. This 
could be rectified by enriching for immune cells and removing stromal cells. Furthermore, this is 
a limitation that likely affects this BFA method of assessing in situ cytokine production more 
than the use of a reporter mouse. The fluorophores used in reporter mice often have longer half-
lives than those of cytokines, meaning that more can accumulate within individual cells88-90. This 
increases the signal and improves the sensitivity of the reporter mice compared to BFA-treated 
mice (at the cost of being less able to resolve cytokine secretion that occurred over shorter 
periods of time). 
 38 
Troubleshooting 
Problem 1:  
Low cell number 
 
Potential Solution:  
If this is accompanied by excessive cell death per the live/dead staining, this could have 
resulted from lysing too long with ACK buffer. Large clumps forming after treatment with ACK 
buffer could suggest this as a culprit. In this case, ensure samples do not remain in ACK buffer 
too long. If working with many samples, lyse only a small group at once and then proceed to 
next group once PBS has been added to ACK-treated samples to stop reaction. Alternatively, 
using too high of a concentration of BFA for too long may result in cell toxicity. In this case, 
lower concentration of BFA used or see if treating mice with BFA for a shorter duration reduces 
cytotoxicity without significantly reducing the signal of your cytokine. 
 If low cell numbers are not accompanied by excessive cell death, this could have resulted 
from plating the wrong number of splenocytes per well for staining or loss of cells during 
washing steps (e.g. aspiration of pellet). Verify that you are correctly counting the number of 
splenocytes obtained and correctly calculating the volume of cell suspension to add into each 
well for staining.  
Lastly, some mouse lines deficient in lymphocytes, such as Rag1–/–, do not have many 
splenocytes. Therefore, a low cell count may be expected for these mouse lines. In these cases, 
the goal is to collect and analyze as many cells as possible.  
Problem 2:  
No cytokine signal 
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Potential Solution:  
Optimization may be required for each model to determine the time point that maximizes 
the likelihood for capturing a cytokine signal. With the proper timing, this protocol can be easily 
applied to a diverse array of models. The main stipulations are that you wait a sufficient amount 
of time to establish an immune response prior to BFA injection to minimize the effect of BFA on 
the immune response (see Limitations for more details), and you treat mice with BFA for 
approximately 6 hours immediately prior to harvesting the mouse. 
Another potential cause of a lack of cytokine signal is that BFA does not always 
efficiently block cytokine secretion. In these cases, another Golgi blocker, monensin, may be 
more successful at inhibiting secretion of the cytokine. Indeed, Sun et al. reported successfully 
treating mice intravenously with 0.5 mg of monensin in 500 µL of PBS instead of BFA to 
successfully visualize IL-10 production91. For reference on which cytokines are known to be 
efficiently inhibited by brefeldin A versus monensin, see the Cytokine Detection subsection of 
the Techniques section on the following website: 
https://www.bdbiosciences.com/us/applications/research/intracellular-flow/. 
Finally, while we found 20 minute fix/perm (step 24) was sufficient for staining of IFN-g, 
this duration of time may be insufficient for other cytokines. Thus, consider extending the 
fix/perm step up to 45 minutes or an hour. 
  
Problem 3:  




Potential Solution:  
Even if you utilize the optimized dilutions suggested for antibody master mix included in 
this protocol, batch variation could cause increased background for a given amount of antibody 
used. Therefore, titrate the antibody to determine the best concentration to use. In addition, 
utilize a fluorescent minus one (FMO) control in which you stain with all of the antibodies in the 
panel except for the one with which you are having trouble. This will enable you to see if there is 
a compensation issue that needs to be corrected as well as improve your gating strategy by 





Figure 3: Graphical summary of protocol. 
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Figure 4. Choosing correct experimental conditions and timing is essential for observing 
robust cytokine signal. When infecting with a large bacterial inoculum (2x107 CFU), a robust 
IFN-g signal is observed at 18 hours post-infection. When using smaller bacterial inoculum (104 
CFU), IFN-g signal is similar to background levels at 18 hours post-infection, a time point at 





Figure 5. Analysis of flow cytometric data. A) Gating strategy used to characterize what cell 
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types constitute the IFN-g-producing cells. Italicized labels indicate what cell population is being 
gated. B) Representative results at 18 hours post-infection with 2x107 CFU B. thailandensis. C) 
Representative results demonstrating gating of ILC1s within the CD3–NK1.1+ subset. D) 
Representative results demonstrating TCRγδ and CD4 and CD8 subpopulations of the 
CD3+NK1.1– subset when including the optional CD4 and CD8 antibodies.  
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CHAPTER 3: NEUTROPHIL CASPASE-11 IS ESSENTIAL TO DEFEND AGAINST A 
CYTOSOL INVASIVE BACTERIUM3 
 
Introduction 
The innate immune system includes multiple cell types that can be classified as either 
myeloid cells or lymphocytes that begin acting in defense against pathogens prior to the onset of 
adaptive responses. The myeloid lineage includes cells like macrophages and neutrophils that 
function to directly kill bacteria and other pathogens. The innate immune cells with lymphoid 
lineage include natural killer cells (NK cells), innate lymphoid cells (ILCs), and innate-like T 
cell lymphocytes92,93. Networks of cross-talk between myeloid and lymphoid lineages in innate 
immunity during bacterial infection is a nascent area of study. 
Tissue resident macrophages are stationed in all the organs of the body in order to survey 
for bacterial contamination. They will typically be the first immune cells to come into contact 
with an infecting bacterium, and thus they are tasked with assessing the threat potential of the 
microbe. Cytosolic inflammasome sensors detect the virulence capabilities of pathogens, 
resulting in the activation of either caspase-1 or caspase-1194. For example, the NAIP/NLRC4 
inflammasome signals to caspase-1 when it detects the activity of virulence-associated bacterial 
 
3This chapter was previously published in Cell Reports. The original citation is as follows: Kovacs SB, Oh C, 
Maltez VI, McGlaughon BD, Verma A, Miao EA, Aachoui Y. Neutrophil Caspase-11 Is Essential to Defend against 
a Cytosol-Invasive Bacterium. Cell Rep. 2020 Jul 28;32(4):107967. doi: 10.1016/j.celrep.2020.107967. Stephen 
Kovacs performed experiments identifying NK cells and T cells as the IFN-producing cells during Burkholderia 
thailandensis infection. Stephen Kovacs also bred two novel mouse lines, one with myeloid-specific deletion of 
caspase-11 (LysM-cre) and one with neutrophil-specific deletion of caspase-11 (Mrp8-cre). Using these lines, 
Stephen Kovacs performed the experiments demonstrating utilizing these lines. Stephen Kovacs was also involved 
in planning and interpreting experiments that he did not perform, wrote the manuscript, and guided it through 
publication. 
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type III secretion systems (T3SS)95-99. This detection alerts the cell to the risk posed: T3SSs 
inject effector proteins into the host cell cytosol, where these effectors reprogram cellular 
physiology to benefit the pathogen. In parallel, the caspase-11 inflammasome monitors for LPS 
contamination as a marker for another virulence trait: cytosolic invasion (Aachoui et al., 2013a; 
Hagar et al., 2013; Kayagaki et al., 2013). Upon activation, either caspase-1 or caspase-11 can 
independently cleave and activate the pore-forming protein gasdermin D, triggering lytic cell 
death called pyroptosis10,11. Caspase-1 can also cleave and activate the cytokines IL-1b and IL-
18, which are not cleaved by caspase-11100. Typically, in vitro studies of pyroptosis have utilized 
cultured macrophages. 
The beneficial responses of caspase-1 and caspase-11 have been studied during infection 
with many bona fide human pathogens. Interpreting these studies has been complicated by the 
fact that bona fide pathogens have experienced intense evolutionary pressure to evade 
inflammasome detection, resulting in inefficient detection by the inflammasome sensors9. On the 
other hand, many environmental bacteria appear to completely fail to evade inflammasomes, and 
these are superb model organisms with which to study inflammasome responses7,9. Burkholderia 
thailandensis uses its T3SS to lyse the vacuole and escape into the cytosol, where it replicates101. 
However, B. thailandensis is not a bona fide mammalian pathogen, and it never evolved 
mechanisms to evade inflammasomes. The result is that wild type mice easily identify the 
extreme virulence capacity of B. thailandensis and can eliminate even 20,000,000 CFU systemic 
challenges within one day. In contrast, Casp1–/–Casp11–/– mice succumb to even a 100 CFU 
challenge8. This change in the lethal dose is the strongest inflammasome-dependent defense 
phenotype of any infectious model as yet published9.  
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Both NLRC4 and caspase-11 can detect and respond to B. thailandensis as well as 
Burkholderia pseudomallei, a related bacterium that causes melioidosis in humans8,102-104. Our 
laboratory previously showed that within the first day of infection, the NLRC4 inflammasome is 
important to limit B. thailandensis8. While the resulting caspase-1-driven pyroptosis is probably 
important, more important was the release of mature IL-18. This IL-18 drove as yet unidentified 
cells to produce IFN-g, which was critical for priming the caspase-11 inflammasome. Caspase-11 
activation then resulted in the clearance of the bacteria, and we previously hypothesized that 
caspase-11 clearance was mediated via pyroptosis8. The importance of NLRC4 and IL-18 could 
be overcome by persistent infection for three days, after which other cytokine responses would 
also trigger IFN-g production. However, the importance of IFN-g and caspase-11 could not be 
bypassed, as both Ifng–/– and Casp11–/– mice succumbed to the low 100 CFU challenge8.   
Here we continue these studies by asking several questions. First, we investigate the cell 
type(s) that respond to IL-18 by producing IFN-g, effectively forming a bridge between caspase-
1 and caspase-11. Second, we investigate the importance of gasdermin D downstream of 
caspase-1 and caspase-11. Third, we investigate why the NLRC4-caspase-1 pathway is 
insufficient to clear B. thailandensis, since either caspase-1 or caspase-11 should be competent to 
drive pyroptosis, and thus they should be functionally redundant.  
 
Results 
Multiple lymphocyte populations respond to B. thailandensis infection 
We first sought to understand which cell types were responding to the IL-18 by secreting 
IFN-g. In the innate immune system, there are two primary cell types that express high levels of 
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the IL-18 receptor (Il18r1 and Il18rap): NK cells and ILCs (Figure 6). In the adaptive immune 
system, activated CD4 and CD8 T cells also express significant levels of the IL-18 receptor.   
To assess which cells produce IFN-g in response to B. thailandensis infection, mice were 
infected with B. thailandensis for 12 hours, then treated with brefeldin A83. Splenocytes were 
collected and assessed for cytokine production by flow cytometric analysis (Figure 7A-B). A 
majority of the cells that produced IFN-g consisted of NK1.1+CD3– cells, essentially all of which 
were conventional NK cells (CD127–) with only a few ILC1s (CD90+CD127+) (Figure 7C-E, 
Figure 8A-C). A smaller but still substantial population of IFN-g-producing cells were CD3+ T 
cells (Figure 8A-C). These CD3+ cells consisted of a variety of different T cell subsets (Figure 
7F-H). While using NK1.1 as opposed to NKp46 to identify NK cells risks underestimating the 
NK cell population, any underestimation is likely minimal since essentially all IFN-g-producing 
NK1.1– cells expressed CD3, which by definition cannot be NK cells. 
Interestingly, in the IFN-g-producing cells, the geometric mean fluorescence intensity 
(MFI) of IFN-g was significantly higher in NK cells than T cells (Figure 8D-E), suggesting that 
each NK cell may be producing more IFN-g than its CD3+ counterpart. Remarkably, a median of 
36% of the total NK cells in the spleen produced IFN-g in response to B. thailandensis infection 
(Figure 8F). Together, these data suggest that NK cells and innately responding T cells produce 
the IFN-g required to prime caspase-11, and that NK cells are exquisitely responsive in this 
model.  
We next asked whether these populations were required to drive the IFN-g response 
necessary to clear B. thailandensis (Figure 9). First, we examined Rag1–/– mice, which lack all T 
cells (as well as B cells), but remain competent for NK cells and ILCs. Rag1–/– mice remained 
fully resistant to B. thailandensis infection, surviving both high dose 2x107 and medium dose 104 
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CFU challenge (Figure 9A, 9E), and sterilizing the burdens in their spleen and liver within 1 day 
(Figure 9B-C, 9F-G). Further, Rag1–/– mice retained their ability to produce significant levels of 
serum IFN-g (Figure 9D, 9H), and flow cytometric analysis revealed that, as expected, IFN-g-
producing cells were virtually all NK cells. Therefore, we conclude that NK cells are sufficient 
to produce IFN-g to resist B. thailandensis infection. 
To study mice that genetically lack all these IFN-g-producing lymphocytes, we used 
Rag2–/– mice that also lack the common g chain (Il2rg), which is required for signaling through 
several cytokines, including IL-15 that is essential for NK and ILC development105,106. Rag2–/–
Il2rg–/– mice were highly susceptible to B. thailandensis infection, succumbing to infection and 
failing to sterilize B. thailandensis organ burdens, as was also seen in Ifng–/– mice (Figure 9A-C, 
9E-G). Despite having high bacterial burdens, these mice were defective in their ability to 
produce IFN-g (Figure 9D, 9H). The Rag2–/–Il2rg–/– mice and the Ifng–/– mice showed equivalent 
susceptibility during high dose infection, but in the medium dose infection the Rag2–/–Il2rg–/– 
mice succumbed ~3 days later, and had somewhat lower spleen burdens than seen in Ifng–/– mice. 
This could be due to the fact that Rag2–/–Il2rg–/– mice have altered splenic architecture, which 
could result in subtle changes in the course of the infection. Alternatively, there may be a very 
weak source of IFN-g from non-lymphocytes that slows the infection, but which is not detectable 
by serum ELISA and ultimately is insufficient to turn the course of the infection.  
Finally, we wanted to confirm that the primary role of these cells is to produce IFN-g, and 
that their cytotoxic function was not involved. Mice deficient in perforin (encoded by Prf1), 
remained fully resistant to B. thailandensis infection and had normal levels of serum IFN-g 
(Figure 10A-B). Furthermore, treatment with exogenous IFN-g or adoptive transfer of WT NK 
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cells restored resistance to infection in Rag2–/–Il2rg–/– mice, whereas negative controls of PBS or 
Ifng–/– NK cells did not (Figure 9I-K). 
In summary, a variety of lymphocyte populations respond within hours of infection by 
producing IFN-g. The predominant responsive cells are NK cells, which are sufficient to produce 
caspase-11-priming levels of IFN-g. It is likely that IFN-g-producing, innately responsive T cells 
are also sufficient. 
 
Gasdermin D is essential for defense against B. thailandensis  
Our laboratory previously showed that pyroptosis of bone marrow-derived macrophages 
(BMM) in vitro is driven in a redundant manner by both caspase-1 and caspase-11, and only 
doubly deficient BMM fully fail to trigger cytotoxicity in response to B. thailandensis 
infection103. Gasdermin D is the recently identified executioner of pyroptosis. In agreement with 
this, infection of BMM with B. thailandensis triggered gasdermin D cleavage that was dependent 
on caspase-1 and, to a lesser extent, caspase-11 (Figure 11A). This data would suggest that 
caspase-1 is more efficient than caspase-11 at cleaving gasdermin D in response to B. 
thailandensis, at least in BMMs. Gasdermin D can be cleaved to activate pore formation by 
either caspase-1 or caspase-11, and thus one might predict that Gsdmd–/– BMMs would resist 
cytotoxicity and phenocopy Casp1–/–Casp11–/– BMMs. However, this was not the case, as 
residual LDH release was observed in Gsdmd–/– BMMs (Figure 11B). The same was true for IL-
1b release as detected by ELISA (Figure 11C). This is actually in agreement with in vitro 
observations by others that found that Gsdmd–/– cells still achieve cytotoxicity after 
inflammasome activation11,12, likely due to apoptotic bypass pathways arising either from a 
signaling branch point from ASC to caspase-8 (reviewed in 1) or branching at caspase-1 itself to 
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BID107, followed by secondary necrosis. While the ASC to caspase-8 pathway should still be 
functional in Casp1–/–Casp11–/– mice, the caspase-1 to BID pathway may be faster, which could 
explain why Gsdmd–/– BMM have higher levels of cytotoxicity at this time point compared to 
Casp1–/–Casp11–/– BMM. These data would suggest that loss of gasdermin D during infection in 
vivo could be less impactful than the combined effect of the loss of caspase-1 and -11.  
We next examined the role of gasdermin D in defense against B. thailandensis in vivo. 
We previously showed that the Casp1–/– proxy mice, Nlrc4–/–Asc–/–, succumb only to high dose 
2x107 CFU infection by B. thailandensis, and survive medium 104 CFU challenges8. We now 
verify that this also holds true in the clean single knockout Casp1–/– mice, whereas Casp11–/– 
mice were verified again to succumb (Figure 12A-B). Although caspase-1 plays a lesser role, it 
can also be seen to slow the course of infection; thus, the caspase-1-sufficient Casp11–/– mice 
succumb slower than Casp1–/–Casp11–/– mice (8 and replicated in Figure 12A-B). This is the 
opposite of the in vitro data where caspase-1 appeared to be more efficient in cleaving gasdermin 
D (in BMMs). 
Gsdmd–/– mice succumbed to the high 2x107, medium 104, and low 102 CFU dose 
challenges, with kinetics that matched Casp1–/–Casp11–/– mice but were faster than Casp11–/– 
mice (Figure 12A-C). We further quantitated these results by determining bacterial burdens at 
day 1 after high dose challenge, or at day 2 following medium dose challenge. Gsdmd–/– mice 
had the highest burdens on par with Casp1–/–Casp11–/– mice, with Casp11–/– only slightly lower, 
and Casp1–/– or their proxy Nlrc4–/–Asc–/– mice having lower burdens still, and wild type (WT) 
mice clearing both doses (Figure 12D-G). Together, these results indicate that bypass pathways 
to other forms of cell death cannot compensate for the loss of pyroptosis in Casp1–/–Casp11–/– 
mice or in Gsdmd–/– mice. This is also in agreement with Wang et al., who observed that Gsdmd–
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/– and Casp1–/–Casp11–/– mice were more susceptible than WT mice to intranasal infection with 
B. thailandensis108. 
Our laboratory previously showed that the importance of NLRC4-ASC and caspase-1 is 
seen only in the first three days of infection when they drive IL-18 release, which in turn triggers 
IFN-g production (Aachoui et al., 2015). We now asked whether gasdermin D was important for 
this release of IL-18. As expected, IL-18 release within the first day of infection was dependent 
on gasdermin D (Figure 12H-I). Casp1–/–Casp11–/– control mice with equivalent burdens to 
Gsdmd–/– mice also did not have detectable levels of serum IL-18 (Figure 12H-I).  
Interestingly, at a later time point two-day post-infection, we observed elevated serum IL-
18 in Gsdmd–/– mice, and a trending elevation in Casp1–/–Casp11–/– mice that did not reach 
statistical significance (Figure 12J-K). Notably, the ELISA kit we used to measure the IL-18 
levels was specific for the cleaved, active form of IL-18 (Figure 13). Our data is consistent with 
that of Wang et al., who observed a delayed elevation of IL-18 levels in bronchoalveolar lavage 
fluid from Gsdmd–/– mice infected intranasally with B. thailandensis108. In Gsdmd–/– mice, the 
IL-18 is likely still cleaved by caspase-1 and is released in a delayed manner after non-pyroptotic 
necrosis of the cell, perhaps secondary to the backup pathways that have been observed in vitro. 
Alternatively, this serum IL-18 may arise from non-specific tissue damage caused by sepsis that 
activates caspase-1 in uninfected cells since these mice had exceptionally high, near lethal 
bacterial burdens (Figure 12J). Indeed, these mice are expected to succumb to the infection by 
the end of the day of harvest in this experiment (Figure 12B). How IL-18 is cleaved in Casp1–/–
Casp11–/– mice, however, is harder to explain. One possibility is that the ASC backup pathway-
mediated caspase-8 activation results in caspase-8 cleaving IL-18109. Indeed, consistent with this 
backup pathway having a subtle effect, we observed that Casp1–/– mice (in which the ASC-
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caspase-8 backup pathway remains intact) survived a day longer to high dose challenge and had 
a small but statistically significant reduction in burdens when compared to Nlrc4–/–Asc–/– mice 
(in which this backup pathway is deficient) (Figure 12A, D, F). Alternatively, unprocessed IL-18 
may be released by non-pyroptotic necrosis, and IL-18 could then be cleaved extracellularly. 
Indeed, several extracellular proteases have been reported as capable of cleaving and activating 
IL-18, including chymase and granzyme B110. Regardless of the mechanism, we can conclude 
that the delayed release of IL-18 is inadequate to clear infection in Gsdmd–/– and Casp1–/–
Casp11–/– mice.  
 
Caspase-11, but not caspase-1, triggers pyroptosis in neutrophils 
Next, we considered the apparent paradoxical separation of the phenotypes of Casp1–/– 
and Casp11–/– mice. Since both caspase-1 and caspase-11 should be competent to cleave 
gasdermin D independently of each other, one would expect redundancy in which Casp1–/–
Casp11–/– mice and Gsdmd–/– mice would be equally susceptible, whereas single Casp1–/– and 
Casp11–/– mice both remain resistant to infection. However, this was not the case, as caspase-1 
could not substitute for caspase-11 in defense (Aachoui et al., 2015; Wang et al., 2018).   
In considering why NLRC4 and caspase-1 were not sufficient to clear B. thailandensis, 
we hypothesized that there was a cell type in vivo that failed to activate NLRC4, and thus a 
single Casp11–/– mouse would phenocopy the double knockout in that cell type. One potential 
candidate cell type is the neutrophil. WT mice have been shown to effectively kill Salmonella 
enterica serovar Typhimurium when engineered to over-express the NLRC4-agonist flagellin37. 
However, if neutrophils are unable to kill phagocytosed bacteria due to loss of the ability to 
produce reactive oxygen species (Ncf1–/– mice lacking the phagocyte oxidase), then flagellin-
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engineered S. Typhimurium will persist and replicate inside a vacuole within neutrophils37. This 
observation suggests that neutrophils do not effectively undergo pyroptosis when exposed to 
NLRC4 agonists. Consistent with this concept, Chen et al. showed that treatment of neutrophils 
with NLRC4 agonists triggers caspase-1 activation to promote IL-1b maturation but does not 
result in pyroptosis32,111. In contrast, neutrophil exposure to cytosolic LPS drives caspase-11 
activation and gasdermin D cleavage to induce pyroptosis111. We thus hypothesized that 
neutrophils were anergic to NLRC4, but would undergo pyroptosis in response to caspase-11 
activation during B. thailandensis infection.   
First, we wanted to compare macrophage and neutrophil responsiveness to NLRC4 and 
caspase-11 agonists. To activate NLRC4, we treated BMM and bone marrow neutrophils with 
the well characterized NLRC4 agonist PrgJ-Tox112. To activate caspase-11, we transfected LPS 
into the cytoplasm of the cells. Treatment with PrgJ-Tox and cytoplasmic LPS resulted in 
gasdermin D cleavage in both macrophages and neutrophils, showing that both NLRC4 and 
caspase-11 activation produce active gasdermin D (Figure 14A-B). Caspase-11 activation with 
cytoplasmic LPS induced caspase-11-dependent cell death as well as IL-1b release in both 
macrophages and neutrophils (Figure 14C-D, G-H). It is worth noting that while we did not 
observe significant cleavage of caspase-11 by western blot, we have historically found western 
blots to be an unreliable way to evaluate caspase-11 activation compared to the downstream 
effects of caspase-11 activation like pyroptosis or gasdermin D cleavage113. In contrast to 
caspase-11 activation, while NLRC4 activation with PrgJ-Tox induced release of IL-1b from 
both macrophages and neutrophils, NLRC4 activation induced significant levels of cell death in 
macrophages, but not in neutrophils (Figure 14E-F, I-J).  
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We next wanted to evaluate inflammasome responses of neutrophils to B. thailandensis 
infection in vitro. We infected neutrophils from WT, Casp1–/– and Casp11–/– mice with B. 
thailandensis. Consistent with our data with PrgJ-Tox and cytoplasmic LPS, WT, Casp1–/–, and 
Casp11–/– neutrophils all exhibited comparable levels of gasdermin D cleavage, demonstrating 
that caspase-1 and caspase-11 are both sufficient to activate gasdermin D in response to B. 
thailandensis (Figure 15A). As expected, release of IL-1b depended on caspase-1, but not 
caspase-11 (Figure 15B), consistent with NLRC4 being sufficient to drive caspase-1 activation. 
However, neutrophil cytotoxicity in response to B. thailandensis depended only on caspase-11 
(Figure 15C), suggesting that NLRC4 activation of caspase-1 is insufficient to cause pyroptosis. 
This is the opposite of what we observed in macrophages, where caspase-1 was more efficient at 
causing gasdermin D cleavage and cell death in response to B. thailandensis (Figure 11A-B). 
These data agree with data from Chen et al. showing that NLRC4 activation triggers cytokine 
release but not pyroptosis in neutrophils32,111. However, unlike Chen et al., who found that 
caspase-1 inefficiently cleaved gasdermin D in neutrophils, we found that caspase-1 was 
similarly efficient as caspase-11 at cleaving gasdermin D in neutrophils, although we agree with 
Chen et al. that this did not result in pyroptosis111. This difference is likely attributable to PrgJ-
Tox and B. thailandensis being more efficient at delivering the NLRC4 agonists into the cytosol 
than transfection of flagellin using FuGene as performed by Chen et al. The mechanism whereby 
neutrophils survive the gasdermin D activation downstream of caspase-1 but not caspase-11 
remains to be elucidated. 
Finally, to assess the effect of inflammasome activation on the ability for neutrophils to 
harbor B. thailandensis, we infected neutrophils in vitro with B. thailandensis and examined 
bacterial recovery in the presence of extracellular membrane-impermeant kanamycin, which kills 
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extracellular bacteria as well as those trapped in pyroptotic cells with ruptured membranes. No 
bacteria were recovered from WT or Casp1–/– neutrophils, whereas Casp11–/– neutrophils had 
significant bacterial recovery (Figure 15D). This indicates that B. thailandensis can survive 
within Casp11–/– neutrophils in vitro. This also suggests that the proposed direct bactericidal 
activity of cleaved gasdermin D16,108, which forms robustly downstream of caspase-1 in these 
cells (Figure 15A), is insufficient to clear B. thailandensis, consistent with our in vivo data 
indicating that caspase-1 alone cannot clear B. thailandensis infection (Figure 12B, 12F 
comparing Casp1–/– to Casp11–/– mice).    
 
Neutrophil caspase-11 is essential for survival of mice infected with B. thailandensis 
Next, we examined the importance of neutrophil caspase-11 during B. thailandensis 
infection in vivo. To delete caspase-11 primarily in neutrophils while retaining it in most other 
cells, we crossed Casp11fl/fl mice with Mrp8 promoter-driven cre transgene mice. Mrp8-cre 
deletes model floxed genes at 80% efficiency in splenic, peripheral blood, and bone marrow 
neutrophils, while deleting at 0-20% efficiency in monocyte and macrophage populations114. 
Thus, Mrp8-cre has been used for neutrophil-specific deletions. In contrast, LysM-cre deletes in 
both macrophages and neutrophils114. Both Casp11fl/flMrp8-cre and Casp11fl/flLysM-cre mice 
were highly susceptible to B. thailandensis infection, showing bacterial burdens and survival 
kinetics that approached that of full body knockout controls (Figure 16A-C). This suggests that 
caspase-11 is absolutely essential in the neutrophil compartment. 
The caveat to drawing definitive conclusions from the use of Mrp8-cre mice is that this 
cre line also causes a relatively smaller 0-20% deletion in monocytes and macrophages114. To 
determine if a potential deletion of caspase-11 in 20% of macrophages could account for the 
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phenotypes observed in Casp11fl/flMrp8-cre mice, we created mixed bone marrow chimeras with 
a ratio of 20% of Casp11–/–: 80% WT bone marrow marked with CD45.2+ and CD45.1+, 
respectively. Maintenance of this ratio upon engraftment was verified by flow cytometry (Figure 
17). In these mice, 20% of both macrophages and neutrophils will be completely deficient in 
caspase-11 and therefore could serve as intracellular niches for B. thailandensis. Notably, after 
infection with B. thailandensis, bacterial burdens in these mice were comparable to those of 
control mice engrafted with 1% Casp1–/–: 99% WT bone marrow, and significantly lower than 
mice engrafted with 99% Casp11–/–: 1% WT bone marrow (Figure 16D-E). Thus, having 20% 
Casp11–/– monocytes and macrophages does not cause susceptibility to B. thailandensis 
infection, arguing that the phenotype of the Mrp8-cre mice cannot be attributed to deletion in the 
monocyte/macrophage compartments. We can also conclude that having 20% Casp11–/– 
neutrophils was not sufficient to cause susceptibility, suggesting that the immune system can 
overcome a relatively small fraction of susceptible cells that harbor the infection. In summary, 
deletion of Casp11 in Mrp8-cre marked cells, most of which are neutrophils, is sufficient to 
cause susceptibility to B. thailandensis infection. However, we do not exclude the possibility that 
deletion of Casp11 in other cell types could also be sufficient to cause susceptibility.   
Gasdermin D in neutrophils has recently been suggested to cause the formation of 
neutrophil extracellular traps (NETs)111,115. Typically, NET formation is dependent upon the 
activity of both the NADPH oxidase (which includes p47phox encoded by Ncf1) and neutrophil 
elastase (encoded by Elane), and in some cases myeloperoxidase (MPO). We therefore infected 
Elane–/–, Ncf1–/–, and Mpo–/– mice with B. thailandensis. Elane–/– mice remained fully resistant, 
whereas Ncf1–/– mice had lower bacterial burdens than Casp11–/– mice at both medium and high 
doses (Figure 16F-G). The Ncf1–/– results are in agreement with our previous observation that 
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Ncf1–/– mice succumbed to B. thailandensis infection significantly slower than Casp1–/–Casp11–/– 
mice (Ncf1–/– mice succumb between days 6-11, whereas Casp1–/–Casp11–/– mice succumb at 
day 2 to a 104 CFU challenge9). The phenotype in Ncf1–/– mice could be due to the role of p47phox 
in direct bactericidal activity via reactive oxygen species, or to its role in NETosis. Finally, Mpo–
/– mice remained fully resistant to infection (Figure 16H). Thus, the genes that are traditionally 
required for NET formation have weaker phenotypes than caspase-11.   
 
Discussion 
We identify a coordinated innate immune defense pathway whereby initial detection of B. 
thailandensis by the NLRC4 inflammasome activates caspase-1, resulting in IL-18 release, and 
also likely a modestly beneficial pyroptosis. These responses occur quickly, but alone are unable 
to clear the infection. Next, a variety of lymphocytes, primarily NK cells and T cells, respond to 
the IL-18 by secreting IFN-g, which is essential for defense. IFN-g is required to prime caspase-
11. Among caspase-11-responding cells, activation of caspase-11 in neutrophils is absolutely 
essential for defense. Caspase-11 activates the pyroptotic pore gasdermin D, which kills the 
infected neutrophil and removes an important intracellular niche for B. thailandensis.   
We demonstrate that NK cells are the largest population that produces IFN-g in this 
model. However, T cells also respond innately and produce IFN-g. This T cell population is a 
conglomeration of various T cells subset, likely including both innate T cells like gamma delta T 
cells and NK T cells, as well as possibly conventional T cells responsive to IL-18116. While 
ILC1s were not a major producer of IFN-g in this model likely owing to their small population in 
the spleen, it would be interesting to determine if resident ILC1s play a major role in other 
tissues where resident ILC1s are more prominent.  
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Why is the immune system organized in such a way that caspase-1 must respond first, 
then lymphocytes must assess the total caspase-1 response via monitoring for IL-18, and only 
then will the resulting IFN-g prime caspase-11? We propose that because caspase-11 detects 
LPS, a ubiquitous component of both commensal and pathogenic gram-negative bacteria, it is 
more prone to false positive responses than NLRC4, which more directly detects virulence in the 
form of T3SS activity. False positives can result in aberrant pyroptosis that is damaging to 
tissues and can lead to sepsis113,117,118. Therefore, caspase-11 is placed behind a priming firewall 
designed to only be opened only when the immune system has reason to “believe” that it is likely 
that a cytosol-invasive pathogen is present. This likelihood arises from detection of T3SS activity 
in the case of B. thailandensis, and the judgement is made by NK cells and T cells.  
Most work on inflammasomes has been done in macrophages. Indeed, despite the fact 
that neutrophils are quickly recruited in copious numbers to sites of early infection, it is unclear 
to what extent inflammasomes are activated in neutrophils or what role this activation could play 
in neutrophil function. We have now bridged that gap by characterizing the importance of the 
neutrophil caspase-11 inflammasome in vitro and in vivo. We show that NLRC4 activation fails 
to clear bacteria from neutrophils, whereas caspase-11 accomplishes this task with extreme 
efficiency. This leads us to ask: what is the benefit of having neutrophils not respond to NLRC4 
agonists with pyroptosis, and why would that be different with caspase-11? Furthermore, why 
would neutrophils use these inflammasomes in different ways compared to macrophages?  
As tissue resident sentinel cells, macrophages are the first responders to infection. 
Macrophages monitor for the activity of T3SS, and trigger pyroptosis to convert an infected cell 
into a pore-induced intracellular trap (PIT). We previously showed that this process does not kill 
the bacteria, but instead detains them within the remains of the pyroptotic macrophage while 
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simultaneously elaborating neutrophil chemoattractants. Neutrophils then efferocytose the PIT 
and the bacteria contained inside and kill the bacteria through the activity of potent microbicidal 
effectors like NADPH oxidase3. In this way, macrophages have the luxury of “passing the buck” 
to the neutrophil, a more bactericidal cell type. 
Neutrophils, however, may not have the luxury of passing a bacterium to another cell. 
Perhaps in most cases they do not need to do so. If a neutrophil encountered a T3SS positive 
bacterium, it should expect that it will phagocytose and kill the bacterium. If the neutrophil were 
instead to kill itself, the neutrophil might fail to kill the bacterium, especially if the bacterium 
was still extracellular. Thus, neutrophils might be best suited to continue to live and to fight 
against infection as long as the bacterium remains in the vacuole, which is the primary location 
for neutrophil bactericidal mechanisms. On the other hand, caspase-1-driven cytokine release 
would be beneficial, because a T3SS positive bacterium has a higher threat level and warrants 
recruitment of a greater inflammatory response.  
In contrast, what would happen to a neutrophil if bacteria escape into the cytosol? B. 
thailandensis escapes to the cytosol of most cells within 15 minutes101. Since most bactericidal 
activity of the neutrophil is directed at the vacuole, the event of cytosolic invasion may represent 
complete evasion of the neutrophil’s primary function. Hence, caspase-11-driven pyroptosis 
should be critical to deny cytosol-invasive bacteria a niche within neutrophils.   
One major outstanding question is if NLRC4 and caspase-1 activation are sufficient to 
produce significant levels of cleaved gasdermin D in neutrophils, why do neutrophils not 
undergo pyroptosis after caspase-1 activation? Chen et al. suggested that caspase-1 was unable to 
cleave sufficient amounts of gasdermin D in the neutrophil111. In contrast, we used more efficient 
means of NLRC4 agonist delivery, and we now observed robust caspase-1-dependent gasdermin 
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D cleavage, but this still failed to cause pyroptosis. The mechanism is likely explained by a 
recent publication, in which Karmakar et al. observed that NLRP3-driven caspase-1 activation 
did not result in significant accumulation of gasdermin D on the neutrophil plasma membrane, 
but instead gasdermin D accumulated on the membrane of azurophilic granules119. Likely, the 
large number of granules packed in each neutrophil could serve as a membrane sink for 
gasdermin D. During caspase-1 activation, the ASC speck usually forms perinuclearly120,121. 
Thus, gasdermin D cleaved at the ASC speck must diffuse from the perinuclear location to the 
outer membrane, and it would likely encounter and insert into granule membranes instead. One 
idea that is raised by gasdermin D pores inserting into neutrophil granules is the possibility that 
this could release granule bactericidal components to the cytosol, thereby killing cytosol-invasive 
bacteria119. However, in the case of B. thailandensis, our data show that this hypothetical 
mechanism is insufficient since caspase-1-sufficient Casp11–/– mice still succumb to infection. 
In contrast to caspase-1, Chen et al. and our data indicate that caspase-11 activation is 
sufficient to cause pyroptosis111. Karmarkar et al. did not study the localization of gasdermin D 
after caspase-11 activation; however, their model introduces concepts that may explain the 
difference. We speculate that caspase-11 can be activated more diffusely throughout the cell. 
This diffuse caspase-11 could cleave gasdermin D in closer proximity to the plasma membrane. 
The resulting plasma membrane pores would be more likely to cause neutrophil pyroptosis. This 
hypothesis will be explored in future work.  
In summary, our work describes how a single pathogen, B. thailandensis, can be detected 
by apparently redundant inflammasome pathways. However, these pathways are deployed 
differentially in macrophages compared to neutrophils. This must be driven by the different 
cellular characteristics and immunologic functions of the macrophage as compared to the 
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neutrophil. This study illustrates the importance of studying inflammasomes in vivo where 
complex cellular interactions occur.  
 
Methods 
Data and code availability: Source data for Supplemental Figure 1 is available through 
the Immunological Genome Project (immgen.org) and can be accessed by searching through the 
microarray database for IL18R (probe set ID 10345807) and IL18RAP (probe set ID 10345824). 
 
Mice  
Wild type (WT) C57BL/6 (Jackson Laboratory), Casp1–/– 28, Nlrc4–/–Asc–/– 8, Casp11–/– 
122, Casp1–/–Casp11129mut/129mut referred to as Casp1–/–Casp11–/– 123, Elane–/– (Jackson # 006112), 
Mpo–/– (Jackson Laboratory # 004265), Ncf1mt/mt referred to as Ncf1–/– (Jackson # 004742), Prf1–
/– (Jackson # 002407), Rag1–/– (Jackson # 002216), Rag2–/–Il2rg–/– (Taconic # 4111), Gsdmd–/– 28, 
Ifng–/– (Jackson # 002287), Casp11fl/fl 124, Mrp8-cre (Jackson # 021614), and LysM-cre (Jackson 
# 004781) mice were used in this study. All mice were 6-12 weeks old, male or female, and 
housed under specific pathogen free condition facilities. All protocols were approved by the 
Institutional Animal Care and Use Committee at the University of Arkansas for medical Sciences 
at Little Rock, or Institutional Animal Care and Use Committee at the University of North 







In this study, we used a Burkholderia thailandensis strain that we previously passaged 
through Casp1–/–Casp11–/– mice (B. thailandensis, strain E264-1); this strain displays more 
synchronized infection kinetics than the parental E264 8. 
 
Primary cells 
Primary neutrophils were isolated from mouse bone marrow using Neutrophil Isolation 
Kit (Miltenyi Biotec) using manufacturer instruction. 
Bone marrow–derived macrophages (BMM) were prepared from the femur and tibia of mice by 
culturing with L929 cell supernatant for 7 day at 37oC, 5% CO2. 
 
METHOD DETAILS 
In vivo infections 
For all experiments, Burkholderia thailandesis were grown in Luria-Bertani medium 
(LB) overnight at 37°C. Bacteria were pelleted from 1 mL of culture and washed in PBS before 
inoculation to mice. Bacteria titer was determined by OD measurement at 600 nm and plating 
serial dilution on LB agar plates. For lethal challenge, mice were inoculated via the 
intraperitoneal (i.p.) route with the doses specified in the text. For bacterial burden 
measurements, spleens and livers were collected on day 1 when dose of infection used 2x107 
CFU, and on day 1 or 2 post-infection when dose of infection used was 104 CFU.  All organ 
harvested were homogenized in sterile PBS. Viable CFUs in homogenates were enumerated by 
plating serial dilutions on agar plates. At the same time of organ harvest, serum was collected 
from blood drawn by cardiac puncture for cytokines measurement. ELISA assays were 
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performed per manufacturer instructions to measure serum levels of mouse IL-18 (MBL 
International) and IFN-g (R&D Systems). Alternatively, in figure 2I, Rag1–/–, Rag2–/–Il2rg–/–, or 
Ifng–/– mice were infected i.p. with 2x106 CFU of B. thailandensis, and treated with recombinant 
murine IFN-g (0.5 mg/mice) at the time of infection and 24 hours post-infection. Bacterial 
burdens in organ homogenates were determined as described above. In Figure 2J-K, Rag1–/–
Il2rg–/– mice were adoptively treated (tail vain injection) at day -14 and -7 with 106 cells of IL-2-
expanded WT or Ifng–/– NK cells. Fourteen days after first adoptive transfer, mice were infected 
i.p. with 104 CFU of B. thailandensis. Bacterial burdens in organs homogenates were determined 
72 hours post-infection as described above. 
 
In vitro infection and analysis of inflammasome activation  
For in vitro infections, B. thailandensis grown as described above were pelleted from 
1mL of culture were opsonized with 50 µl of mouse sera for 30 min at 37°C and then suspended 
in 1 ml of DMEM. BMMs were prepared as described 37. For infections, macrophages were 
seeded into 96-well tissue culture treated plates at a density of 5x104 cells/well. Macrophages 
were primed with Pam3CSK4 (1 µg/ml) (InvivoGen) overnight. Bacteria were added to BMMs at 
MOI 50, centrifuged for 5 min at 300 g, and then incubated at 37°C for 1hr. After 1 hour, 
extracellular bacterial growth was stopped by addition of 300 µg/ml kanamycin and supernatant 
samples were collected at 3 hours. For neutrophil infections, bone marrow neutrophils (isolated 
using Neutrophil Isolation Kit (Miltenyi Biotec)) were seeded into 96-well tissue culture treated 
plates at a density of 4x105 cells/well. Neutrophil were primed with Pam3CSK4 (1 µg/ml) 
(InvivoGen) for 4 hours. Bacteria were added to BMMs at MOI 100, centrifuged for 5 min at 
300 g, and then incubated at 37°C for 1 hour. After 1 hour, extracellular bacterial growth was 
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stopped by addition of 300 µg/ml kanamycin, and CFU was determined at 5 hours. Alternatively, 
macrophages or neutrophils were primed with IFN-g (10 ng/ml, Peprotech) and ultra-pure LPS 
(50ng/ml) (E. coli O111:B4; InvivoGen) for 4 hours. Then, cells were treated with NLRC4 
agonist PrgJ-Tox112 (2 µg/well) or transfected with LPS (10 µg/ml) for 5 hours. Cytotoxicity was 
defined as the percentage of total lactate dehydrogenase released into the supernatant and was 
determined as described125. IL-1b secretion was determined by enzyme-linked immunosorbent 
assay (ELISA) (R&D Systems). Lysates and supernatants were combined and analyzed by 
Western blot for GSDMD activation (EPR19828; Abcam), caspase-1 activation (Casper-1; 
AdipoGen), caspase-11 (EPR18628; Abcam) and actin (ACTN05 (C4); Invitrogen) 
 
IFN-g intracellular cytokine staining  
WT C57BL/6 or Rag1–/– mice were infected with 2x107 CFU of B. thailandensis. Twelve 
hours later, mice were i.v. treated with 250 µg, i.v of brefledin A (Sigma-Aldrich) as previously 
described83 . Six hours later, mice were euthanized, spleens were harvested, and splenocytes 
were extracted by mechanical disruption. Red blood cells were lysed with ACK lysing buffer, 
and splenocytes were counted using a hemocytometer. 2x106 cells from each spleen were first 
stained with LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit (Thermo Fisher) followed by 
extracellular staining for 30 minutes at room temperature. Extracellular antibodies used include: 
Alexa Fluor (AF) 488 anti-CD127 (clone A7R34); Brilliant Violet (BV) 570 anti-CD3 (clone 
17A2); APC-Cy7 anti-CD45R (clone RA3-6B2); APC-Cy7 anti-Ly6G (clone 1A8); PE-Cy7 
anti-CD90.2 (clone 53-2.1); BV650 anti-NK1.1 (clone PK136); BV421 anti-TCR    (clone 
GL3). For analyzing the distribution of CD4 and CD8 T cells, a parallel aliquot of cells was 
stained using the same panel as above with AF594 anti-CD4 (clone GK1.5) and PE anti-CD8 
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(clone 53-6.7). Cells were then fixed and permeabilized with BD Cytofix/Cytoperm for 20 
minutes at 4oC before being stained with APC anti-IFN-γ (clone XMG1.2; BioLegend). Cells 
were washed, acquired on a BD LRSII (UNC Flow Cytometry Core Facility), and analyzed using 
FlowJo (TreeStar; version 9.9.6). All antibodies were purchased from BioLegend. Absolute 
counts were determined by multiplying frequencies of population of interest determined by flow 
cytometry with the total number of splenocytes collected as determined by hemocytometer. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
All statistics were performed using Prism 8 (GraphPad) using either two-way ANOVA 
followed by Sidak’s multiple comparison test, one way ANOVA followed by Tukey’s multiple 
comparison test, or Log-rank as specified in the figure legends. Number of mice used in each in 
vivo survival experiment are specified in Table 7. Flow data was analyzed using FlowJo 




Figure 6. NK 
cells, ILC1 cells, and activated T cells highly express IL-18 receptor components.  
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(A) IL-18 Receptor 1 expression based on data from the Immunological Genome Project 
(immgen.org; microarray probe set ID 10345807).  
(B) IL-18 Receptor Accessory Protein expression based on data from the Immunological 




Figure 7. Gating strategy and subset analysis of IFN-γ-producing cells during B. 
thailandensis infection.  
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Mice were infected i.p. with 2x107 CFU B. thailandensis for 12 hours then treated i.v. with 250 
ug of brefeldin A. Six hours later, splenocytes were collected (total 18 hours post-infection) and 
analyzed by flow cytometry using the schema showed in (A). Absolute counts of each subset 
population in the spleen were determined in uninfected and infected mice (B). ILC1 cells were 
defined as live CD45R–Ly6G–CD3– lymphocytes that were CD90+CD127+ within either the 
NK1.1+ or NK1.1– populations (C). The NK cells were defined as the remainder of NK1.1+ 
cells that were CD127–. Cell populations were analyzed to determine determined percent of all 
IFN-g- producing cells that were ILC1s or NK cells (D), as well as the absolute counts of IFN-g- 
producing ILC1s and NK cells (E). CD3+ T cells were also analyzed for CD4, CD8, and TCR- 
gamma delta expression on the using the gating strategy in (F). These cells were analyzed to 
determined percent (G) and absolute count (H) of IFN-γ-producing CD3+ T cells that expressed 





Figure 8. NK cells and T cells are the primary producers of IFN-g during B. thailandensis 
infection. 
Mice were infected i.p. with 2x107 CFU B. thailandensis, and 12 hours later treated i.v. with 250 
µg of brefeldin A. Six hours later, splenocytes were collected (total 18 hours post-infection). 
Ly6G–/CD45R– live cells were analyzed by flow cytometry for IFN-g+ production. A 
representative analysis is shown in (A). IFN-g+ subpopulations were analyzed for percent of total 
IFN-g+ cells (B) and absolute count (C).  
(D-E) Geometric mean fluorescent intensity (MFI) of IFN-g in IFN-g+ and IFN-g– NK1.1+ and 
CD3+ subsets were compared by two-way ANOVA. Sidak’s multiple comparison test was used 
for post-hoc pairwise comparison between MFI of NK1.1+ and CD3+ subsets from the same 
sample. Groups that do not share a letter are statistically different from each other with p ≤ 0.05. 
(F) Total spleen populations of NK1.1+ and CD3+ subsets were analyzed for percent that were 
IFN-g+.  
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Figure 9. Innate lymphocyte production of IFN-g is required for defense against B. 
thailandensis. 
(A–H) Mice were infected i.p. with the indicated dose of B. thailandensis. Survival was 
monitored (A, E), or mice were harvested one day post infection (p.i.) and bacterial burdens in 
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spleens (B, F) and livers (C, G) were determined, or serum IL-18 levels were determined by 
ELISA (D, H).  
(I) Mice were infected i.p. with 2x106 CFU B. thailandensis, and injected i.p. with PBS or 
recombinant mouse IFN-g (0.5 mg/dose) at 0 and 24 hours p.i. Splenic burdens were determined 
48 hours p.i. 
(J-K) Mice were adoptively treated with 106 NK cells at 14 and 7 days prior to infection with 104 
CFU B. thailandensis. Splenic burdens (J) and serum IFN-g levels, as determined by ELISA (K), 
were assessed day 3 p.i. 
All data are pooled from two experiments. Bar represents median. Dashed line indicates limit of 
detection. For number of mice in survival panel see Table 7. Survival curves were compared 
using Log-rank tests using Bonferroni-corrected threshold for statistical significance of p ≤ 
0.008. Bacterial burden and IFN-g levels were analyzed using one-way ANOVA followed by 
Tukey’s multiple comparisons test with a statistical threshold of p ≤ 0.05. Groups that do not 




Figure 10. NK and T cell response to B. thailandensis infection is independent of perforin.  
Mice were infected i.p. with 2x107 CFU B. thailandensis. We determined splenic bacterial 
burdens (A), and serum IFN-g levels by ELISA (B).  
All data are pooled from two experiments. Bar represents median. Dashed line indicates limit of 
detection. Bacterial burdens and IFN-g levels were analyzed using one-way ANOVA followed 
by Tukey’s multiple comparisons test with a statistical threshold of p ≤ 0.05. Groups that do not 





Figure 11. B. thailandensis induces gasdermin D-mediated pyroptosis and cytokine 
secretion in macrophages in vitro. 
(A-C) Pam3CSK4-primed BMMs were infected at MOI 50 for 4 hours. Gasdermin D (GSDMD) 
cleavage was determined by western blot (A), cytotoxicity was determined by LDH release assay 
(B), and IL-1b was determined by ELISA (C).  
Bar represents mean ± SEM.  Data are representative of three independent experiments. Data 
was analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test. Groups 




Figure 12. Gasdermin D is essential for defense against B. thailandensis in vivo. 
(A-C) Mice were infected i.p. with B. thailandensis at the indicated dose and survival was 
monitored.  
(D-G) Mice were infected i.p. with B. thailandensis at the indicated dose and bacterial burdens 
were determined in spleen or liver at the indicated time post-infection (p.i.).  
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(H-K) Mice were infected i.p. with 104 CFU B. thailandensis and bacterial burdens in the spleen 
were determined on the indicated days p.i (H, J). Serum IL-18 levels were determined by ELISA 
(I, K). 
All data for survival are pooled from three experiments and pooled from two experiments for 
bacterial burden analysis. Bar represents median. Dashed line indicates limit of detection. For 
number of mice in survival panel see Table 7. Survival curves were compared using Log-rank 
tests. Bonferroni-corrected thresholds for statistical significance were used (p ≤ 0.003 for A and 
B, p ≤ 0.017 for C). Bacterial burden and IL-18 levels were analyzed using one-way ANOVA 
followed by Tukey’s multiple comparisons test. Groups that do not share a letter are statistically 





Figure 13. MBL IL-18 ELISA kit is specific for cleaved IL-18.  
Pam3CSK4 primed BMMs were treated with NLRC4 agonist PrgJ-Tox (2 μg/well) for 4hours. 




Figure 14. Neutrophils undergo pyroptosis in response to caspase-11 agonists but not 
NLRC4 agonists. 
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(A-E) IFN-g/LPS-primed macrophages or neutrophils were treated with NLRC4 agonist PrgJ-
Tox (2 µg/well) or transfected by LPS (10 µg/ml) for 5 hours. Gasdermin D, caspase-1, and 
caspase-11 cleavage were determined by western blot in macrophages (A) and neutrophils (B). 
Cytotoxicity was determined by LDH release assay (C, E, G, I), and IL-1b release was 
determined by ELISA (D, F, H, J). Dashed line indicates limit of detection. Bar represents mean 
± SEM. Data are representative of three independent experiments. Cytotoxicity and IL-1b levels 
were analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test. Groups 
that do not share a letter are statistically different from each other with p ≤ 0.05. NT: No 







Figure 15. Neutrophils require caspase-11 to trigger pyroptosis and clear B. thailandensis 
infection in vitro. Pam3CSK4 primed Neutrophils were infected with B. thailandensis (Bt) at 
MOI 100 for 5 hours. Gasdermin D, caspase-1, and caspase-11 cleavage were determined by 
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western blot (A), IL-1b release was determined by ELISA (B), and cytotoxicity was determined 
by LDH release assay (C). 
(D). Neutrophils were infected at MOI 100 for 4 hours. After 1 hour, extracellular bacterial 
growth was stopped by addition of 500 µg/ml kanamycin and CFU was determined at 4 hours.  
Data are representative of three independent experiments. Bar represents mean ± SEM for (B-C), 
median for (D). IL-1b, cytotoxicity, and recovered CFUs were analyzed using one-way ANOVA 
followed by Tukey’s multiple comparisons test. Groups that do not share a letter are statistically 





Figure 16. Caspase-11 in neutrophils is essential to clear B. thailandensis infection in vivo.  
Mice were infected i.p. with 104 CFU B. thailandensis and survival was monitored (A).  
Bacterial burdens at three days post-infection (p.i.) were determined in spleen (B) and liver (C). 
Mrp8 littermate controls and LysM littermate controls consisted of Casp11+/fl Mrp8-cre and 
Casp11+/+ Mrp8-cre, and Casp11+/fl LysM-cre and Casp11+/+ LysM-cre, respectively.  
(D-E) Lethally irradiated mice were transferred CD45.1+ wild type and CD45.2+ Casp11–/– at the 
ratios indicated and allowed to engraft for 6 weeks. Mice were then infected i.p. with 104 CFU B. 
thailandensis, and splenic (D) and liver (E) bacterial burdens were determined three days p.i. 
(F-H) Mice were infected i.p. with B. thailandensis at the indicated doses, and splenic burdens 
were determined at the times p.i. indicated. 
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All data are pooled from two experiments. Bar represents median. Dashed line indicates limit of 
detection. For number of mice in survival panel see Table 7. Survival curves were compared 
using Log-rank tests using Bonferroni-corrected threshold for statistical significance of p ≤ 
0.005. Bacterial burdens were analyzed using one-way ANOVA followed by Tukey’s multiple 
comparisons test with a statistical threshold of p ≤ 0.05. Groups that do not share a letter are 




Figure 17. Ratios of bone marrow transplant was maintained after engraftment.  
(A) WT mice were lethally irradiated and transplanted with bone marrow from CD45.1+ WT 
mice and CD45.2+ Casp11–/– mice. After 6 weeks of engraftment, mice were infected i.p. with 
104 CFU B. thailandensis and harvested 3 days post-infection. Representative flow cytometry of 
splenocytes from these mice are shown. 
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Figure Mice Genotype n 
Fig.9A C57Bl/6 11 
 Ifng–/– 6 
 Rag1–/– 6 
 Rag2–/–Il2rg–/– 12 
Fig.9E C57Bl/6 9 
 Ifng–/– 6 
 Rag1–/– 6 
 Rag2–/–Il2rg–/– 11 
























Fig.12C C57Bl/6 7 
 Casp1–/–Casp11–/–  9 
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Casp11–/– 10 
 GsdmD–/– 9 
Fig. 16A Casp11+/+ or fl/+ Mrp8-cre 13 
 Casp11–/– 14 
 Casp11fl/fl Mrp8-cre 11 
 Casp11+/+ or fl/+ LysM-cre 8 
 Casp11fl/fl LysM-cre 11 
 
Table 7.  Numbers of mice used in survival experiments.
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CHAPTER 4: DEVELOPING A MOUSE MODEL TO EXPLORE CELL AND TISSUE-
SPECIFIC ROLES OF GASDERMIN D4 
 
Introduction 
Originally, inflammasomes were thought to be primary restricted to traditional immune 
cell types, most notably macrophages. Most experiments characterizing the function and activity 
of inflammasomes were performed using primary macrophages or monocyte/macrophage cell 
lines. However, recent studies have demonstrated the fallacy of restricting our understanding of 
inflammasomes to macrophages. Indeed, our studies using Burkholderia thailandensis described 
in Chapter 3 demonstrate that even within the immune compartment, inflammasomes and 
gasdermin D behave differently in neutrophils compared to macrophages8. In addition, others 
have demonstrated that inflammasome pathways can trigger pyroptosis of non-immune cells. For 
example, Rauch et al. demonstrated that caspase-1 and gasdermin D can trigger pyroptosis of 
intestinal epithelial cells28 while Mitchell et al. demonstrated that inflammasome activation 
within intestinal epithelial cells is sufficient to clear infection with Shigella in mice126. Similarly, 
inflammasome activation and gasdermin D-triggered pyroptosis in respiratory epithelial cells has 
been implicated in both infection and asthma127,128. 
 Given these diverse cell types and cell type-dependent responses to inflammasome 
activation, it becomes essential to have tools available to properly differentiate the contributions 
of inflammasomes within various cell compartments in vivo using mouse disease models. 
 
4Stephen Kovacs performed everything described once the mouse line was generated by UNC animal 
core. This data may be included in an eventual publication in which the final correct mice are generated 
and used in a disease model. 
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Therefore, the development of cell-specific knockout lines for components of these pathways 
and gasdermin D specifically is of high priority.  
The modern method to generate cell-specific knockout-ready mice is to use CRISPR to 
insert loxP sites surrounding genes or exons in the gene of interest. When these mice are then 
crossed with mice expressing Cre recombinase, the gene is either completely removed from Cre-
expressing cells or truncated to the point that the resulting transcript is nonfunctional and quickly 
degraded. Cre can be expressed under promotors functional only within the desired cell 
population, thereby giving cell specificity to the knockout.  
The utility of Cre-lox-based, cell-specific knockout models has been clearly 
demonstrated with our Mrp8-specific knockouts of caspase-11 used to evaluate the role of 
neutrophil caspase-11 during B. thailandensis infection as described in Chapter 3. To date, cell-
specific deletions of caspase-11and IL-1b have been published124,129. Cell-specific inducible 
expression of NLRC4 on a Nlrc4–/– background have also been published28. We sought to 
develop a mouse model for cell-specific deletions of gasdermin D to allow further 
characterization of this important protein in various infectious and inflammatory models.  
 
Generation of “knockout first” gasdermin D mouse line 
We purchased from European Mutant Mouse Repository (EuMMCR) C57BL/6 
embryonic stem cells in which the construct shown in Figure 18A replaced the wild type 
gasdermin D gene. The insertion of lacZ followed by a stop codon after exon 2 of gasdermin D 
leads to expression of a truncated gasdermin D with b-galactosidase (encoded by lacZ) attached 
at the end, resulting in a non-functional protein. Since this nonfunctional gasdermin D is not cell 
type-restricted, this genotype is considered “knockout first”. The UNC animal model core 
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verified the presence of the construct in the genome using Southern blotting (not shown), and 
then injected these embryonic stem cells into developing wild type embryos, which were then 
implanted into female mice. The resulting offspring were chimeras in which some cells were 
wild type and some contained our desired construct. F1 offspring with the desired construct were 
then bred to homozygosity.  
We verified the presence of the construct by performing PCR for the presence of the neo 
cassette. Similarly, primary macrophages obtained from mice homozygous for this construct 
resisted pyroptosis in response to nigericin (mouse 1 in Figure 18B), demonstrating that the 
resulting mice were “knockout first” as expected. However, we also attempted to validate the 
location of this insert using primers that spanned the wild type region of the genome and the 
construct insert; however, these attempts failed, suggesting that the chromosomal construct as 
predicted by EuMMCR may not have been precisely correct. More alarming, when we 
sequenced the region of the genome where the distal-most loxP site should have been, we could 
not identify a loxP sequence, instead our sequencing showed the normal chromosomal region 
where the loxP site should be located. Since the construct is introduced by two homologous 
recombination events, it was possible that only the main part of the construct (containing the neo 
cassette and lacZ followed by a stop codon, resulting in a nonfunctional, truncated gasdermin D) 
was successfully inserted into the genome, but this distal lox site was not. For this to occur, we 
think that it is possible that the first recombination event occurred upstream of the construct as 
intended, but that the second recombination event could have occurred within exon 3, thus 
omitting the introduction of the distal loxP site.  This is an error that would not have been 
detected by the animal core’s southern blotting due to the small size of the distal loxP insert. If 
this was indeed the case, then it would be impossible to generate the cell-specific knockout lines 
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desired with our current mice. However, it remained possible that the location of the distal lox 
site was merely incorrectly annotated, and that it was actually present somewhere else in the 
gene. If this were the case, we would be able to successfully generate the cell-specific knockouts 
by crossing with Cre mice. 
 
Attempt to generate the cell-specific knockout mouse for gasdermin D 
 To assess if the distal lox site was present but its precise location was misannotated, we 
decided to try to generate the cell-specific knockouts and phenotype our mice. First, we crossed 
the knockout first mice with mice constitutively expressing the recombinase flippase, which 
removes all the sequences between the two Frt sites (Figure 1A. Since the lacZ and neo cassettes, 
alongside their premature stop locations, are both removed, the full length gasdermin D can now 
be produced in all tissues regardless if the distal lox was present. 
 Since the flippase should have removed the lacZ and neo cassettes in all cells including 
germline cells, we next bred flippase out of the line. Then, we wanted to definitively identify if 
the distal lox site was present and the mice were indeed cell-specific knockout-ready as would be 
expected if the construct was correct. Therefore, we crossed these mice with Mrp8-cre and bred 
to homozygosity for the construct. The first round of breeding yielded one mouse that was 
homozygous for the Gsdmd construct and contained Mrp8-cre. We infected this resulting mouse 
with 5x104 CFU Burkholderia thailandensis and assessed bacterial burdens three days post-
infection. Given that Mrp8-specific deletion of caspase-11 resulted in susceptibility to B. 
thailandensis infection as shown in Chapter 3, a MRP8-specific deletion of gasdermin D would 
almost certainly also be susceptible to B. thailandensis infection; however, the tested mouse had 
completely cleared the infection, suggesting that these mice behaved like wild type mice and did 
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not have Mrp8-specific deletions of gasdermin D (not shown). Only a single mouse was tested, 
so this experiment should be repeated to validate these results. Nevertheless, this result supports 




 Generating a mouse model for cell-specific deletions of gasdermin D would be an 
important step for discriminating the cell-specific roles of gasdermin D in various disease 
models. Our results here suggest that we have successfully generated a mouse line with a lox site 
proximal to exon 3 of Gsdmd, but that the distal lox site required for making this line cell-
specific knockout-ready is missing. The next step should be correcting this error by performing 
CRISPR to restore the missing lox site through the mouse core. Since this would require only a 
single CRISPR recombination of a short sequence, correcting the construct in these mice would 
still be easier than starting from scratch and attempting to insert both proximal and distal lox 
sites. 
Methods 
Cytotoxicity assay:  Bone marrow–derived macrophages (BMM) were prepared from the femur 
and tibia of mice by culturing with L929 cell supernatant for 7 day at 37oC, 5% CO2. 5x104 
macrophages were plated into a 96 well plate. Macrophages were primed overnight with 50 
ng/mL of S. typhimurium LPS. Macrophages were then treated with 10 µM for 1 hour. 
Cytotoxicity was defined as the percentage of total lactate dehydrogenase released into the 




Figure 18. Creating a conditional KO mouse line for Gsdmd.  
(A) Expected Gsdmd–/– genotypes in the generated EuMMCR mouse line. 
(B) Percent lysis of LPS-primed primary macrophages from EuMMCR mice (mice 1-6) of 
unclear genotype and Casp1–/–-Casp11–/– and WT controls, as measured by LDH assay. 
(C) What we suspect the actual genotype of the EuMMCR mice to be. 
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CHAPTER 5: EXPLORATIONS INTO FUNCTION AND ACTIVATION MECHANISM 
OF GASDERMIN A5 
 
Introduction 
Gasdermin A is a member of the pore-forming gasdermin family whose expression is 
restricted to the epidermis of the skin and epithelial cells of the upper gastrointestinal tract40,42,43. 
Whereas humans only express a single form of gasdermin A, mice have triplicated the gene such 
that gasdermin A1 most closely resembles human gasdermin A by sequence and is expressed in 
both the skin and the stomach14,43-45, gasdermin A2 is restricted to the stomach40, and gasdermin 
A3 is restricted to the skin14,43,44,46,47. Similar to gasdermin D and gasdermin E, the N-terminal 
domains of both human and mouse gasdermin A can oligomerize, form pores, and trigger 
pyroptosis of cells15. 
Unlike for gasdermin D, neither the physiologic function nor activation mechanism of 
gasdermin A have been well characterized. However, several mutations within the C-terminal 
inhibitory domain of gasdermin A3 have been observed to cause autoactivation of the protein 
and lead to an inflammatory form of alopecia in mice that resembles the human disorder alopecia 
areata44,46-50. Thus, activation of gasdermin A likely promotes inflammation in the skin, though 
 
5Stephen Kovacs was involved in deciding all models tested. He performed the candidiasis and bullous pemphigoid 
mouse model experiments and all in vitro experiments exploring gasdermin A activation mechanisms. Dr. Ine 
Jorgenson bred Gsdma–/– mice to homozygosity. Dr. Helen Lazear performed the HSV model. Dr. Sanajay Sarkar 
from the lab of Dr. Mark Heise performed the CHIKV model. Susan Burette from the lab of Dr. Zhi Liu performed 
psoriasis and contact hypersensitivity models. Elena Mulligan and Susan Burette from the lab of Dr. Zhi Liu 
performed the atopic dermatitis model. Given the negative nature of most of the included data, it will likely be 
published as supplemental data to any publication from the Miao lab in which a phenotype for the Gsdma–/– is 
discovered. 
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what normally triggers activation of wild type gasdermin A nor the precise biochemical 
mechanism by which it is activated is known. SNPs within gasdermin A have also been 
associated with asthma in humans53, though the mechanism by which a protein with expression 
restricted to skin and the upper gastrointestinal tract could promote lung pathology remains 
unknown. 
We hypothesized that gasdermin A functions analogous to gasdermin D to trigger 
pyroptosis of epithelial cells and inflammation in the skin and upper gastrointestinal tract in 
defense against infections. We aimed to further characterize models in which wild type 
gasdermin A promotes inflammation either in defense against microbes or contributing 
pathology during autoimmune/autoinflammatory disorders using various mouse models. We then 
hoped to leverage such a model to complement in vitro experiments and ultimately characterize 
physiologic cleavers of gasdermin A in mice and humans. 
 
Generation of a gasdermin A triple knockout mouse  
To study the function of gasdermin A in various infectious and disease models, we 
developed C57BL/6 mice deficient in gasdermin A (Gsdma–/– mice) through the UNC Animal 
Models Core using CRISPR. Mice have triplicated gasdermin A compared to humans, so it is 
possible that these various gasdermin A proteins have some redundancy with each other or that 
the mouse gasdermin A proteins each have specialized to perform some of the functions 
performed by the single human gasdermin A. Therefore, we generated a triple knockout mouse 
line deficient in all forms of gasdermin A. However, it is possible that as the gasdermin A 
protein triplicated, the functions of each of these gasdermins diversified. In this case, gasdermin 
A1, the mouse gasdermin with most sequence homology with human gasdermin A, may be the 
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functional equivalent to human gasdermin A, and gasdermin A2 and A3, whose sequences have 
diverged more from human gasdermin A, may fulfill unique functions. As a result, using the 
triple knockout in disease models may risk identifying these potential “unique functions” of 
gasdermin A2 or A3 that may not be translatable to humans.  
Generating this triple knockout was facilitated by the fact that all three gasdermin A 
genes are adjacent to each other; therefore, only a single CRISPR deletion was required (Figure 
19A). Deficiency of gasdermin A expression was verified by western blot (Figure 19B). 
Interestingly, when performing these western blots, we observed three smaller bands in wild type 
mice in the range of 25-30 kDa. The commercial antibody used is raised against a peptide from 
the amino-terminal domain, thus this size range is approximately the expected size for the 
cleaved, active gasdermin A N-terminus. Two bands were predominantly within the PBS extract, 
which signifies the protein is mostly found in the cytosol. The third band was predominantly 
within the RIPA buffer extracts, which signifies the protein is mostly found in hydrophobic 
membrane compartments. These bands disappeared in the Gsdma–/– mice, suggesting that these 
bands are in fact derived from full length gasdermin A. However, if these bands in fact are 
gasdermin A, it is hard to determine if this cleavage signifies a basal level of cleavage of 
gasdermin A that occurs in normal skin, or if the creation of these fragments is an artifact 
resulting from the procedures used to process the tissue and extract proteins. 
We bred the Gsdma–/– mice in a specific pathogen free facility. The Gsdma–/– mice 
appeared grossly normal, displaying no sign of alopecia or developmental defects. Similarly, 
histology of ears from these mice demonstrated normal skin structure with no signs of 
inflammation (Figure 19C). These observations support the conclusion made by others that the 
Gsdma3 mutations that promote inflammation and alopecia are in fact auto-activating130,131. 
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Importantly, the lack of inflammation and the absence of spontaneous infections while in our 
breeding colony suggest that loss of gasdermin A does not inherently make mice extremely 
susceptible to infection from commensals or other potential pathogens commonly found in 
specific pathogen free mouse facilities. Thus, if gasdermin A plays an active immunologic role, 
then either gasdermin A is primarily involved in the defense against particular pathogens or 
under specific conditions (e.g. scratches that damage the cornified layer of the skin), or 
redundant immunologic mechanisms protect mice from the low inoculum of various bacteria that 
the mice encounter every day in our facilities.  
 
Evaluating the role of gasdermin A in infectious models  
To assess the role of gasdermin A in promoting defense against infection in skin akin to 
gasdermin D, we utilized several models of infections of the skin and upper gastrointestinal tract: 
 
Herpes Simplex Virus (HSV) 
 HSV is a DNA virus that initially infects the keratinocytes at the inoculation site, causing 
the formation of a characteristic lesion. It then travels retrograde through neurons until it reaches 
a sensory ganglion132. In humans, HSV can persist in the ganglion for a person’s life, 
occasionally traveling anterograde through the neurons’ axons to cause skin outbreaks132. In 
mice, this anterograde movement happens soon after infection, causing the formation of a lesion 
that can in its most severe form encompass the entire dermatome innervated by the infected 
neurons132,133. Since HSV is a prominent skin infection in both mice and humans that directly 
infects keratinocytes, the cell type expressing gasdermin A, we assessed the contribution of 
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gasdermin A to the defense in a mouse model of HSV in collaboration with the lab of Dr. Helen 
Lazear. 
 Dr. Lazear infected mice with HSV-1 strain NS (a low passage clinical variant) on 
depilated and scratched skin, and monitored these mice for 10 days for development and extent 
of skin lesions. Gsdma–/– mice failed to develop lesions, whereas WT mice transiently developed 
mild lesions and positive control Ifnlr1–/– developed severe lesions (Figure 20A). This data 
suggests that deficiency of gasdermin A does not lead to high susceptibility to HSV, unlike 
deficiency in interferon-lambda signaling; however, the strain of HSV used in this experiment 
tends to not to be highly virulent in C57BL/6 mice, and is more typically used in mouse models 
involving BALB/c mice. Indeed, few WT mice developed substantial lesions in this experiment, 
whereas WT BALB/c mice would typically develop more significant lesions. Thus, this 
experiment should be repeated using a strain of HSV that is better at infecting C57BL/6 mice, or 
a higher dose of viral inoculum, to explore the possibility that gasdermin A deficiency leads to a 
mild susceptibility. 
 
Chikungunya virus (CHIKV) 
 CHIKV is a positive sense RNA virus transmitted by mosquitos that causes flu-like 
symptoms and arthralgias134. After a mosquito bite, CHIKV is deposited within the skin, where it 
replicates within fibroblasts in the dermis, and then spreads systemically134. Since the skin is the 
initial replicative niche of CHIKV, we hypothesized that gasdermin A could induce 
inflammation to prevent systemic spread of CHIKV and thereby promote clearance. 
 To test this, we collaborated with the lab of Dr. Mark Heise to test the role of gasdermin 
A in a mouse model of CHIKV. These experiments were performed by Dr. Sanjay Sarkar, a 
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post-doc within Dr. Heise’s lab, using a protocol previously described135,136. Gsdma–/– mice 
phenocopied WT mice with similar kinetics of joint swelling, suggesting that gasdermin A does 
not play a significant role during CHIKV infection (Figure 20B). This result was perhaps not 
completely unexpected as the primary cell type within the skin infected by CHIKV is the dermal 
fibroblast whereas gasdermin A expression is restricted to the keratinocytes in the epidermis. 
Thus, any activation of gasdermin A would have necessitated an external signal to keratinocytes, 
whereas the paradigm established by other gasdermins is that gasdermins trigger pyroptosis 
within the cells that are infected. 
 
Candida albicans 
 C. albicans is a fungal yeast that causes multiple types of infections at the interface 
between oral thrush in immunocompromised patients or patients with recent antibiotic treatment, 
vaginal candidiasis, and dermatitis in infants. Others have previously implicated inflammasomes 
in the defense and pathology of infection by C. albicans137. Importantly, Hise et al. observed that 
IL-1R (the receptor for IL-1b, a cytokine released as a consequence of pyroptosis) promoted 
defense both locally in the oral cavity as well as systemically137. In contrast, caspase-1 promoted 
defense against systemic infection without significantly affected local oral burdens. We therefore 
hypothesized that while caspase-1 and gasdermin D primarily contribute to systemic defense, 
gasdermin A could fulfill a similar function at the local level by activating pyroptosis and 
mediating cytokine release at the initial site of infection.  
 To test our hypotheses, we utilized a mouse model of C. albicans previously described 
using both untreated and cortisone-treated mice138. Cortisone treatment makes wild type mice 
mildly immunocompromised and susceptible to thrush. This model is clinically relevant because 
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steroid treatment is a common predisposing factor to development of thrush in otherwise 
immunocompetent individuals. 
Contrary to our hypothesis, gasdermin A did not significantly affect local oral burdens of 
Candida. In the groups that did not receive cortisone treatment, Gsdma–/– mice completely 
cleared infection by day 5, while a couple of WT mice had mild burdens (Figure 20C). In 
cortisone-treated mice, WT and Gsdma–/– mice had similarly elevated burdens of C. albicans on 
the tongue (Figure 20C). Together, these data suggest that gasdermin A does not lead to an overt 
increase in local susceptibility to thrush. However, these results do not completely exclude the 
possibility that gasdermin A restricts local infection. Indeed, the burdens of C. albicans 
accumulating on the surface of the tongue (giving the white tongue appearance characteristic of 
thrush) likely overwhelm the number of yeasts that have locally invaded the tissue of the tongue. 
It remains possible that gasdermin A could reduce the local invasion without affecting surface 
yeast burdens. Future experiments could incorporate histology with staining for C. albicans to 
definitively explore this possibility. 
 Intriguingly, when looking for systemic spread, both Gsdma–/– mice treated with 
cortisone had about a log elevated number of C. albicans in the liver compared with cortisone-
treated WT mice that trended toward significance (p=0.08), despite having comparable levels of 
burden on the tongue (Figure 20C). These results suggest the possibility that gasdermin A could 
actually contribute to the prevention of systemic spread of the yeast, and increasing the sample 
size may allow a significant difference to be observed. While the relatively low burdens in the 
liver and the fact that elevated burdens within the kidney make this possibility less likely, a 
barrier defect caused by loss of gasdermin A in the presence of an otherwise intact systemic 
immune system could mean that kinetics of infection may be slow, at least initially. Thus, it may 
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be worth repeating this experiment with a larger sample size, as well as extending the timepoints 
being observed beyond the five days used here. 
 
Evaluating the role of gasdermin A in skin autoinflammation models 
While our primary hypothesis was that gasdermin A promoted inflammation in the skin 
to defend against infections, this inflammation could also have the potential of damaging host 
tissue. Indeed, this potential is most clearly demonstrated by the autoactivating mutations of 
gasdermin A3 that cause inflammatory alopecia in mice44,46-50. Thus, we hypothesized that 
aberrant activation of gasdermin A could contribute to common skin inflammatory conditions. 
Identification of such a condition involving wild type gasdermin A could provide an alternative 




 Bullous pemphigoid (BP) is an autoimmune disorder characterized by the formation of 
tense, fluid-filled blisters on the skin of patients. BP typically develops in elderly patients, and is 
the most common autoimmune blistering disorder139. BP is driven by autoantibodies targeting 
BP180, a component of the hemidesmosomes that attach basal keratinocytes to the basement 
membrane and anchor the epidermis to the dermis140. Accumulation of antibodies on the 
basement membranes leads to complement fixation, ultimately recruiting neutrophils that release 
proteases that directly cleave BP180 as well as other components of the hemidesmosome141-144. 
The destruction of hemidesmosomes leads to separation of the epidermis from the dermis and the 
formation of blisters. One of the primary functions of gasdermin D is to promote neutrophil 
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recruitment through the release of IL-1b and DAMPs. Therefore, if gasdermin A functioned 
analogous to gasdermin D within keratinocytes, the target cell of the BP antibodies, then we 
hypothesized that gasdermin A may promote neutrophil recruitment and ultimately contribute to 
BP pathology. 
 To test this hypothesis, we utilized a mouse model for BP developed by Dr. Zhi Liu145,146. 
In this model, we intradermally inject polyclonal pathogenic anti-mouse BP180 antibody into the 
ears of adult mice, and 24 hours later assess inflammation and blister formation by histology. 
This model likely represents the pathogenesis of an acute outbreak of BP. Initial experiments 
using our Gsdma–/– mice in the BP model were promising: Gsdma–/– mice lacked disease 
pathology and had lower levels of IL-1b in the ears compared to wild type mice, consistent with 
gasdermin A promoting inflammation and pathology in the BP model (Figure 21A, B, D). 
Furthermore, pathology could be restored by intradermally injecting IL-1b alongside the 
pathogenic antibody (Figure 21C). However, attempts to use pathogenic antibodies generated in 
different rabbits as well as more recent attempts to replicate the phenotype using the original 
batch of antibodies failed (Figure 21E, F). We did not repeat assessments of IL-1b levels given 
the lack of significant difference in pathology and low supplies of pathogenic antibody.  
Why we previously observed a significant phenotype using the Gsdma–/– mice but no 
longer observed one remains an unanswered question. Furthermore, inflammation appeared more 
severe in all samples (both WT and Gsdma–/–) in 2020 compared to 2016, with markedly 
increased neutrophil infiltrate visible on H&E (Figure 21E, F). The reason for this change 
between the experiments performed several years apart remains unclear. Regardless, this data 
suggests that if gasdermin A does in fact play a role in BP pathology, its role is likely mild, and 
that alternative mechanisms may compensate for any role gasdermin A plays. 
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Atopic dermatitis  
 Atopic dermatitis is a common Th2-mediated skin disorder in which the skin becomes 
itchy and a characteristic rash forms. We next tested the role of gasdermin A as well as 
gasdermin D in atopic dermatitis using a previously characterized mouse model of atopic 
dermatitis in which mice are treated with the vitamin D-derivative MC903147. However, we 




 Psoriasis is a Th17-mediated skin disorder characterized by the development of skin 
rashes. We tested the potential role of gasdermin A in psoriasis using a well characterized model 
of psoriasis in which we treat the backs and ears of mice with the TLR7 agonist imiquimod. 
While we potentially observed a small decrease in redness in Gsdma–/– mice compared to WT 
mice, the fact that this difference was small and that there were no significant differences in 
either scaliness or ear thickness suggests that any contribution by gasdermin A to psoriasis 
pathology is likely minimal (Figure 22D-F). 
 
Contact hypersensitivity 
 The final skin disorder we tested was contact hypersensitivity, a skin allergy response to 
a sensitized allergen. To test the contribution of gasdermin A to contact hypersensitivity, we first 
sensitized mice to oxazolone by treatment on their backs, and then we challenged these mice five 
days later with oxazolone on their ears. However, we observed no significant difference in either 
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ear thickness or weight between Gsdma–/– and WT mice, suggesting that gasdermin A does not 
significantly contribute to contact hypersensitivity (Figure 22G-H). 
  
The search for the activation mechanism of gasdermin A 
Since all other known activation mechanisms of gasdermin family members involve 
cleavage of the linker by a protease, we reasoned that gasdermin A would similarly be activated 
by cleavage with a protease. Since mouse gasdermin A1 is most closely similar to human 
gasdermin A and therefore likely functions as its most direct ortholog, we focused on using 
mouse gasdermin A1 and human gasdermin A for screening for potential cleavers.  
 
Caspases 
Given that gasdermin D and gasdermin E are both activated by caspases (caspase-1 and -
3, respectively), we first focused on the potential ability for caspases to cleave gasdermin A. 
Indeed, as I discuss further in Chapter 6, Human gasdermin A and mouse gasdermin A1 have a 
conserved QASD motif that could serve as a caspase cleavage site within its linker region 
(Figure 23A red box). However, consistent with what others have observed, neither recombinant 
caspase-1 nor caspase-3 could cleave gasdermin A despite cleavage of other substrates (Figure 
23B).  
Since expression of caspase-14 is restricted to the skin in a similar manner as gasdermin 
A, caspase-14 is an intriguing candidate as a potential cleaver of gasdermin A148. However, the 
mechanism by which caspase-14 becomes activated remains unclear, and obtaining active 
caspase-14 is significantly more difficult than for other caspases. Indeed, while previous 
publications said that granzyme B cleaved caspase-14 into its active form, granzyme B did not 
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cleave mouse caspase-14 in my hands (data not shown) 148,149. To bypass this issue of how to 
obtain active caspase-14, we generated a caspase-14 construct with an artificial cleavage site for 
PreScission protease within the protein’s linker region (Figure 23C). The second obstacle to 
obtaining active caspase-14 is that under typical caspase activity assay conditions, cleaved 
caspase-14 has low activity. Instead, others have shown that high concentrations of salts (1.1-
1.3M sodium citrate) were required to see significant levels of caspase-14 activity149. Why such 
high salt concentration is required in vitro remains unknown, as no other caspase has this 
requirement for activity. Regardless, this high salt concentration also makes several of the more 
typical assays for assessing caspase-14 activity and cleavage capabilities more difficult (for 
example, the high salt concentration makes western blots difficult to run without dialysis of 
samples). Thus, further optimization needs to be completed in order to properly assess if caspase-
14 can cleave gasdermin A. 
 
Granzymes 
 Granzymes are serine proteases produced primarily by NK cells and CD8+ T cells150. 
While the function of granzyme B as a trigger for apoptosis is well known, the function of other 
granzymes are not as well understood150. With the recent discovery that granzyme A cleaves 
human gasdermin B to trigger pyroptosis68, we became intrigued by the possibility that granzyme 
A or another granzyme could cleave gasdermin A. However, while granzyme A did successfully 
cleave gasdermin A, the resulting small fragment indicates that granzyme A cleaves gasdermin A 
within the N-terminal domain, which would likely be deactivating (Figure 23D). Granzymes B 
and K failed to cleave gasdermin A despite cleaving other known control substrates (caspase-7 
for granzyme B, SET for granzyme K; Figure 23D-E).  
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Trypsin-like proteases 
Trypsin-like proteases are serine proteases that cleave after positively charged residues, 
and gasdermin A has several conserved lysines within its linker region (Figure 23 A blue boxes) 
150. To test for cleavage of gasdermin A by trypsin-like proteases, we used human recombinant 
mast cell tryptase as a representative protease for this family. However, while tryptase 
successfully cleaved its fluorogenic substrate N-benzoyl-Phe-Val-Arg-p-nitroanilide (assessed 
by increased absorption at 405 nm; not shown), it could not cleave gasdermin A (Figure 23F).   
 
Chymotrypsin-like proteases 
Chymotrypsin-like proteases are serine proteases that tend to cleave after large aromatic 
residues (tryptophan, phenylalanine) or leucine150, of which there are several in the linker region 
of gasdermin A (Figure 23A yellow boxes). Mast cells and the mast cell protease MCPT4 have 
been implicated in the pathology of the murine BP model by Dr. Liu’s lab151. To test the 
cleavage potential by this family, we used recombinant human mast cell chymase (which is 
considered the functional homolog of murine MCPT4) as a representative protease for this 
family. Intriguingly, we observed significant cleavage of all gasdermin A proteins from mouse 
and humans yielding fragments approximately the expected size of active N-terminal domains 
(perhaps a kDa or two smaller than expected, but within the margin of error of reading a western 
blot and which may yield an active N-terminal domain even if it is a little short; Figure 24A-D). 
In contrast, chymase cleaves gasdermins B and D within their N-terminal domain, which is likely 
inactivating and suggests specificity for cleaving gasdermin A (Figure 24E-F).  
However, when performing protein transfections of chymase into HEK293T cells that 
express the various gasdermin A proteins, we could not trigger gasdermin A-specific cytotoxicity 
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prior to achieving levels of chymase that were cytotoxic to cells. This result suggests that even if 
the cleaved fragment is capable of forming pores, it may require concentrations of chymase that 
are in themselves cytotoxic, which would appear to defeat the purpose of activating gasdermin 
A. Chymase and MCPT4 have been published to cause significant skin edema when 
intradermally injected into the ear of BALB/c mice152,153. In contrast, when we performed this 
injection into the ears of C57BL/6 wild type mice, we did not observe significant edema (as 
determined by weight of standardized area of ear) or gross inflammation, which suggests that 
extracellular chymase may have difficulty in entering the cells in sufficient enough concentration 
to trigger gasdermin A activation (data not shown). Finally, this proposed mechanism lacks 
specificity to target only the subset of cells that would need to undergo pyroptosis, which is 
contrary to the paradigm established by activation mechanisms of other gasdermins. This 
specificity is currently a hallmark of gasdermin activation, and is important since aberrant 
activation can lead to significant tissue damage. Thus, while our in vitro data suggests that 
chymase can cleave gasdermin A to perhaps produce pore-forming fragments (though their pore-
forming capabilities were never assessed), we do not believe that chymase is the physiological 
cleaver of gasdermin A. It remains possible that during BP, human chymase or murine MCP-4 
might enter keratinocytes by unknown mechanisms and thereby activate gasdermin A, resulting 
in skin pathology. Note that this pathway would represent pathologic activation of gasdermin A, 
which may be different from the evolved mechanism to activate gasdermin A to defend against 
keratinocyte infection.  However, since the in vivo BP model in Gsdma–/– mice was not 
reproducible, this line of investigation was not continued in this thesis research. 
 Our results do suggest the possibility that another chymotrypsin-like protease may be the 
cleaver. However, at least one other chymotrypsin-like protease found in the skin, KLK7154, 
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could not cleave gasdermin A despite being capable of cleaving gasdermin D to a size that could 
be an active fragment (Figure 24G-H). Thus, the search for the identity of a chymotrypsin-like 




The immune system plays several indispensable roles in the skin. First, it prevents local 
infection. Second, since the skin forms one of the primary interfaces between the body and the 
external environment and therefore can serve as the entryway for microbes, immune responses in 
the skin prevents the systemic spread of many potential pathogens. Finally, since the skin houses 
many commensals that can actually be beneficial to the host, immunity of the skin must 
discriminate between these commensals and potentially pathogenic and invasive microbes. 
Historically, keratinocytes were considered to play a relatively passive role in immunity, 
providing the structural barrier via epithelial layer and the overlying cornified layer of dead 
keratinocytes. However, more recently, their active roles in immunology have been appreciated 
via the release of cytokines, chemokines, DAMPs, and anti-microbial peptides.  
Gasdermin A likely fits in this same paradigm as another mechanism by which 
keratinocytes can actively promote inflammation, as auto-activating mutations in Gsdma3 that 
lead to massive alopecia demonstrate the profound potential for gasdermin A to trigger 
inflammation and pathology of the skin. How might gasdermin A promote immunity and 
inflammation? Just as gasdermin D and E trigger pyroptosis in the cells they are expressed in, 
Gasdermin A may trigger pyroptosis of keratinocytes. Furthermore, regardless of whether or not 
gasdermin A triggers keratinocyte pyroptosis, gasdermin A could mediate release of DAMPs as 
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well as IL-1 family cytokines within the cytosol of keratinocytes simply by forming pores. 
Notably, keratinocytes constitutively produce IL-1a, which promotes Th1/17 type inflammation, 
IL-18, which promotes Th1 type inflammation, and IL-33, which promotes Th2 type 
inflammation, all of which require pore formation or cell damage for release110,155. These IL-1 
family cytokines could be released by non-programmed cellular lysis, or might be released by 
programmed opening of the gasdermin A pore. 
Despite gasdermin A’s clear potential for causing inflammation, our studies did not 
identify a mouse model in which gasdermin A played a prominent role. Future studies could 
continue our targeted screening using potential pathogens. Since we know that gasdermins and 
pyroptosis generally defend against intracellular infection, of most interest would be assessing 
the role of gasdermin A during skin infection with Staphylococcus aureus, one of the most 
prominent bacterial skin pathogens and one of the few bacteria documented to potentially enter 
keratinocytes and for which epicutaneous infection models have been described156-158, and viral 
pathogens. Viral pathogens of note to test include using an optimized protocol for HSV (e.g. a 
strain of HSV that is more virulent in C57BL/6 mice), human papillomavirus (a prominent skin 
pathogen that causes warts for which model viruses that infect mice are available)159, and 
vaccinia (a well-established model for poxvirus family of viruses that cause prominent skin 
infections such as smallpox or molluscum contagiosum)160. Other pathogens to consider are 
Pseudomonas aeruginosa (another prominent bacterial cause of skin infections), fungal 
pathogens (e.g. ring worms), and flaviviruses (which include arboviruses such as West Nile virus 
or Zika virus, and which usually locally infect keratinocytes at the site of the inoculating 
mosquito bite before spreading systemically)161,162.  
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All of our negative data do raise an important question: if the inflammation potential for 
gasdermin A is high, why is it so difficult to find an adequate model in which wild-type 
gasdermin A plays a prominent role? 
 One obvious possibility is that we merely chose the wrong type of models to test. Indeed, 
infections chosen were “true” pathogens. If gasdermin A is in fact important for skin immunity, 
then true pathogens may have developed mechanisms of avoiding gasdermin A activation or its 
effects. Thus, may need to find an environmental pathogen that would not have developed these 
avoidance mechanisms similar to how we used Burkholderia thailandensis to study 
inflammasomes. Furthermore, none of the infection models we performed involved bacteria. The 
skin models chosen have well established mechanisms for inducing inflammation, be it 
complement in the BP model or toll-like receptor activation in the psoriasis model, and with the 
exception of the BP model reflect more subacute or chronic pathologies (1-2 weeks+). 
Gasdermin A may play more of a role in acute pathologies similar to how other gasdermins 
primarily play prominent roles in the innate phase of immunity. 
 It also cannot be discounted that our lack of identification of a significant role for 
gasdermin A in any of our tested models could also reflect true characteristics of gasdermin A’s 
place in skin immunity. The skin is constantly in contact with microbes and microbial products, 
many of which have no significant pathogenic potential, as well as allergens. As the auto-
activating Gsdma3 mutations demonstrate, the potential for devastating consequences of errant 
gasdermin A activation is high. Therefore, the barrier for activation of gasdermin A may be 
particularly high, requiring specific signals to signify that gasdermin A could be detecting a true 
pathogen and to reduce the potential for false positives. As a consequence, the circumstances that 
activate gasdermin A may be more limited. Second, since the skin is such an important location 
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for stopping potential pathogens before they spread systemically, multiple redundant 
mechanisms may promote skin inflammation with similar kinetics. Indeed, damage to 
keratinocytes caused by the pathogens themselves could lead to the release of DAMPs, including 
IL-1a, which may reduce the need for a pore. Similarly, multiple cell types act as sentinels in the 
skin, including Langerhans cells, mast cells, and dendritic epithelial T cells163. Thus, knocking 
out gasdermin A may not have a significant impact on phenotypes or may result in milder 
phenotypes so long as the other redundant or compensatory mechanisms persist. The 
counterpoint to redundancy is the observation that the presence of a gasdermin A gene is highly 
conserved among mammals. Whereas other gasdermins may be lost, gasdermin A is not, 
suggesting that it is important and not merely redundant.  
 Our studies did not identify the physiological activator for gasdermin A. However, the 
identification of chymase as capable of cleaving gasdermin A suggests that testing other 
chymotrypsin-like proteases presents a potentially promising avenue for further exploration. 
Given the similar expression pattern of gasdermin A and caspase-14 and the precedence of 
gasdermins being activated by caspases, the potential for caspase-14 to cleave and activate 
gasdermin A should also be continued to be explored. Notably, human gasdermin A and mouse 
gasdermin A1 contain a conserved QASD within their linkers that could serve as potential 
caspase cleavage sites. In contrast, mouse gasdermins A2 and A3 do not contain this sequence or 
any other obvious potential caspase cleavage site, so their activation mechanisms likely do not 






Assessing gasdermin A in mouse skin: For each mouse, two ears were treated with 
liquid nitrogen and crushed using mortar/pestle. 200 uL of PBS with 1X protease inhibitor 
(Sigma; Cat#11836153001) was added to the powder, spun at 13,800 RPM for 10 minutes at 
4oC. The supernatant was taken for western blot, and the powder was washed twice with 500 uL 
of PBS with protease inhibitor. Finally, 200 uL of RIPA buffer with protease inhibitor was added 
to the powder, spun at 13,800 RPM for 10 minutes at 4oC. The supernatant was taken for western 
blot. Western blot was performed using anti-gasdermin A antibody (Santa Cruz; customized 




HSV: Mice were infected with HSV-1 strain NS (a low passage clinical variant) using a 
model previously described by others133. Briefly, mouse flanks were shaved and treated with 
Nair to remove overlying hair at the inoculation sites. The next day, 5x105 PFU of HSV in 10 uL 
of PBS was placed on the bare skin of the mice, and the inoculation sites were scratched 40 times 
with a 27G needle through the drop. The mice were then monitored and graded for 10 days for 
development and extent of the characteristic rash. 
CHIKV: CHIKV infections were performed as previously described135,136. Mice were 
injected with 100 PFU of CHIKV isolate SL15649 (a clinical isolate) in 10 uL of sterile PBS into 
the left rear footpad. Control mice were injected with 10 uL of sterile PBS without virus. Mice 
were monitored for 10 days post infection. Inflammation was measured by using calipers to 
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measure swelling of the ipsilateral footpad, normalized to initial caliper measurements on the day 
of infection. 
C. albicans: Oral infections with C. albicans were performed using a previously 
published protocol138. Briefly, for each genotype tested, we had two experimental groups: a 
cortisone-treated group and an untreated mice. Cortisone treatment makes the mice mildly 
immunocompromised and is required for the reliable development of thrush in wild type mice. 
Cortisone-treated mice were injected subcutaneously with 225 mg/kg of cortisone acetate 
starting one day prior to infection, and were given repeated doses every two days for the duration 
of the experiment. The inoculum was created by growing C. albicans strain SC5134 (wild type 
strain) in yeast extract-peptone-dextrose (YPD) media at 30oC overnight, and soaking a calcium 
alginate swab in an HBSS solution containing 1x106 C. albicans/ml for 5 minutes. Mice were 
anesthetized with ketamine and xylazine, and the inoculation swabs were then placed under the 
tongues of the anesthetized mice for 90 minutes. Five days after infection, mice were euthanized. 
Tongue, esophagus, liver, and kidney were harvested and evaluated for CFUs by spot dilution 
plating. 
Skin inflammation models: 
Bullous pemphigoid: The BP model was performed using pathogenic antibodies against 
mouse NC16A component of BP180, as previously characterized. 20 uL of titrated pathogenic 
antibody were injected intradermally into the ears of 8-12 week old mice. After 24 hours, mice 
were euthanized. For histology, ears were frozen in OCT, and sectioned and stained for H&E by 
the UNC dermatology pathology core. In parallel experiments, to assess IL-1b levels within the 
ear, we injected 100 uL of PBS into the ears and then removed this volume after one minute to 
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generate a “PBS wash” of the ear’s interstitium. We then assessed IL-1b levels in the PBS wash 
by ELISA.  
Atopic dermatitis: The MC903 model of atopic dermatitis was performed as previously 
described147. Briefly, the ears of mice were treated with 90 uM of MC903 in ethanol every day 
for 16 days. Clinical scores for redness and scaliness were assessed daily, and ear thickness was 
measured using a caliper on days 5, 12, and 16. 
Psoriasis: Mice 6-8 weeks of age receive daily topical dose of 62.5 mg (2.125 mg each 
day) of either imiquimod cream (Aldara) or control vehicle cream on shaved back and right ear 
for 6-10 consecutive days. Erythema and scaling at treated sites were observed pre-treatment and 
every other day after treatment. Additionally, ear thickness was measured every other day using 
a caliper. On day 10, mice were euthanized. Ears were frozen in OCT, and sectioned and stained 
for H&E by the UNC dermatology pathology core. 
Contact hypersensitivity: On day one, backs of mice were dilapidated using Nair. Mouse 
backs were treated with 100 uL of 3% oxazolone in ethanol. On day five, base ear thicknesses 
were measured using a caliper. Then, 100 uL of 3% oxazolone in ethanol was applied to the 
mouse ears. On day 6, ear thickness was measured using a caliper. In addition, mice were 
euthanized, and punch biopsies of uniform size of the ears were taken and weighed. 
Source of caspase-14 or gasdermin proteins: HEK293T cells transfected with plasmids 
expressing the various proteins were grown to confluence in 6 well plates and lysed with 200 uL 
of 1% IGEPAL. Lysates were spun 15,000 RPM on a tabletop minicentrifuge at 4oC for 10 





Caspase-1 and 3: HEK293T lysates containing myc-tagged bird or human gasdermin A, 
bird gasdermin E, or human gasdermin D were treated with 2 U of either recombinant active 
human caspase-1 (Sigma; Cat#CC126) or caspase-3 (Sigma; Cat#CC119) for 90 min at 37oC in 
buffer containing 50 mM HEPES, 3 mM EDTA, 150 mM NaCl, 0.005% Tween20, 5 mM DTT, 
pH7.44. Cleavage was evaluated by western blot. 
Caspase-14 cleavage by PreScission protease: Caspase-14 cloned with a PreScission 
protease cleavage site (LEVLFQGP) inserted into the linker region of caspase-14. HEK293T 
lysate containing this construct was treated with 4 U of PreScission protease (Sigma; Cat#GE27-
0843-01) for up to 20 minutes at 37oC in buffer containing 50 mM Tris•HCl, 150 mM NaCl, 1 
mM EDTA, pH 7.0. Cleavage was evaluated by western blot using anti-caspase-14 (CST; 
Cat#8519S).  
Granzyme A: Recombinant human granzyme A was first activated by treating 1.5 ug of 
granzyme A with 0.1 ug/mL of lysyl-endopeptidase in 0.05 M Tris, pH 9 buffer for 1 hour at 
37oC. 4 uL of 293T lysate containing the protein substrate of interest was then treated with 16 
ng/uL of granzyme A in 25 mM Tris, pH 8 buffer for a total reaction volume of 20 uL for 2 
hours at 37oC. 2 ug of recombinant SET protein was added in parallel reactions to serve as a 
positive control. 
Granzyme B: 4 uL of 293T lysate containing the protein substrates of interest were 
treated with 16 ng/uL of recombinant human granzyme B in PBS for a total reaction volume of 
20 uL for 2 hours at 37oC. Cleavage of caspase-7 endogenous to 293T lysate was used as a 
positive control. 
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Granzyme K: 4 uL of 293T lysate containing the protein substrates of interest were 
treated with 16 ng/uL of recombinant human granzyme K in buffer containing 20 mM Tris, 150 
mM NaCl, pH 8, for a total reaction volume of 20 uL for 2 hours at 37oC. 2 ug of recombinant 
SET protein was added in parallel reactions to serve as a positive control. 
Tryptase: 10 uL of 293T lysate containing the protein substrates of interest were treated 
with either 50 ng/uL or 0.5 ng/uL recombinant human tryptase (Millipore; Cat#650366) in buffer 
containing 12.5 mM Tris•HCl, 10 mM EDTA, pH 8 for a total reaction volume of 100 uL for 30 
or 90 minutes at RT.  
Chymase: 10 uL of 293T lysate containing the protein substrates of interest were treated 
with 1:10 serial concentrations of recombinant human chymase (highest concentration was 16 
ng/uL) in buffer containing 50 mM NaCl, 25 mM Tris, pH 7.4 for a total reaction volume of 100 
uL for 90 minutes at 37oC.  
KLK7:  Recombinant human KLK7 was first activated by treating 2 ug  of KLK7 with 20 
ug/ml of thermolysin in buffer containing 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.5% (v/v) 
Brij-35, pH 7.5 for 2 hours at 37oC. 10 uL of 293T lysate containing the protein substrates of 
interest were then treated with 1:10 serial dilutions of activated KLK7 (highest concentration 





Figure 19: Generation of Gsdma–/– mice. 
(A) Gsdma–/– mice deficient in all three gasdermin A genes was generated by CRISPR deletion 
at the arrows. 
(B) Western blot for gasdermin A of protein extracts of ears in PBS or RIPA buffer. FL is full 
length gasdermin A, cl? is potential cleaved bands of gasdermin A, and bt are background 
staining of endogenous biotinylated proteins. 
(C) H&E staining of section from ear of Gsdma–/– mouse. E = epidermis. D = dermis. C = 
cartilage. Arrow points to epidermal-dermal junction.
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Figure 20: Gasdermin A does not significantly contribute to defense in several infectious 
models.  
(A) Mice were infected with 5x105 PFU of HSV-1 strain NS on skin that was disrupted by 
needle abrasion, and evaluated for skin lesion formation on the indicated days post-infection. 
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(B) Mice were infected with 100 PFU of CHIKV isolate SL15649 by injection into left rear 
footpad. Swelling of ipsilateral footpad was measured daily and normalized to baseline 
measurements. 
(C) Mice were orally infected with 1x106 CFU of C. albicans strain SC5134, and burdens in the 




Figure 21: Gasdermin A likely does not significantly contribute to bullous pemphigoid 
pathology.  
Mice were injected intradermally in the ears with control or pathogenic antibody and evaluated 
24 hours post-treatment. (A-D) Initial experiments performed in 2016. H&E in WT (A), Gsdma–
/– (B), or Gsdma–/– mice treated with intradermal IL-1b alongside pathogenic antibody. IL-1b 
levels in PBS washout of ears were measured by ELISA and expressed as relative level to the 
average level in Gsdma–/– mice treated with pathogenic antibody. (E-F) Results from repeat 
experiment performed in 2020. E = epidermis. D = dermis. C = cartilage. B = blister. n = 
neutrophil infiltrate into blister fluid. 
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Figure 22: Gasdermin A does not significantly contribute to common skin pathology 
models. 
(A-C) Mouse ears were treated with 90 µM of MC903 to trigger development of atopic 
dermatitis. Redness (A) and scaliness (B) were evaluated daily on a scale of 0 (none), 1 (mild), 2 
(moderate), 3 (severe), and 4 (very severe). We measured ear thickness using a caliper on days 
indicated. 
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(D-E) Mice were treated daily with 2.125 mg of imiquimod to trigger development of psoriasis, 
and evaluated for redness (D), scaliness (E), and ear thickness (F).  
(G-H) Mice were treated with 4% oxazolone on their backs on day 1 followed by treatment of 
their ears on day 5 to trigger contact hypersensitivity. Change in ear thickness from day 5 prior to 
treatment (baseline) and day 6 (one day post-hypersensitivity challenge) (G) and weight of ear 
punch biopsies on day 6 (H) were measured. 
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Figure 23: Assessment of various proteases abilities to cleave gasdermin A. 
(A) Alignment of human and mouse gasdermin A proteins. Red box is potential caspase cleavage 
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 (B-F) Assessment of the indicated proteases to cleave gasdermin A (B-D, F) or SET (E). GzB = 
granzyme B. GzA = granzyme A. GzK = granzyme K. FL = full-length. CTD = C-terminal 
domain. Cl = cleaved fragment. CTD (L) = long fragment of CTD. CTD (S) = short fragment of 





Figure 24: Chymase specifically cleaves gasdermin A to yield fragments approximating the 
expected sizes for an activating cleavage.  
The indicated gasdermins were treated with human recombinate chymase (A-F) or KLK7 (E-F) 




























































































CHAPTER 6: MOLECULAR EVOLUTION OF THE GASDERMIN FAMILY6 
 
Introduction 
The gasdermin family consists of novel pore-forming proteins. The gasdermin family 
includes six members: gasdermin A, B, C, D, and E, and pejvakin. Recent interest in this family 
has been driven by the discovery that one member of this family, gasdermin D, was identified as 
the substrate for caspase-1 that directly mediates pyroptosis, a significant defense mechanism in 
innate immunity10-12. 
Gasdermins A-E each contain an N-terminal pore-forming domain that can oligomerize 
and form pores in plasma membranes, a C-terminal repressor domain that inhibits this 
oligomerization, and a linker that holds these two domains together15. Cleavage of the linker 
region allows the pore-forming domain to dissociate from the repressor domain and trigger 
pyroptosis. Activating proteases have been identified for human and mouse gasdermin D 
(caspase-1/11) and gasdermin E (caspase-3) and human gasdermin B (granzyme A), while the 
activation mechanisms for gasdermins A and C remain uncertain10-12,21,41,68. 
Pejvakin contains an N-terminal domain that is homologous to that of the other 
gasdermin family members, but has not yet been demonstrated to oligomerize and form pores. 
Furthermore, the C-terminal domain is notably shorter than that of other members of this family. 
 
6Stephen Kovacs performed all analyses discussed in this chapter. This data will form the basis of an 
eventual paper as first author. Other authors will include Dr. Cisse Ousmane, our collaborator from NIH 
who mentored Stephen on molecular evolution and performed some of the more advanced computational 
analyses, Dr. Edward Miao, and other lab members of the Miao lab who finish any remaining 
experiments. 
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It is believed that cysteines within this domain detect reactive oxidative species to activate the 
protein and promote replication of peroxisomes in response to redox stresses77,78. 
The gasdermin family is still actively evolving in mammals. Indeed, compared to 
humans, mice have lost gasdermin B, triplicated gasdermin A, and quadruplicated gasdermin C. 
Therefore, we sought to integrate molecular evolutionary analyses with what we already know 
about individual members of this family in an effort to obtain new insights into the function and 
activation mechanisms of gasdermins. Some insights into gasdermin roles across evolutionarily 
diverse species have recently been published. While mammalian caspase-1 can cleave gasdermin 
D but not gasdermin E, it was recently shown that gasdermin E in fish (which lack gasdermin D) 
is activated predominantly by the fish caspase-1 ortholog and, to a lesser degree, caspase-3 and -
710,164. Thus, the connections between caspases and gasdermins has changed over time. To this 
end, we have performed molecular evolution studies examining the evolution and co-evolution 
of the gasdermin and caspase families. In collaboration with the molecular evolutionist Dr. 
Ousmane Cisse at the National Institutes of Health, more thorough analyses are currently 
underway.   
 
Collection of sequences of gasdermin family for preliminary analyses 
 We first wanted to understand the general topography of gasdermin evolution to guide 
further analyses. Therefore, we sought to identify which major phylogenetic groups have 
gasdermin homologues by performing homology searches of the NCBI non-redundant protein 
database using HMMER on each member of the gasdermin family from humans.  
Using this methodology, gasdermin A could be identified in amphibians (specifically 
caecillians), reptiles, birds, and mammals, whereas gasdermins B, C, and D could only be 
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identified in mammals (with gasdermin D identified in monotremes, marsupials, and placentals 
and gasdermins B and C identified in marsupials and placentals). This suggests that gasdermin A 
arose prior to gasdermins B, C, and D, which arose from gene duplication events in mammals. 
Pejvakin was identified as far back as fish. Gasdermin E homologues could be identified as far 
back as cnidarians, mollusks, brachiopods, and lancelets by both us and other labs. Notably, 
cnidarian proteins were recently identified to function similar to gasdermin E165. This suggests 
that pejvakin emerged from the ancestor gasdermin E after fish diverged from lancelets.  
Gasdermin B interestingly had not only the fewest sequences, but also a large number 
designated as “low quality” or were only partial sequences. Low quality sequences are defined as 
those where the protein sequence was altered during annotation relative to the genome sequence 
in order to correct potential indels or other protein-altering mutations, accounting for the 
possibility that sequencing errors interrupted the coding sequence. Furthermore, the complete 
collection of gasdermin B genes had a relatively high frequency of gaps within their sequences. 
Together, these observations suggest that there may have been difficulty properly annotating 
gasdermin B sequences. However, gasdermin B is known to be absent in at least one species: 
Mus musculus (house mouse). Thus, it remains possible that gasdermin B’s evolution remains 
significantly in flux, and that it remains as one of the more expendable members of this family. 
Thus, the genomic sequences of the “low quality” reads may be correct, and represent gasdermin 
B genes that have been disrupted by mutation. A more thorough examination of the genome 
annotations will be necessarily to further explore these possibilities. 
The phylogenetically oldest species in which a possible gasdermin homologue could be 
identified by both us and Saeki et al. was Trichoplax adhaerens166; however, the current 
annotation of this hypothetical protein appears to be missing most of the gasdermin C-terminal 
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domain. Thus, given that gasdermin C-terminal domains function to inhibit lytic pore formation, 
if this gene is in fact a gasdermin ancestor, it may have a partial annotation such that the C-
terminal domain is not yet annotated, or the C-terminal domain may in fact be absent, which 
would suggest that the T. adhearens protein functions significantly differently than other 
gasdermins.  
Notably, there appears to be a phylogentic gap, where species that diverged after 
cnidarians but before mollusks/brachiopods lack gasdermin genes. This gap includes several 
well-studied and well-annotated genomes like Drosophila melanogaster and Caenorhibditis 
elegans. This gap could represent missed gene annotations, true losses of this gene (similar to the 
loss of NLRs in D. melanogaster and C. elegans), or significant evolution of the gasdermins that 
make it more difficult to identify genes by protein sequence homology167.  
 
Evolutionary relationship of gasdermin proteins 
 To allow for a more thorough evaluation of evolutionary relationships, we built a 
phylogenetic tree using PhyML maximum likelihood model from a pooled multiple sequence 
alignment of collected gasdermin sequences (performed in the software SeaView version 4.6). 
The sequences chosen for this preliminary tree were chosen by collected all annotated gasdermin 
A-E and pejvakin proteins and excluding all proteins annotated as “low quality” or “partial”. 
When multiple isoforms for a single gasdermin was predicted within a species, we chose the 
isoform that minimized insertions, deletions, and frameshifts compared to that of closely related 
species aligned using ClustalO. A complete list of proteins sequences used to generate this tree 
can be found in the Appendix. We used FigTree to visualize the generated tree (Figure 25). The 
tree generated correctly grouped gasdermins of a given type together, and tended to group the 
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same protein from similar phylogenetic groups together, suggesting that the overall tree 
topography was reliable.  
Given that cnidaria are the phylogenetically oldest organisms with an identified 
gasdermin that we are confident is complete (Trichoplax adhaerens was not included in this 
tree), we rooted the tree using these cnidarian gasdermins as the outgroup. However, this leads to 
a tree topography implying that gasdermin E and pejvakin together evolved separately from the 
remaining gasdermins, yet an ancient relative to those other gasdermins does not exist in the fish 
as the tree suggests it should. One possibility is that this topology is in fact correct, and that fish 
lost the ancient ancestor for gasdermin A-D. However, another possibility is an abrupt and large 
genetic change could have resulted in the generation of pejvakin. Generation of phylogenetic 
trees relies on the assumption that the molecular clock dictating the rate of accumulations of 
mutations in a given gene or protein is relatively constant; as a result, if an abrupt large change 
occurs like domain rearrangements or large insertions or deletions occur, the algorithms could 
produce trees with incorrect topology. Given that pejvakin is the only gasdermin protein with a 
C-terminal domain that is not homologous with the other family members, such an abrupt change 
to generate pejvakin from the ancient common ancestor to the gasdermin family seems likely.  
Consistent with the earliest phyla in which we could identify each gasdermin, gasdermin 
A first emerged from gasdermin E. The tree shows that gasdermin B emerged next, followed by 
gasdermin C and D.  
In the future, we will want to perform analyses that will better assess for violations of the 
molecular clock to assess for this possibility, as well as generate a tree that utilizes known 
timings for speciation events to place constraints on the tree and hopefully generate a tree with 
more accurate topology. 
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Assessing conservation of gasdermin cleavage and activation residues 
One potential utility of performing an extensive molecular evolutionary analysis is the 
ability to identify novel conserved residues that could play important roles in the proteins’ 
functions, and conversely, the ability to assess the conservation of purported important residues. 
Perhaps the most important residues to understanding and differentiating gasdermin function are 
those that form the activation sites of the proteins. We used the multisequence alignments for 
each gasdermin to assess conservation of residues involved in activation or identify potential 
activation sites. A full list of proteins for each family used in the sequence can be found in the 
Appendix. 
Gasdermin A: Gasdermin A has no known activation mechanism. We therefore aligned 
gasdermin A sequences with gasdermins with known cleavage sites (representative subset shown 
in Figure 26). Remarkably, when we aligned sequences for gasdermin A from bird species 
(which phylogenetically predate the emergence of gasdermin D) with other gasdermins, we 
observed that bird gasdermin A proteins had a sequence of YVAD (or similar) that aligned with 
the inferred gasdermin linker region. This is notable because YVAD is the prototypical caspase-1 
cleavage sequence, even used for the generation of caspase-1-specific inhibitors. Birds that did 
not have exactly a YVAD sequence, as well as amphibians and reptiles, generally contained 
variations of this tetrapeptide sequence with a bulky P4 and aspartate or (less commonly, 
glutamate) P1, consistent with common caspase-1 cleavage sites168. In contrast, mammals did not 
have this conserved sequence but instead had a nearby conserved QASD, which we and others 
have observed cannot be cleaved by either pyroptotic (caspase-1,4,11) and the primary apoptotic 
effector caspase, caspase-3 in humans and mice (Figure 23B) 15. These results suggest that 
caspase-1 may be the activator for gasdermin A in branches of the phylogeny that predate the 
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emergence of gasdermin D, including birds. If this is true, then caspase-1 has long been able to 
cleave some gasdermin, but which gasdermin family member is cleaved has changed over time. 
Indeed, consistent with this difference in activation mechanism of gasdermin A in 
amphibians/reptiles/birds versus that in mammals, these two types of gasdermin A proteins 
grouped separately on our phylogenetic tree, with mammalian gasdermins being significantly 
more conserved than in amphibians/reptiles/birds. 
Gasdermin B: Zhou et al. showed that granzyme A can cleave gasdermin B in the linker 
region after lysine (K) residues68. There are four lysines of note in the human gasdermin B linker 
region: K227, K229, K235, and K244. Among these, Zhou et al. identified K244 as the major 
cleavage site for gasdermin B by granzyme A, and K229 as the minor cleavage site. They 
showed that mutating both K244 and K229 completely abrogated gasdermin B cleavage by 
granzyme A. Generally speaking, K244 was well conserved; some species have the P1 K 
substituted with R, another residue after which granzyme A can cleave (Figure 27). The notable 
exception was marsupials, for which K244 equivalent was absent, though other lysines or 
arginines could be identified nearby with one in proximity to the location of K229 (aligning at 
228), but with different surrounding residues (Figure 27). Panganiban et al. have also proposed 
that caspase-1 can cleave human gasdermin B at D236 (with the tetrapeptide sequence EEKD), 
though others have observed that gasdermin B cannot be cleaved by caspase-1 15,169. This 
tetrapeptide residue sequence is moderately well conserved in most species except marsupials 
(Figure 27). 
Gasdermin C: Hou et al. proposed that caspase-8 cleaves human gasdermin C at D365 (in 
the tetrapeptide sequence LELD) 170. They performed a brief alignment with human sequences 
and several other mammals, and observed that these cleavage site is indeed conserved (albeit 
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several had a conserved substitution of D365E, and caspases generally cleave after D and only 
relatively rarely cleave after E). We too observe that this proposed cleavage site is conserved in a 
number of species; however, several species not included in the alignment shown by Hou et al. 
do not conserve this particular cleavage site (Figure 28). Notably, several rodents (including all 
four forms of gasdermin C in mice) do not have this cleavage site. However, a few of these 
species have nearby aspartates that could serve as potential cleavage sites. 
Gasdermin D: Caspase-1 cleaves and activates gasdermin D at D275 (in the tetrapeptide 
sequence FLTD) in humans and D276 (in the tetrapeptide sequence LLSD) in mice10-12. This 
cleavage site is well conserved in all species with gasdermin D (Figure 29).  
Gasdermin E: Two types of cleavage sites in gasdermin E have been identified by others, 
as can be visualized in Figure 30. First, caspase-3 cleaves and activates gasdermin E in humans 
at D270 (in the tetrapeptide sequence DMPD), which is broadly conserved in placental 
mammals21,41. This cleavage site was also more recently identified in cnidarian species165. 
Second, caspase-1/3/7 can cleave gasdermin E in fish (at D246 in the tetrapeptide FEVD in 
Cynoglossus semilaevis), with caspase-1 cleaving with the greatest efficiency164. Analysis of 
conservation of this site demonstrates that these two types of cleavage sites are conserved 
throughout their respective phylogenetic groups and otherwise mutually exclusive. Notably, the 
separation of activation mechanisms of caspase-1 and caspase-3 to different gasdermins also 
occurred at least once in fish, as zebrafish (Danio rerio) have duplicated gasdermin E to yield 
one that preserves the fish caspase cleavage site and can be activated by pyroptotic but not 
apoptotic caspases (Gsdmeb), and one with a unique cleavage site that can be activated by 
pyroptotic but not apoptotic caspases (Gsdmea) 41,171,172. However, this separation was the 
exception, as most fish had single gasdermin E proteins with the conserved caspase-1/3/7 
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cleavage site identified in Cynoglossus semilaevis. Finally, when aligning the sequences of 
gasdermin E from marsupials and monotremes (the oldest mammals), amphibians, reptiles, and 
birds, two conserved and overlapping potential cleavage sites (FHPDDAVD in chickens) align 
closely with cleavage sites in placental mammalian gasdermin E (Figure 30).  
Pejvakin: While pejvakin is not known to be activated by cleavage, two cysteines within 
its short C-terminal domain (C328 and C343 in both humans and mice) have been implicated in 
detecting reactive oxidative species (ROS), allowing pejvakin to activate in response to increased 
intracellular ROS to promote proliferation of peroxisomes and ultimately reduce ROS back to 
more manageable levels78. Consistent with their proposed importance in activation of pejvakin, 
both cysteines are well conserved throughout the phylogenetic tree (Figure 31). Conserved 
cysteines are notable in this region of pejvakin, forming a possible motif of CX2CX12CX2CX15C 
(Figure 31), where the last two cysteines in this string are the ones implicated in ROS sensing. 
 
Bird gasdermin A and E likely functionally mimic mammalian gasdermin D and E 
 The protease that can cleave and activate a gasdermin determines the pathways in which 
the gasdermin is involved. Given the fact that amphibian/reptile/bird gasdermin A have 
sequences within their linker region highly suggestive for being caspase-1 cleavage sites, we 
hypothesized that gasdermin A from these species may be cleaved and activated by caspase-1 to 
trigger cell lysis. Thus, while the primary sequence of gasdermin A from these organisms may 
more closely resemble mammalian gasdermin A, its function may more closely mimic that of 
mammalian gasdermin D. Furthermore, with the emergence of a second pyroptotic gasdermin, 
we hypothesized that the activation mechanisms of pyroptotic and apoptotic caspases could be 
separated to different gasdermins. Indeed, the fact that the gasdermin E cleavage site found in 
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most fish, which can be cleaved by both pyroptotic and apoptotic caspases, is not conserved 
beyond fish is consistent with this hypothesis. 
 To test these hypotheses, we purchased plasmids that express gasdermin A and 
gasdermin E from Corvus brachyrhynchos (American crow) generated using the predicted 
sequences based on current genome annotations. Corvus brachyrhynchos was chosen as the 
initial model organism because it was one of the birds with YVAD in the linker region (as 
opposed to one of the ones with conserved mutations), thereby making it more likely to be 
cleaved by human caspase-1.  
Consistent with our hypothesis, crow gasdermin A was cleaved by caspase-1 to yield a 
fragment in similar size to that produced by human gasdermin D cleavage by caspase-1, 
suggesting caspase-1 could cleave and activate crow gasdermin A (Figure 23B). Furthermore, 
human recombinant caspase-3 cleaved crow gasdermin E to yield fragments consistent with a 
cleavage of human gasdermin D by caspase-3 previously identified to be inactivating (Figure 
23B). In contrast, human gasdermin A completely resisted cleavage by either caspase-1 or -3 
(Figure 23B). Thus, the cleavage pattern of crow gasdermin A more closely matches that of 
human gasdermin D than human gasdermin A, suggesting that crow gasdermin A is functionally 
more similar to human gasdermin A. 
Recombinant human caspase-3 cleaved crow gasdermin E to produce the expected N-
terminal fragment, whereas crow gasdermin E completely resisted cleavage by caspase-1 (Figure 
23B). This cleavage pattern matches that of mammalian gasdermin E, again consistent with our 
hypotheses.  
It is notable that the loss of cross-species efficacy of the recombinant human caspases to 
cleave crow gasdermins was greater for caspase-1 than for caspase-3. This likely reflects the 
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further divergence of caspase-1 as it specialized to cleave gasdermin D. Indeed, whereas 
caspase-3 is well conserved between birds and mammals (63% identity and 74% similarity 
between chicken and human caspase-3), caspase-1 is less well conserved (42% identity and 52% 
similarity between chicken and human caspase-1).  
We next want to test cleavage of bird gasdermin A with bird caspase-1 to validate this 
observation, as well as assess lytic potential of any resulting cleaved fragments. To this end, we 
have obtained chicken macrophages and tissues from the lab of Dr. Luke Borst (North Carolina 
State University), and we have successfully cloned chicken caspase-1, caspase-3, and gasdermin 
E. Further, I have successfully PCR amplified chicken gasdermin A from the spleen, I have 
verified that the PCR product is gasdermin A by Sanger sequencing (performed by GeneWiz),  
and I am currently in the process of cloning this product. In addition, we want to generate 
gasdermin A and E with the hypothesized cleavage sites mutated to confirm cleavage locations. 
 
Discussion and future directions 
The gasdermin family contains pore-forming proteins that form an essential part of the 
innate immune system. While we are currently knowledgeable about a few of the gasdermins in 
mammals, much remains to be understood. With our initial studies here, we provide insights into 
this family that extend beyond mammalian gasdermins. In particular, our findings regarding bird 
gasdermins have potential utility for the agriculture industry as poultry is a major food source. 
Our data as well as others suggests that since the emergence of this family, there has been 
constant connection of traditional cell death pathways to gasdermin and gasdermin-mediated cell 
death. Importantly, with the discovery of bird gasdermin A being integrated with caspase-1 and 
inflammasome pathways, we fill an evolutionary gap. Our results suggest that since emergence 
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of caspase-1-like proteases in fish, there has been an uninterrupted connection of caspase-1 to 
gasdermins, even if the specific gasdermin connected with caspase-1 shifts between different 
gasdermin genes. Significantly, this suggests that caspase-1 did not merely evolve as a processor 
of IL-1 family cytokines, but functionally was likely involved in promoting pyroptotic cell death 
via cleavage of gasdermins from its inception. Consistent with this hypothesis, caspase-1 cannot 
cleave IL-1b in at least several species of fish173. 
Gasdermin E in fish, which phylogenetically predates the emergence of gasdermin A, 
was recently demonstrated to be activated by caspase-1, 3, and 7, suggesting that gasdermin E 
originally functioned as the convergence point downstream of both pyroptotic caspase and 
apoptotic caspase activation164. Our results now suggest that in birds, the development of 
gasdermin A coincided with the separation of activation of gasdermins by pyroptotic caspases 
(e.g. caspase-1) and apoptotic caspases (e.g. caspase-3), and this is likely true in both amphibians 
and reptiles as well given similarities in potential cleavage sites.  
The observation that there is always a gasdermin associated with inflammasome 
pathways also has implications for zoonotic infections. As our lab and others have demonstrated, 
many true intracellular pathogens require mechanisms for avoiding or inhibiting pyroptotic 
pathways to allow successful infection of a host. Thus, potential pathogens that evolve zoonotic 
hosts like birds must evolve to fight the pressures of gasdermin-mediated cell death. Even if the 
particulars of the gasdermins vary between species, the common origin of these pathways 
suggests that pathogens adapted to one host jumping to a new species is likely facilitated by the 
fact that these pathogens do not have to develop mechanisms for avoiding these pathways from 
scratch. Indeed, as our lab has demonstrated through the use of environmental pathogens like 
Burkholderia thailandensis (see Chapter 3) or Chromobacterium violaceum, microbes that 
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evolved outside of these hosts with no mechanism for avoiding gasdermin-mediated cell death, 
are quickly cleared by mammalian immune systems7,8. Of note, this has particular relevance for 
influenza, for which inflammasome activation has been implicated in the defense and for which a 
number of strains evolve in the context of birds prior to becoming infectious in humans174. 
With these preliminary molecular evolution analyses, we have demonstrated the utility of 
using such studies to analyze the gasdermin family. Both the large multisequence alignment of 
all currently identified gasdermins and the tree generation could serve as useful tools for both 
generating and supporting novel hypotheses, and for identifying and studying potentially 
important residues. Indeed, upon inspection of the multisequence alignment, we hypothesized 
that bird gasdermin A could be cleaved by caspase-1 and likely triggers pyroptosis in response to 
inflammasomes, a hypothesis that our subsequent in vitro studies now support and which has 
significant implications for bird immunity.  
Recently, Schutter et al. also generated and published their own phylogenetic tree of the 
gasdermin family using a similar algorithm as the tree we generated175. Similar to what we 
observed, the tree generated by Schutter et al. suggests that gasdermin E and pejvakin evolved 
separately from other gasdermins. Interestingly, the broad topology of Schutter et al.’s tree 
differs from our tree regarding the emergence of the mammalian gasdermins. While their tree 
agrees with ours that gasdermin A emerged prior to gasdermins B-D, their tree suggests that 
mammalian gasdermin A and gasdermin B evolved separately from gasdermin C and D, whereas 
the topology of our tree suggests a sequential emergence of A then B, followed by the emergence 
of C and D. Furthermore, the identification of gasdermin A in caecillians in our analyses, which 
are located at the base of the amphibian evolutionary tree, pushes the emergence of gasdermin A 
significantly earlier compared to what Schutter et al identified. 
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Schutter et al. also contend that the identified gasdermin D in platypus (a monotreme and 
the phylogenetically oldest mammal included in both our trees) aligned more closely with 
gasdermin A, and therefore suggested that platypuses lacked gasdermin D but instead had two 
gasdermin A-like proteins. However, platypus gasdermin D grouped more closely with 
gasdermin D while platypus gasdermin A grouped closely with mammalian gasdermin A. Given 
that platypus gasdermin D is located proximal to other genes located proximal to gasdermin D in 
other animals (eg Mroh6) and that the linker region contains the conserved gasdermin D 
cleavage site (which is absent in mammalian gasdermin A), it is likely that this gasdermin is in 
fact truly a gasdermin D.  
Finally, Schutter et al. contend that gasdermin B is completely lost in the branch that 
includes rabbits, rats, and mice. However, while no gasdermin B could be identified in NCBI 
annotations of both rabbits and most rodents, gasdermin B could be identified in at least two 
species of hamsters (Mesocricetus auratus and Cricetulus griseus), which would be located 
within this same branch, between rabbits and rats and mice (according to the mammalian tree of 
life176), suggesting that the possibility remains that gasdermin B could be present in other 
members of this branch. Thus, absence of the gene from current annotations, especially in lower 
quality annotations, should be interpreted carefully as to whether the genes are truly lost or if the 
genes are merely missing from current genome sequences or annotations.  
 Future molecular evolutionary analyses will first focus on performing more rigorous 
analyses of gasdermins from 38 representative organisms. Furthermore, we are reannotating 
genomes of non-model organisms (which tend to have less well-annotated gasdermins) from this 
list in which particular gasdermins are absent but present in related species, or which current 
annotations of the gasdermin is questionable. Using these sequences, we will assess residues for 
 141 
selection and generate a new tree using BEAST, which will enable us to use known speciation 
times to place constraints on the tree-making algorithm and should hopefully result in a more 
accurate tree. Finally, we will consider performing further analyses, such as assessing 
conservation of sites, to provide a more granular understanding of the evolution of these proteins. 
In addition to these evolutionary analyses on the gasdermin family, we will perform parallel 










Figure 25: Phylogenetic tree of gasdermin family. Identified gasdermins were aligned by 
ClustalO, a tree was built using a PhyML maximum likelihood model, and the tree was 
visualized using FigTree. The tree was rooted using cnidarian sequences as an outgroup. 
  
Monotremes Marsupials Placentals
Gsdma X X X X X X
Gsdmb X X
Gsdmc X X
Gsdmd X X X
Gsdme X X X X X X X X X X
Pjvk X X X X X X X X
Mammals







Figure 26: Sequence alignment of linker region of gasdermin A proteins. 
Collected gasdermin A sequences were aligned by ClustalO, representative sequences shown 
here. Alignment with gasdermin D with known caspase-1/4/5/11 cleavage site (red box) was 
used to aid in assessing for potential cleavage sites in gasdermin A. Aligned or nearby potential 
cleavage sites in gasdermin A shown in blue box. Nearby potential cleavage site experimentally 
shown not to be cleaved by caspase-1/3 shown in yellow box. 
 
 
Figure 27: Sequence alignment of linker region of gasdermin B proteins. 
Collected gasdermin B sequences were aligned by ClustalO, representative sequences shown 
here. Conserved residue aligned with lysine identified as major cleavage site for granzyme B 
shown in red box. Conserved residue aligned with lysine identified as minor cleavage site for 
granzyme B shown in red box. Site aligned with potential caspase-1 cleavage site identified in 



























































Figure 28: Sequence alignment of linker region of gasdermin C proteins. 
Collected gasdermin C sequences were aligned by ClustalO, representative sequences shown 




Figure 29: Sequence alignment of linker region of gasdermin D proteins. 
Collected gasdermin D sequences were aligned by ClustalO, representative sequences shown 
here. Residues aligned with known caspase-1/4/5/11 cleavage site in human and mouse 

















































































Figure 30: Sequence alignment of linker region of gasdermin E proteins. 
Collected gasdermin E sequences were aligned by ClustalO, representative sequences shown 
here. Residues aligned with known caspase-3 cleavage site in human and mouse gasdermin D 
shown in red box. Residues aligned with known caspase-1/3/7 cleavage site identified in the fish 
Cynoglossus semilaevis gasdermin E shown in green box. Likely caspase-3 cleavage site in 
Danio rerio (zebrafish) gasdermin Ea shown in blue. Potential caspase cleavage sites in 




















































































































Collected pejvakin sequences were aligned by ClustalO, representative sequences shown here. 




CHAPTER 7: CONCLUSIONS 
 
Inflammasomes and gasdermins together form an essential part of the innate immune 
system. When functioning correctly, they detect intracellular pathogens and promote pyroptosis 
and inflammation. For my dissertation, I have first undertaken granular studies to elucidate cell-
specific characteristics of inflammasome and gasdermins by studying their functions within 
neutrophils during Burkholderia thailandensis infection and by completing the initial steps for 
generating a cell-specific knockout mouse line for Gsdmd. I then attempted to expand our global 
understanding of the entire gasdermin family through my studies of gasdermin A and molecular 
evolution analyses of this essential family.  
 As we studied the role of inflammasomes and gasdermins in neutrophils, we observed 
that gasdermin D was cleaved and activated downstream of both caspase-1 and caspase-11 
pathways, but only gasdermin D cleaved by caspase-11 lead to pyroptosis, a stark contrast with 
macrophages in which gasdermin D cleaved by either caspase-1 and caspase-11 leads to 
pyroptosis. The fact that both caspase-1 and caspase-11 cleave gasdermin D at the same residues 
suggests the possibility that differences in the cellular characteristics contributing to differences 
in responses to inflammasome and gasdermin activation, such as the presence of granules or 
other organelles serving as gasdermin sinks. 
 Ultimately, when the behavior of a single gasdermin can vary based on the cell type in 
which it is being expressed, similar considerations must be made when studying other members 
of the gasdermin family. Indeed, each gasdermin has a specific expression pattern, meaning that 
 148 
each must deal with a different set of cell and tissue-specific characteristics that will influence 
the behavior of the gasdermin.  
For example, gasdermin A is predominantly expressed in keratinocytes within the skin. A 
keratinocyte is larger than most immune cells (meaning that the surface area-to-volume ratio is 
much smaller), and it has a scaffolding of cytokeratin intermediate filaments that provides 
increased mechanical strength to the cell177. Furthermore, as the keratinocyte differentiates and 
ultimately transitions into a corneocyte, its membrane composition shifts and stiffens as 
phospholipids and cholesterols are replaced by ceramides and saturated triglycerides178. Each of 
these unique characteristics could potentially affect the ability for gasdermin A to trigger cell 
lysis.  
At the tissue level, a keratinocyte is physically interlocked with surrounding 
keratinocytes via desmosomes, meaning neighboring cells constantly exert force against a 
keratinocyte that may counter the expansive osmotic forces triggered by gasdermin pore 
formation (unlike immune cells that are usually found in relative isolation). Furthermore, the 
extracellular concentrations of salts are significantly elevated in the skin, and differences in salt 
concentrations in the intracellular and extracellular compartments ultimately drive cell swelling 
and lysis during pyroptosis179. Thus, future studies into gasdermin A as well as other members of 
the gasdermin family may need to take into account both the cellular and tissue characteristics 
that may sharply diverge from those of macrophages, the cell type in which inflammasomes and 
gasdermins are traditionally studied, and cultured HEK293T, the cell type in which gasdermins 
are often transfected into to study their pore-forming and lytic capabilities. Indeed, these 
differences in cell and tissue types may have been a force that helped drive the expansion of the 
gasdermin family.  
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 Gasdermins were first identified as the effector of pyroptosis at the beginning of my 
thesis research. This discovery revolutionized our understanding of inflammasomes and 
pyroptosis. Through my focus on understanding the cell-specific roles of inflammasomes and 
gasdermins, my thesis research furthers our understanding of the gasdermin family and provides 
new avenues for research into the gasdermin family, members of which will likely prove to be 
valuable therapeutic targets. 
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APPENDIX: PROTEINS USED IN MOLECULAR PHYLOGENETICS 
   
Gasdermin A   
NCBI Accession ID Organism Abbreviation 
NP_835465.2 Homo_sapiens hGsdma 
XP_014975037.1 Macaca_mulatta   
XP_023060010.1 Piliocolobus_tephrosceles   
XP_025218676.1 Theropithecus_gelada   
XP_008955035.1 Pan_paniscus   
XP_011723579.1 Macaca_nemestrina   
XP_001171222.1 Pan_troglodytes   
XP_024091062.1 Pongo_abelii   
XP_012658360.1 Otolemur_garnettii   
XP_021784852.1 Papio_anubis   
XP_008063364.1 Carlito_syrichta   
XP_012307501.1 Aotus_nancymaae   
XP_012621524.1 Microcebus_murinus   
XP_004041806.1 Gorilla_gorilla_gorilla   
XP_017724755.1 Rhinopithecus_bieti   
XP_017352685.1 Cebus_capucinus_imitator   
XP_005584115.1 Macaca_fascicularis   
XP_012516382.1 Propithecus_coquereli   
XP_011785254.1 Colobus_angolensis_palliatus   
XP_011854366.1 Mandrillus_leucophaeus   
XP_003942931.1 Saimiri_boliviensis_boliviensis   
XP_010373819.1 Rhinopithecus_roxellana   
XP_008580237.1 Galeopterus_variegatus   
XP_008011013.1 Chlorocebus_sabaeus   
NP_067322.1 Mus_musculus mGsdma 
NP_084003.2 Mus_musculus mGsdma2 
NP_001007462.1 Mus_musculus mGsdma3 
NP_001101767.1 Rattus_norvegicus   
XP_028745379.1 Peromyscus_leucopus   
XP_028611014.1 Grammomys_surdaster   
XP_027778953.1 Marmota_flaviventris   
XP_026645688.1 Microtus_ochrogaster   
XP_026242881.1 Urocitellus_parryii   
XP_004633937.1 Octodon_degus   
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XP_013005065.1 Cavia_porcellus   
XP_005322019.1 Ictidomys_tridecemlineatus   
XP_021509099.1 Meriones_unguiculatus   
XP_004859525.1 Heterocephalus_glaber   
XP_012973102.1 Mesocricetus_auratus   
XP_020031928.1 Castor_canadensis   
XP_006971892.1 Peromyscus_maniculatus_bairdii   
XP_015351255.1 Marmota_marmota_marmota   
XP_013374647.1 Chinchilla_lanigera   
XP_012893237.1 Dipodomys_ordii   
XP_004655518.1 Jaculus_jaculus   
XP_012581601.1 Condylura_cristata   
XP_006833732.1 Chrysochloris_asiatica   
XP_029784118.1 Suricata_suricatta   
XP_012917953.1 Mustela_putorius_furo   
XP_014446163.1 Tupaia_chinensis   
XP_004608992.1 Sorex_araneus   
XP_017497970.1 Manis_javanica   
XP_002719393.1 Oryctolagus_cuniculus   
XP_004591216.1 Ochotona_princeps   
XP_007531080.1 Erinaceus_europaeus   
XP_007940243.1 Orycteropus_afer_afer   
XP_027984604.1 Eptesicus_fuscus   
XP_006924750.1 Pteropus_alecto   
XP_024429158.1 Desmodus_rotundus   
XP_019494184.1 Hipposideros_armiger   
XP_016057700.1 Miniopterus_natalensis   
XP_016020090.1 Rousettus_aegyptiacus   
XP_005861942.1 Myotis_brandtii   
XP_011381342.1 Pteropus_vampyrus   
XP_006774377.2 Myotis_davidii   
XP_025852001.1 Vulpes_vulpes   
XP_025296309.1 Canis_lupus_dingo   
XP_026889645.1 Acinonyx_jubatus   
XP_025773357.1 Puma_concolor   
XP_019673388.1 Felis_catus   
XP_019271588.1 Panthera_pardus   
XP_007085856.1 Panthera_tigris_altaica   
XP_004012902.1 Ovis_aries   
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XP_005693821.2 Capra_hircus   
XP_011997233.1 Ovis_aries_musimon   
XP_015103368.1 Vicugna_pacos   
XP_026368703.1 Ursus_arctos_horribilis   
XP_019665612.1 Ailuropoda_melanoleuca   
XP_008687546.1 Ursus_maritimus   
NP_001071558.1 Bos_taurus   
XP_019836267.1 Bos_indicus   
XP_005898083.1 Bos_mutus   
XP_006068650.1 Bubalus_bubalis   
XP_010840931.1 Bison_bison_bison   
XP_001500838.3 Equus_caballus   
XP_014689408.1 Equus_asinus   
XP_008517125.1 Equus_przewalskii   
XP_004434607.1 Ceratotherium_simum_simum   
XP_006176398.1 Camelus_ferus   
XP_010990107.1 Camelus_dromedarius   
XP_010958761.1 Camelus_bactrianus   
XP_013835119.1 Sus_scrofa   
XP_020745726.1 Odocoileus_virginianus_texanus   
XP_027945757.1 Eumetopias_jubatus   
XP_027423431.1 Zalophus_californianus   
XP_025715235.1 Callorhinus_ursinus   
XP_021560076.1 Neomonachus_schauinslandi   
XP_012416038.1 Odobenus_rosmarus_divergens   
XP_006749918.1 Leptonychotes_weddellii   
XP_012411464.1 Trichechus_manatus_latirostris   
XP_020853178.1 Phascolarctos_cinereus   
XP_027729048.1 Vombatus_ursinus   
XP_012403791.1 Sarcophilus_harrisii   
XP_007654365.3 Ornithorhynchus_anatinus   
XP_028558572.1 Podarcis_muralis   
XP_015279010.1 Gekko_japonicus   
XP_008111551.1 Anolis_carolinensis acGsdma 
XP_019405871.1 Crocodylus_porosus   
XP_019362599.1 Gavialis_gangeticus   
XP_014451785.1 Alligator_mississippiensis   
XP_006022649.1 Alligator_sinensis   
XP_025022523.1 Python_bivittatus pbGsdma 
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XP_015687751.1 Protobothrops_mucrosquamatus   
XP_013929683.1 Thamnophis_sirtalis   
XP_026573339.1 Pseudonaja_textilis   
XP_026535498.1 Notechis_scutatus   
XP_026510609.1 Terrapene_carolina_triunguis   
XP_006117469.1 Pelodiscus_sinensis   
XP_008160950.1 Chrysemys_picta_bellii   
XP_021388636.1 Lonchura_striata_domestica   
NP_001026532.1 Gallus_gallus ggGsdma 
XP_021233895.1 Numida_meleagris   
XP_015741468.1 Coturnix_japonica   
XP_025973622.1 Dromaius_novaehollandiae   
XP_029878858.1 Aquila_chrysaetos_chrysaetos   
XP_027763648.1 Empidonax_traillii   
XP_027603785.1 Pipra_filicauda   
XP_026720458.1 Athene_cunicularia   
XP_025928753.1 Apteryx_rowi   
XP_025897146.1 Nothoprocta_perdicaria   
XP_015506851.1 Parus_major   
XP_014813419.1 Calidris_pugnax   
XP_013800181.1 Apteryx_australis_mantelli   
XP_013057526.1 Anser_cygnoides_domesticus   
XP_011592385.1 Aquila_chrysaetos_canadensis   
XP_010583858.1 Haliaeetus_leucocephalus   
XP_019149421.2 Corvus_cornix_cornix   
XP_010007212.1 Chaetura_pelagica   
XP_009933676.1 Opisthocomus_hoazin   
XP_009897998.1 Picoides_pubescens   
XP_009883759.1 Charadrius_vociferus   
XP_009672097.1 Struthio_camelus_australis   
XP_009640852.1 Egretta_garzetta   
XP_009568865.1 Cuculus_canorus   
XP_009463179.1 Nipponia_nippon   
XP_009333228.1 Pygoscelis_adeliae   
XP_009288830.1 Aptenodytes_forsteri   
XP_009094796.1 Serinus_canaria   
XP_009082361.1 Acanthisitta_chloris   
XP_008634137.1 Corvus_brachyrhynchos cbGsdma 
XP_008503983.1 Calypte_anna   
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XP_005531574.2 Pseudopodoces_humilis   
XP_005513819.1 Columba_livia   
XP_026655008.1 Zonotrichia_albicollis   
XP_014135543.1 Falco_cherrug   
XP_013150873.1 Falco_peregrinus   
XP_016159802.1 Ficedula_albicollis   
XP_027301037.1 Anas_platyrhynchos   
XP_012426589.1 Taeniopygia_guttata   
XP_030077862.1 Microcaecilia_unicolor muGsdma 
XP_029428328.1 Rhinatrema_bivittatum   
   
Gasdermin B   
NCBI Accession ID Organism Abbreviation 
NP_001159430.1 Homo_sapiens hGsdmb 
XP_009430521.1 Pan_troglodytes   
XP_018883925.1 Gorilla_gorilla_gorilla   
XP_008955037.1 Pan_paniscus   
XP_012658361.1 Otolemur_garnettii   
XP_003278296.2 Nomascus_leucogenys   
XP_002827669.2 Pongo_abelii   
XP_032019389.1 Hylobates_moloch   
XP_012973048.1 Mesocricetus_auratus   
XP_027279932.1 Cricetulus_griseus   
XP_006833730.1 Chrysochloris_asiatica   
XP_012581499.1 Condylura_cristata   
XP_007940378.1 Orycteropus_afer_afer   
XP_027630559.1 Tupaia_chinensis   
XP_023441904.1 Dasypus_novemcinctus   
XP_028377233.1 Phyllostomus_discolor   
XP_024429114.1 Desmodus_rotundus   
XP_016057754.1 Miniopterus_natalensis mnGsdmb 
XP_032947748.1 Rhinolophus_ferrumequinum   
XP_022279619.1 Canis_lupus_familiaris   
XP_025296608.1 Canis_lupus_dingo   
XP_015314316.2 Bos_taurus btGsdmb 
XP_010840944.1 Bison_bison_bison   
XP_005898079.1 Bos_mutus   
XP_025135973.1 Bubalus_bubalis   
XP_023508346.1 Equus_caballus   
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XP_014689450.1 Equus_asinus   
XP_008517122.1 Equus_przewalskii   
XP_010990153.1 Camelus_dromedarius   
XP_010958860.1 Camelus_bactrianus   
XP_013827805.2 Capra_hircus   
XP_012041444.2 Ovis_aries   
XP_023409166.1 Loxodonta_africana laGsdmb 
XP_005653979.2 Sus_scrofa   
XP_004434611.1 Ceratotherium_simum_simum   
XP_016285970.1 Monodelphis_domestica mdGsdmb 
XP_023358160.1 Sarcophilus_harrisii shGsdmb 
   
Gasdermin C   
NCBI Accession 
ID Organism Abbreviation 
NP_113603.1 Homo_sapiens hGsdmc 
XP_028708741.1 Macaca_mulatta   
XP_005564120.1 Macaca_fascicularis   
XP_011758353.1 Macaca_nemestrina   
XP_001153860.1 Pan_troglodytes   
XP_032614393.1 Hylobates_moloch   
XP_032109296.1 Sapajus_apella   
XP_025250365.1 Theropithecus_gelada   
XP_023078764.2 Piliocolobus_tephrosceles   
XP_017725971.1 Rhinopithecus_bieti   
XP_017354851.1 Cebus_capucinus_imitator   
XP_011921019.1 Cercocebus_atys   
XP_011831848.1 Mandrillus_leucophaeus   
XP_011793570.1 Colobus_angolensis_palliatus   
XP_030793163.1 Rhinopithecus_roxellana   
XP_007999718.1 Chlorocebus_sabaeus   
XP_004047578.3 Gorilla_gorilla_gorilla   
XP_010342559.1 Saimiri_boliviensis_boliviensis   
XP_003903208.1 Papio_anubis   
XP_003820501.1 Pan_paniscus   
XP_012664852.2 Otolemur_garnettii   
XP_003256254.2 Nomascus_leucogenys   
XP_002819473.1 Pongo_abelii   
XP_008981514.1 Callithrix_jacchus   
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NP_113555.1 Mus_musculus mGsdmc1 
NP_001161746.1 Mus_musculus mGsdmc2 
NP_899017.2 Mus_musculus mGsdmc3 
NP_083268.1 Mus_musculus mGsdmc4 
XP_017450238.1 Rattus_norvegicus rnGsdmc 
XP_032771866.1 Rattus_rattus   
XP_028629109.1 Grammomys_surdaster   
XP_032729332.1 Lontra_canadensis   
XP_029779186.1 Suricata_suricatta   
XP_032171903.1 Mustela_erminea   
XP_027804089.1 Marmota_flaviventris   
XP_026263122.1 Urocitellus_parryii   
XP_021501085.1 Meriones_unguiculatus   
XP_021073018.1 Mus_pahari   
XP_021039645.1 Mus_caroli   
XP_015341781.1 Marmota_marmota_marmota   
XP_010641186.1 Fukomys_damarensis   
XP_008843720.1 Nannospalax_galili   
XP_013376750.1 Chinchilla_lanigera   
XP_021578221.1 Ictidomys_tridecemlineatus   
XP_021107746.1 Heterocephalus_glaber   
XP_012578355.1 Condylura_cristata   
XP_004656383.1 Jaculus_jaculus   
XP_023419805.1 Cavia_porcellus   
XP_005078752.1 Mesocricetus_auratus   
XP_017197091.1 Oryctolagus_cuniculus ocGsdmc 
XP_027630809.1 Tupaia_chinensis   
XP_004602662.1 Sorex_araneus   
XP_007941614.1 Orycteropus_afer_afer   
XP_012377894.1 Dasypus_novemcinctus   
XP_028389399.1 Phyllostomus_discolor   
XP_024427836.1 Desmodus_rotundus   
XP_016071620.1 Miniopterus_natalensis mnGsdmc 
XP_023401449.1 Loxodonta_africana laGsdmc 
NP_001039469.1 Bos_taurus btGsdmc 
XP_019829042.1 Bos_indicus   
XP_005900062.1 Bos_mutus   
XP_010842633.1 Bison_bison_bison   
XP_006042923.1 Bubalus_bubalis   
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XP_013843492.1 Sus_scrofa ssGsdmc 
XP_020730911.1 Odocoileus_virginianus_texanus   
XP_019650518.1 Ailuropoda_melanoleuca   
XP_026351145.1 Ursus_arctos_horribilis   
XP_008687605.1 Ursus_maritimus   
XP_022282826.1 Canis_lupus_familiaris   
XP_025306872.1 Canis_lupus_dingo   
XP_019678683.1 Felis_catus fcGsdmc 
XP_030160404.1 Lynx_canadensis   
XP_025778779.1 Puma_concolor   
XP_019315398.1 Panthera_pardus   
XP_026919714.1 Acinonyx_jubatus   
XP_031803207.1 Sarcophilus_harrisii shGsdmc 
XP_025726321.1 Callorhinus_ursinus   
   
Gasdermin D   
NCBI Accession ID Organism Abbreviation 
NP_001159709.1 Homo_sapiens hGsdmd 
XP_015001617.2 Macaca_mulatta   
XP_005564295.1 Macaca_fascicularis   
XP_001152706.2 Pan_troglodytes   
XP_008981331.1 Callithrix_jacchus   
XP_032616510.1 Hylobates_moloch   
XP_032111043.1 Sapajus_apella   
XP_025250524.1 Theropithecus_gelada   
XP_017738915.1 Rhinopithecus_bieti   
XP_017367031.1 Cebus_capucinus_imitator   
XP_012608366.1 Microcebus_murinus   
XP_012503394.1 Propithecus_coquereli   
XP_021527750.1 Aotus_nancymaae   
XP_011905474.1 Cercocebus_atys   
XP_011831038.1 Mandrillus_leucophaeus   
XP_011750785.1 Macaca_nemestrina   
XP_010383809.2 Rhinopithecus_roxellana   
XP_008581297.1 Galeopterus_variegatus   
XP_008054914.2 Carlito_syrichta   
XP_007999960.1 Chlorocebus_sabaeus   
XP_003942159.1 Saimiri_boliviensis_boliviensis   
XP_003903292.1 Papio_anubis   
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XP_003819507.1 Pan_paniscus   
XP_003802420.1 Otolemur_garnettii   
XP_024106658.1 Pongo_abelii   
NP_081236.1 Mus_musculus mGsdmd 
NP_001124025.1 Rattus_norvegicus rnGsdmd 
XP_008832746.1 Nannospalax_galili   
XP_021078648.1 Mesocricetus_auratus maGsdmd 
XP_032772926.1 Rattus_rattus   
XP_031202285.1 Mastomys_coucha   
XP_027806786.1 Marmota_flaviventris   
XP_026265627.1 Urocitellus_parryii   
XP_021072889.1 Mus_pahari   
XP_021039083.1 Mus_caroli   
XP_015342041.1 Marmota_marmota_marmota   
XP_012889351.1 Dipodomys_ordii   
XP_010637563.1 Fukomys_damarensis   
XP_015863152.1 Peromyscus_maniculatus_bairdii   
XP_006830929.1 Chrysochloris_asiatica   
XP_005395830.1 Chinchilla_lanigera   
XP_005316153.1 Ictidomys_tridecemlineatus   
XP_021106782.1 Heterocephalus_glaber   
XP_004656438.1 Jaculus_jaculus   
XP_004639026.2 Octodon_degus   
XP_004618751.1 Sorex_araneus   
XP_004580923.1 Ochotona_princeps   
XP_003510483.1 Cricetulus_griseus   
XP_013001158.1 Cavia_porcellus   
XP_032171400.1 Mustela_erminea   
XP_032704245.1 Lontra_canadensis   
XP_029779202.1 Suricata_suricatta   
XP_006152136.1 Tupaia_chinensis   
XP_006879495.1 Elephantulus_edwardii   
XP_017525087.1 Manis_javanica   
XP_004480061.1 Dasypus_novemcinctus   
XP_008252155.1 Oryctolagus_cuniculus ocGsdmd 
XP_007954323.1 Orycteropus_afer_afer   
XP_016040631.1 Erinaceus_europaeus eeGsdmd 
XP_004697675.1 Echinops_telfairi   
XP_007488898.1 Monodelphis_domestica   
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XP_028389413.1 Phyllostomus_discolor   
XP_019513341.1 Hipposideros_armiger   
XP_016075669.1 Miniopterus_natalensis mnGsdmd 
XP_015994746.1 Rousettus_aegyptiacus   
XP_011373217.1 Pteropus_vampyrus   
XP_008157982.1 Eptesicus_fuscus   
XP_006913014.1 Pteropus_alecto   
XP_015426878.1 Myotis_davidii   
NP_001039625.1 Bos_taurus btGsdmd 
XP_005888687.1 Bos_mutus   
XP_010852842.1 Bison_bison_bison   
XP_006045211.2 Bubalus_bubalis   
XP_010600015.1 Loxodonta_africana laGsdmd 
XP_014652722.1 Ceratotherium_simum_simum   
XP_022282557.1 Canis_lupus_familiaris   
XP_025843337.1 Vulpes_vulpes   
XP_025306643.1 Canis_lupus_dingo   
XP_031546305.1 Vicugna_pacos   
XP_017914166.1 Capra_hircus   
XP_020946165.1 Sus_scrofa   
XP_027829189.1 Ovis_aries   
XP_023504872.1 Equus_caballus   
XP_014713657.1 Equus_asinus   
XP_008534512.1 Equus_przewalskii   
XP_023104116.1 Felis_catus fcGsdmd 
XP_030160048.1 Lynx_canadensis   
XP_019290543.1 Panthera_pardus   
XP_026919519.1 Acinonyx_jubatus   
XP_032323580.1 Camelus_ferus   
XP_031295648.1 Camelus_dromedarius   
XP_010959450.1 Camelus_bactrianus   
XP_026344710.1 Ursus_arctos_horribilis   
XP_008682309.1 Ursus_maritimus   
XP_019658251.1 Ailuropoda_melanoleuca   
XP_020736699.1 Odocoileus_virginianus_texanus   
XP_032465962.1 Phocoena_sinus   
XP_032271700.1 Phoca_vitulina   
XP_030732008.1 Globicephala_melas   
XP_029059666.1 Monodon_monoceros   
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XP_027949315.1 Eumetopias_jubatus   
XP_027467977.1 Zalophus_californianus   
XP_026988031.1 Lagenorhynchus_obliquidens   
XP_025727038.1 Callorhinus_ursinus   
XP_024596904.1 Neophocaena_asiaeorientalis_asiaeorientalis   
XP_022411150.1 Delphinapterus_leucas   
XP_021544405.1 Neomonachus_schauinslandi   
XP_007464679.1 Lipotes_vexillifer   
XP_007167001.1 Balaenoptera_acutorostrata_scammoni   
XP_007113167.2 Physeter_catodon   
XP_004265441.1 Orcinus_orca   
XP_023597400.1 Trichechus_manatus_latirostris   
XP_030875078.1 Leptonychotes_weddellii   
XP_020850599.1 Phascolarctos_cinereus   
XP_012397449.2 Sarcophilus_harrisii shGsdmd 
XP_028917767.1 Ornithorhynchus_anatinus oaGsdmd 
   
Gasdermin E   
NCBI Accession ID Organism Abbreviation 
NP_001120925.1 Homo_sapiens hGsdme 
XP_001096213.2 Macaca_mulatta   
XP_003318404.2 Pan_troglodytes   
XP_003270464.1 Nomascus_leucogenys   
XP_024105635.1 Pongo_abelii   
XP_009000514.1 Callithrix_jacchus   
XP_017719435.1 Rhinopithecus_bieti   
XP_017382493.1 Cebus_capucinus_imitator   
XP_012628783.1 Microcebus_murinus   
XP_012496187.1 Propithecus_coquereli   
XP_021525833.1 Aotus_nancymaae   
XP_011937000.1 Cercocebus_atys   
XP_011825996.1 Mandrillus_leucophaeus   
XP_011793945.1 Colobus_angolensis_palliatus   
XP_011729491.1 Macaca_nemestrina   
XP_010374233.1 Rhinopithecus_roxellana   
XP_008070518.1 Carlito_syrichta   
XP_007980048.1 Chlorocebus_sabaeus   
XP_005550020.1 Macaca_fascicularis   
XP_004045238.1 Gorilla_gorilla_gorilla   
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XP_003935184.1 Saimiri_boliviensis_boliviensis   
XP_003896238.1 Papio_anubis   
XP_003807976.1 Pan_paniscus   
XP_003788653.1 Otolemur_garnettii   
XP_032615042.1 Hylobates_moloch   
XP_032142871.1 Sapajus_apella   
XP_025236017.1 Theropithecus_gelada   
XP_023081708.1 Piliocolobus_tephrosceles   
NP_001178678.1 Rattus_norvegicus   
NP_061239.1 Mus_musculus mGsdme 
XP_021109770.1 Heterocephalus_glaber   
XP_020034992.1 Castor_canadensis   
XP_027272248.1 Cricetulus_griseus   
XP_008839709.1 Nannospalax_galili   
XP_005087240.1 Mesocricetus_auratus   
XP_021486754.1 Meriones_unguiculatus   
XP_021046698.1 Mus_pahari   
XP_021020548.1 Mus_caroli   
XP_015345627.1 Marmota_marmota_marmota   
XP_012879848.1 Dipodomys_ordii   
XP_010626527.1 Fukomys_damarensis   
XP_006982246.1 Peromyscus_maniculatus_bairdii   
XP_006832344.1 Chrysochloris_asiatica   
XP_005366675.2 Microtus_ochrogaster   
XP_021577894.1 Ictidomys_tridecemlineatus   
XP_012576204.1 Condylura_cristata   
XP_004652861.1 Jaculus_jaculus   
XP_004626528.1 Octodon_degus   
XP_003467957.1 Cavia_porcellus   
XP_032762429.1 Rattus_rattus   
XP_031237728.1 Mastomys_coucha   
XP_028645887.1 Grammomys_surdaster   
XP_027788502.1 Marmota_flaviventris   
XP_026256023.1 Urocitellus_parryii   
XP_013366053.1 Chinchilla_lanigera   
XP_004604319.1 Sorex_araneus   
XP_006902459.1 Elephantulus_edwardii   
XP_004582613.1 Ochotona_princeps   
XP_002713872.1 Oryctolagus_cuniculus   
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XP_032728909.1 Lontra_canadensis   
XP_004743370.1 Mustela_putorius_furo   
XP_032160672.1 Mustela_erminea   
XP_029786190.1 Suricata_suricatta   
XP_017506043.1 Manis_javanica   
XP_004447610.1 Dasypus_novemcinctus   
XP_007944697.1 Orycteropus_afer_afer   
XP_007529121.1 Erinaceus_europaeus   
XP_004702903.1 Echinops_telfairi   
XP_006912064.1 Pteropus_alecto   
XP_019507556.1 Hipposideros_armiger   
XP_016072537.1 Miniopterus_natalensis   
XP_016015049.1 Rousettus_aegyptiacus   
XP_023387299.1 Pteropus_vampyrus   
XP_028011374.1 Eptesicus_fuscus   
XP_006779071.1 Myotis_davidii   
XP_005872327.1 Myotis_brandtii   
XP_028381748.1 Phyllostomus_discolor   
XP_024418892.1 Desmodus_rotundus   
NP_001075358.1 Equus_caballus   
XP_008515297.1 Equus_przewalskii   
XP_014694495.1 Equus_asinus   
XP_020934334.1 Sus_scrofa   
NP_001180041.1 Bos_taurus btGsdme 
XP_005902937.1 Bos_mutus   
XP_019824428.1 Bos_indicus   
XP_010853670.1 Bison_bison_bison   
XP_006055333.1 Bubalus_bubalis   
XP_031310922.1 Camelus_dromedarius   
XP_010966934.1 Camelus_bactrianus   
XP_020733682.1 Odocoileus_virginianus_texanus   
XP_017902561.1 Capra_hircus   
XP_014950834.1 Ovis_aries   
XP_023400115.1 Loxodonta_africana laGsdme 
XP_004418969.1 Ceratotherium_simum_simum   
XP_015092757.1 Vicugna_pacos   
XP_853956.2 Canis_lupus_familiaris   
XP_025848911.1 Vulpes_vulpes   
XP_025320189.1 Canis_lupus_dingo   
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XP_006929316.1 Felis_catus   
XP_019299169.1 Panthera_pardus   
XP_026930937.1 Acinonyx_jubatus   
XP_007089104.1 Panthera_tigris_altaica   
XP_030163969.1 Lynx_canadensis   
XP_025785639.1 Puma_concolor   
XP_019654189.1 Ailuropoda_melanoleuca   
XP_008684626.1 Ursus_maritimus   
XP_026363612.1 Ursus_arctos_horribilis   
XP_007466126.1 Lipotes_vexillifer   
XP_004397435.1 Odobenus_rosmarus_divergens   
XP_019782285.1 Tursiops_truncatus   
XP_004265687.1 Orcinus_orca   
XP_032257813.1 Phoca_vitulina   
XP_030713228.1 Globicephala_melas   
XP_029089784.1 Monodon_monoceros   
XP_027975160.1 Eumetopias_jubatus   
XP_027429302.1 Zalophus_californianus   
XP_026958176.1 Lagenorhynchus_obliquidens   
XP_025729082.1 Callorhinus_ursinus   
XP_022440687.1 Delphinapterus_leucas   
XP_004377520.1 Trichechus_manatus_latirostris   
XP_027728246.1 Vombatus_ursinus   
XP_031796450.1 Sarcophilus_harrisii shGsdme 
XP_020849090.1 Phascolarctos_cinereus   
XP_007505411.1 Monodelphis_domestica   
XP_028926176.1 Ornithorhynchus_anatinus oaGsdme 
XP_021393912.1 Lonchura_striata_domestica   
XP_021243122.1 Numida_meleagris   
XP_017679311.1 Lepidothrix_coronata   
XP_015709261.1 Coturnix_japonica   
XP_015473236.1 Parus_major   
XP_014749818.1 Sturnus_vulgaris   
XP_013027320.1 Anser_cygnoides_domesticus   
XP_010575897.1 Haliaeetus_leucocephalus   
XP_019141156.1 Corvus_cornix_cornix   
XP_010220413.1 Tinamus_guttatus   
XP_010199052.1 Colius_striatus   
XP_010183520.1 Mesitornis_unicolor   
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XP_010165530.1 Antrostomus_carolinensis   
XP_010144987.1 Eurypyga_helias   
XP_010131040.1 Buceros_rhinoceros_silvestris   
XP_010116360.1 Chlamydotis_macqueenii   
XP_010072951.1 Pterocles_gutturalis   
XP_010009916.1 Nestor_notabilis   
XP_010005878.1 Chaetura_pelagica   
XP_009960564.2 Tyto_alba_alba   
XP_009960492.1 Leptosomus_discolor   
XP_009939657.1 Opisthocomus_hoazin   
XP_009928905.1 Haliaeetus_albicilla   
XP_009906998.1 Picoides_pubescens   
XP_009877840.1 Charadrius_vociferus   
XP_009863572.1 Apaloderma_vittatum   
XP_009808686.1 Gavia_stellata   
XP_009674755.1 Struthio_camelus_australis   
XP_009636961.1 Egretta_garzetta   
XP_009582421.1 Fulmarus_glacialis   
XP_009561166.1 Cuculus_canorus   
XP_009506330.1 Phalacrocorax_carbo   
XP_009489562.1 Pelecanus_crispus   
XP_009464781.1 Nipponia_nippon   
XP_009324004.1 Pygoscelis_adeliae   
XP_009280316.1 Aptenodytes_forsteri   
XP_030090516.1 Serinus_canaria   
XP_009076145.1 Acanthisitta_chloris   
XP_008933812.1 Merops_nubicus   
XP_017930682.2 Manacus_vitellinus   
XP_017586669.1 Corvus_brachyrhynchos cbGsdme 
XP_030301104.1 Calypte_anna   
XP_014104276.1 Pseudopodoces_humilis   
XP_005480924.2 Zonotrichia_albicollis   
XP_027670555.1 Falco_cherrug   
XP_014162807.1 Geospiza_fortis   
XP_027642249.1 Falco_peregrinus   
XP_005041048.1 Ficedula_albicollis   
XP_012955994.2 Anas_platyrhynchos   
XP_010711078.1 Meleagris_gallopavo   
XP_030120727.2 Taeniopygia_guttata   
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NP_001006361.1 Gallus_gallus ggGsdme 
XP_032566913.1 Chiroxiphia_lanceolata   
XP_032037140.1 Aythya_fuligula   
XP_031965418.1 Corvus_moneduloides   
XP_031445980.1 Phasianus_colchicus   
XP_030799876.1 Camarhynchus_parvulus   
XP_030345602.1 Strigops_habroptila   
XP_029866133.1 Aquila_chrysaetos_chrysaetos   
XP_027751877.1 Empidonax_traillii   
XP_027594245.1 Pipra_filicauda   
XP_027531052.1 Neopelma_chrysocephalum   
XP_027495202.1 Corapipo_altera   
XP_026697503.1 Athene_cunicularia   
XP_025959584.1 Dromaius_novaehollandiae   
XP_025889163.1 Nothoprocta_perdicaria   
XP_023776256.1 Cyanistes_caeruleus   
XP_030909399.1 Melopsittacus_undulatus   
XP_020636651.1 Pogona_vitticeps   
XP_015285233.1 Gekko_japonicus   
XP_008110872.1 Anolis_carolinensis acGsdme 
XP_028605735.1 Podarcis_muralis   
XP_019390343.1 Crocodylus_porosus   
XP_019364145.1 Gavialis_gangeticus   
XP_019353382.1 Alligator_mississippiensis   
XP_025063881.1 Alligator_sinensis   
XP_015666066.1 Protobothrops_mucrosquamatus   
XP_013909822.1 Thamnophis_sirtalis   
XP_007433152.1 Python_bivittatus pbGsdme 
XP_032093603.1 Thamnophis_elegans   
XP_026562200.1 Pseudonaja_textilis   
XP_026529423.1 Notechis_scutatus   
XP_027689547.1 Chelonia_mydas   
XP_014436716.1 Pelodiscus_sinensis   
XP_023962559.1 Chrysemys_picta_bellii   
XP_032629745.1 Chelonoidis_abingdonii   
XP_030406666.1 Gopherus_evgoodei   
XP_029766858.1 Terrapene_carolina_triunguis   
XP_018431097.1 Nanorana_parkeri   
XP_012821030.1 Xenopus_tropicalis xtGsdme 
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XP_030057926.1 Microcaecilia_unicolor muGsdme 
XP_029444983.1 Rhinatrema_bivittatum   
XP_014351702.1 Latimeria_chalumnae   
XP_022071512.1 Acanthochromis_polyacanthus   
XP_018544241.1 Lates_calcarifer   
XP_007233439.2 Astyanax_mexicanus   
XP_020565794.1 Oryzias_latipes   
XP_020793187.1 Boleophthalmus_pectinirostris   
XP_020492757.1 Labrus_bergylta   
XP_019948910.1 Paralichthys_olivaceus   
XP_019741943.1 Hippocampus_comes   
XP_017327120.1 Ictalurus_punctatus   
XP_017282053.1 Kryptolebias_marmoratus   
XP_016419594.1 Sinocyclocheilus_rhinocerous   
XP_016337634.1 Sinocyclocheilus_anshuiensis   
XP_016142929.1 Sinocyclocheilus_grahami   
XP_015259533.1 Cyprinodon_variegatus   
XP_014892308.1 Poecilia_latipinna   
XP_014859812.1 Poecilia_mexicana   
XP_012718094.1 Fundulus_heteroclitus   
XP_010773239.1 Notothenia_coriiceps   
XP_010740226.3 Larimichthys_crocea   
XP_017165221.1 Poecilia_reticulata   
XP_008289283.1 Stegastes_partitus   
XP_016536172.1 Poecilia_formosa   
XP_005934833.1 Haplochromis_burtoni   
XP_023186332.1 Xiphophorus_maculatus   
XP_005738539.1 Pundamilia_nyererei   
XP_004541527.2 Maylandia_zebra   
XP_003454487.2 Oreochromis_niloticus   
XP_031441875.1 Clupea_harengus   
XP_005170134.1 Danio_rerio   
NP_001001947.1 Danio_rerio   
XP_024123324.1 Oryzias_melastigma   
XP_022621341.1 Seriola_dumerili   
XP_032413990.1 Xiphophorus_hellerii   
XP_032375584.1 Etheostoma_spectabile   
XP_031709071.1 Anarrhichthys_ocellatus   
XP_031602092.1 Oreochromis_aureus   
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XP_031432605.1 Clupea_harengus   
XP_031154890.1 Sander_lucioperca   
XP_030606161.1 Archocentrus_centrarchus   
XP_030248788.1 Sparus_aurata   
XP_030012894.1 Sphaeramia_orbicularis   
XP_029958404.1 Salarias_fasciatus   
XP_029927409.1 Myripristis_murdjan   
XP_029588348.1 Salmo_trutta   
XP_029360163.1 Echeneis_naucrates   
XP_029307874.1 Cottoperca_gobio   
XP_028983881.1 Betta_splendens   
XP_028835239.1 Denticeps_clupeoides   
XP_028674104.1 Erpetoichthys_calabaricus   
XP_028435836.1 Perca_flavescens   
XP_028326593.1 Gouania_willdenowi   
XP_028280814.1 Parambassis_ranga   
XP_027868606.1 Xiphophorus_couchianus   
XP_026855871.1 Electrophorus_electricus   
XP_026226820.1 Anabas_testudineus   
XP_026149143.1 Mastacembelus_armatus   
XP_026041600.1 Astatotilapia_calliptera   
XP_023658342.1 Paramormyrops_kingsleyae   
XP_023258886.1 Seriola_lalandi_dorsalis   
XP_023155220.1 Amphiprion_ocellaris   
XP_016893587.1 Cynoglossus_semilaevis csGsdme 
XP_011604087.2 Takifugu_rubripes   
XP_020468482.1 Monopterus_albus   
NP_001279331.1 Callorhinchus_milii cmGsdme 
XP_020389028.1 Rhincodon_typus   
XP_032903802.1 Amblyraja_radiata   
XP_022788280.1 Stylophora_pistillata spGsdme 
XP_020910515.1 Exaiptasia_pallida epGsdme 
   
Pejvakin   
NCBI Accession ID Organism Abbreviation 
NP_001036167.1 Homo_sapiens hPjvk 
XP_009442091.1 Pan_troglodytes   
XP_014965926.1 Macaca_mulatta   
XP_005573657.1 Macaca_fascicularis   
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XP_002749314.1 Callithrix_jacchus   
XP_032611165.1 Hylobates_moloch   
XP_032148968.1 Sapajus_apella   
XP_025260082.1 Theropithecus_gelada   
XP_023068107.1 Piliocolobus_tephrosceles   
XP_017723775.1 Rhinopithecus_bieti   
XP_017388169.1 Cebus_capucinus_imitator   
XP_012641314.1 Microcebus_murinus   
XP_012506180.1 Propithecus_coquereli   
XP_012326893.1 Aotus_nancymaae   
XP_011902507.1 Cercocebus_atys   
XP_011847215.1 Mandrillus_leucophaeus   
XP_011799435.1 Colobus_angolensis_palliatus   
XP_011717756.1 Macaca_nemestrina   
XP_030772352.1 Rhinopithecus_roxellana   
XP_008565265.1 Galeopterus_variegatus   
XP_008053529.1 Carlito_syrichta   
XP_007963659.1 Chlorocebus_sabaeus   
XP_004032916.1 Gorilla_gorilla_gorilla   
XP_003921870.1 Saimiri_boliviensis_boliviensis   
XP_009180787.1 Papio_anubis   
XP_008966740.1 Pan_paniscus   
XP_030658207.1 Nomascus_leucogenys   
XP_009236151.1 Pongo_abelii   
NP_001074180.1 Mus_musculus mPjvk 
XP_006224560.1 Rattus_norvegicus   
XP_021050472.1 Mus_pahari   
XP_005065182.1 Mesocricetus_auratus   
XP_004868199.1 Heterocephalus_glaber   
XP_008853561.1 Nannospalax_galili   
XP_032757859.1 Rattus_rattus   
XP_031226566.1 Mastomys_coucha   
XP_028618841.1 Grammomys_surdaster   
XP_027801937.1 Marmota_flaviventris   
XP_026247819.1 Urocitellus_parryii   
XP_021505179.1 Meriones_unguiculatus   
XP_021012402.1 Mus_caroli   
XP_020033549.1 Castor_canadensis   
XP_015336589.1 Marmota_marmota_marmota   
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XP_012883962.1 Dipodomys_ordii   
XP_010635075.1 Fukomys_damarensis   
XP_015843885.1 Peromyscus_maniculatus_bairdii   
XP_006866750.1 Chrysochloris_asiatica   
XP_005373436.1 Chinchilla_lanigera   
XP_005346676.1 Microtus_ochrogaster   
XP_005324712.1 Ictidomys_tridecemlineatus   
XP_004674538.1 Condylura_cristata   
XP_004660349.1 Jaculus_jaculus   
XP_004634773.1 Octodon_degus   
XP_003501070.1 Cricetulus_griseus   
XP_003478567.1 Cavia_porcellus   
XP_032712096.1 Lontra_canadensis   
XP_006151718.1 Tupaia_chinensis   
XP_004601427.1 Sorex_araneus   
XP_006878851.1 Elephantulus_edwardii   
XP_032211508.1 Mustela_erminea   
XP_004769035.1 Mustela_putorius_furo   
XP_029790180.1 Suricata_suricatta   
XP_007935422.1 Orycteropus_afer_afer   
XP_007534290.1 Erinaceus_europaeus   
XP_004701516.1 Echinops_telfairi   
XP_017517118.1 Manis_javanica   
XP_004476912.1 Dasypus_novemcinctus   
XP_002712360.1 Oryctolagus_cuniculus   
XP_004577070.1 Ochotona_princeps   
XP_005857693.1 Myotis_brandtii   
XP_028365357.1 Phyllostomus_discolor   
XP_024417351.1 Desmodus_rotundus   
XP_019509576.1 Hipposideros_armiger   
XP_016065696.1 Miniopterus_natalensis   
XP_016008059.1 Rousettus_aegyptiacus   
XP_032968392.1 Rhinolophus_ferrumequinum   
XP_011355082.1 Pteropus_vampyrus   
XP_008136734.1 Eptesicus_fuscus   
XP_006921303.1 Pteropus_alecto   
XP_006760637.1 Myotis_davidii   
XP_006083120.1 Myotis_lucifugus   
XP_535979.2 Canis_lupus_familiaris   
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XP_025849734.1 Vulpes_vulpes   
XP_025316114.1 Canis_lupus_dingo   
XP_023115271.1 Felis_catus   
XP_030181704.1 Lynx_canadensis   
XP_025767998.1 Puma_concolor   
XP_019316325.1 Panthera_pardus   
XP_014942207.1 Acinonyx_jubatus   
XP_007083963.1 Panthera_tigris_altaica   
NP_001180112.1 Bos_taurus btPjvk 
XP_005907581.1 Bos_mutus   
XP_019825658.1 Bos_indicus   
XP_010858060.1 Bison_bison_bison   
XP_006059644.1 Bubalus_bubalis   
XP_001500909.3 Equus_caballus   
XP_014689590.1 Equus_asinus   
XP_008513713.1 Equus_przewalskii   
XP_002918869.3 Ailuropoda_melanoleuca   
XP_026348228.1 Ursus_arctos_horribilis   
XP_008685415.1 Ursus_maritimus   
XP_003406242.2 Loxodonta_africana laPjvk 
XP_004426736.1 Ceratotherium_simum_simum   
XP_020738717.1 Odocoileus_virginianus_texanus   
XP_017894275.1 Capra_hircus   
XP_004004594.1 Ovis_aries   
XP_006210278.1 Vicugna_pacos   
XP_010989669.1 Camelus_dromedarius   
XP_010958274.1 Camelus_bactrianus   
XP_006194628.1 Camelus_ferus   
XP_032494333.1 Phocoena_sinus   
XP_032275467.1 Phoca_vitulina   
XP_030706721.1 Globicephala_melas   
XP_029081400.1 Monodon_monoceros   
XP_027447016.1 Zalophus_californianus   
XP_026982887.1 Lagenorhynchus_obliquidens   
XP_025743405.1 Callorhinus_ursinus   
XP_024588595.1 Neophocaena_asiaeorientalis_asiaeorientalis   
XP_022425842.1 Delphinapterus_leucas   
XP_021558921.1 Neomonachus_schauinslandi   
XP_007450786.1 Lipotes_vexillifer   
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XP_007190463.1 Balaenoptera_acutorostrata_scammoni   
XP_007130807.2 Physeter_catodon   
XP_006733299.1 Leptonychotes_weddellii   
XP_004403794.1 Odobenus_rosmarus_divergens   
XP_004311474.1 Tursiops_truncatus   
XP_004267423.1 Orcinus_orca   
XP_004375524.1 Trichechus_manatus_latirostris   
XP_027722001.1 Vombatus_ursinus   
XP_003764058.1 Sarcophilus_harrisii shPjvk 
XP_020846715.1 Phascolarctos_cinereus   
XP_001368857.1 Monodelphis_domestica   
XP_028928169.1 Ornithorhynchus_anatinus oaPjvk 
XP_426573.2 Gallus_gallus ggPjvk 
XP_032920040.1 Catharus_ustulatus   
XP_021145491.1 Columba_livia   
XP_032549672.1 Chiroxiphia_lanceolata   
XP_032046572.1 Aythya_fuligula   
XP_031970077.1 Corvus_moneduloides   
XP_031456993.1 Phasianus_colchicus   
XP_030808482.1 Camarhynchus_parvulus   
XP_030341457.1 Strigops_habroptila   
XP_029874976.1 Aquila_chrysaetos_chrysaetos   
XP_027752516.1 Empidonax_traillii   
XP_027587289.1 Pipra_filicauda   
XP_027534255.1 Neopelma_chrysocephalum   
XP_027493193.1 Corapipo_altera   
XP_026708820.1 Athene_cunicularia   
XP_025948212.1 Dromaius_novaehollandiae   
XP_025931524.1 Apteryx_rowi   
XP_025907871.1 Nothoprocta_perdicaria   
XP_023786694.1 Cyanistes_caeruleus   
XP_021408102.1 Lonchura_striata_domestica   
XP_021255407.1 Numida_meleagris   
XP_017691037.1 Lepidothrix_coronata   
XP_015723838.1 Coturnix_japonica   
XP_015491030.1 Parus_major   
XP_014809935.1 Calidris_pugnax   
XP_014745550.1 Sturnus_vulgaris   
XP_013816192.1 Apteryx_mantelli_mantelli   
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XP_013027050.1 Anser_cygnoides_domesticus   
XP_010564222.1 Haliaeetus_leucocephalus   
XP_010405022.1 Corvus_cornix_cornix   
XP_010309352.1 Balearica_regulorum_gibbericeps   
XP_010285122.1 Phaethon_lepturus   
XP_010217678.1 Tinamus_guttatus   
XP_010198933.1 Colius_striatus   
XP_010178165.1 Mesitornis_unicolor   
XP_010173029.1 Antrostomus_carolinensis   
XP_010133399.1 Buceros_rhinoceros_silvestris   
XP_010123753.1 Chlamydotis_macqueenii   
XP_010079514.1 Pterocles_gutturalis   
XP_010021626.1 Nestor_notabilis   
XP_009994488.1 Chaetura_pelagica   
XP_009985399.1 Tauraco_erythrolophus   
XP_009964462.2 Tyto_alba_alba   
XP_009957273.1 Leptosomus_discolor   
XP_009932320.1 Opisthocomus_hoazin   
XP_009912995.1 Haliaeetus_albicilla   
XP_009897380.1 Picoides_pubescens   
XP_009883913.1 Charadrius_vociferus   
XP_009868885.1 Apaloderma_vittatum   
XP_009813285.1 Gavia_stellata   
XP_009694144.1 Cariama_cristata   
XP_009674596.1 Struthio_camelus_australis   
XP_009644325.1 Egretta_garzetta   
XP_009580620.1 Fulmarus_glacialis   
XP_009553924.1 Cuculus_canorus   
XP_009498492.1 Phalacrocorax_carbo   
XP_009491858.1 Pelecanus_crispus   
XP_009460604.1 Nipponia_nippon   
XP_009330652.1 Pygoscelis_adeliae   
XP_009276888.1 Aptenodytes_forsteri   
XP_009086279.1 Serinus_canaria   
XP_009082354.1 Acanthisitta_chloris   
XP_008945516.1 Merops_nubicus   
XP_017927185.1 Manacus_vitellinus   
XP_008632943.1 Corvus_brachyrhynchos cbPjvk 
XP_008503297.1 Calypte_anna   
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XP_005519906.1 Pseudopodoces_humilis   
XP_005484170.1 Zonotrichia_albicollis   
XP_005442982.1 Falco_cherrug   
XP_005415947.1 Geospiza_fortis   
XP_005237060.1 Falco_peregrinus   
XP_005049151.1 Ficedula_albicollis   
XP_027317868.1 Anas_platyrhynchos   
XP_019472642.1 Meleagris_gallopavo   
XP_002199531.1 Taeniopygia_guttata   
XP_005152626.1 Melopsittacus_undulatus   
XP_032624383.1 Chelonoidis_abingdonii   
XP_030435617.1 Gopherus_evgoodei   
XP_024054274.1 Terrapene_carolina_triunguis   
XP_007069837.1 Chelonia_mydas   
XP_025038578.1 Pelodiscus_sinensis   
XP_028604312.1 Podarcis_muralis   
XP_020659760.1 Pogona_vitticeps   
XP_015269242.1 Gekko_japonicus   
XP_003225734.2 Anolis_carolinensis acPjvk 
XP_019410239.1 Crocodylus_porosus   
XP_019378569.1 Gavialis_gangeticus   
XP_014454831.1 Alligator_mississippiensis   
XP_006034600.1 Alligator_sinensis   
XP_032087879.1 Thamnophis_elegans   
XP_026552782.1 Pseudonaja_textilis   
XP_026523899.1 Notechis_scutatus   
XP_015674337.2 Protobothrops_mucrosquamatus   
XP_013916399.1 Thamnophis_sirtalis   
XP_007433246.1 Python_bivittatus pbPjvk 
XP_017953002.1 Xenopus_tropicalis XtPjvk 
XP_018417121.1 Nanorana_parkeri   
XP_030065796.1 Microcaecilia_unicolor muPjvk 
XP_029461755.1 Rhinatrema_bivittatum   
XP_014354128.1 Latimeria_chalumnae   
XP_021332701.1 Danio_rerio drPjvk 
XP_017336878.1 Ictalurus_punctatus   
XP_024144772.1 Oryzias_melastigma   
XP_030208891.1 Gadus_morhua   
XP_032412353.1 Xiphophorus_hellerii   
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XP_032362115.1 Etheostoma_spectabile   
XP_031707545.1 Anarrhichthys_ocellatus   
XP_031605025.1 Oreochromis_aureus   
XP_031147629.1 Sander_lucioperca   
XP_030639171.1 Chanos_chanos   
XP_030610804.1 Archocentrus_centrarchus   
XP_030266265.1 Sparus_aurata   
XP_030014755.1 Sphaeramia_orbicularis   
XP_029941737.1 Salarias_fasciatus   
XP_029930250.1 Myripristis_murdjan   
XP_029377974.1 Echeneis_naucrates   
XP_029300217.1 Cottoperca_gobio   
XP_028984917.1 Betta_splendens   
XP_028809593.1 Denticeps_clupeoides   
XP_028663992.1 Erpetoichthys_calabaricus   
XP_028427897.1 Perca_flavescens   
XP_028322965.1 Gouania_willdenowi   
XP_028255869.1 Parambassis_ranga   
XP_027977177.1 Eumetopias_jubatus   
XP_027866688.1 Xiphophorus_couchianus   
XP_027015817.1 Tachysurus_fulvidraco   
XP_026874502.1 Electrophorus_electricus   
XP_026789215.1 Pangasianodon_hypophthalmus   
XP_026217304.1 Anabas_testudineus   
XP_024265015.1 Oncorhynchus_tshawytscha   
XP_023657402.1 Paramormyrops_kingsleyae   
XP_023282857.1 Seriola_lalandi_dorsalis   
XP_023125432.1 Amphiprion_ocellaris   
XP_022616901.1 Seriola_dumerili   
XP_022068643.1 Acanthochromis_polyacanthus   
XP_021428733.1 Oncorhynchus_mykiss   
XP_029133251.1 Labrus_bergylta   
XP_019746234.1 Hippocampus_comes   
XP_029112536.1 Scleropages_formosus   
XP_018516757.1 Lates_calcarifer   
XP_017295653.1 Kryptolebias_marmoratus   
XP_016304616.1 Sinocyclocheilus_anshuiensis   
XP_015813551.1 Nothobranchius_furzeri   
XP_015232892.1 Cyprinodon_variegatus   
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XP_014847085.1 Poecilia_mexicana   
XP_014007857.1 Salmo_salar   
XP_013867462.1 Austrofundulus_limnaeus   
XP_012724997.1 Fundulus_heteroclitus   
XP_031414807.1 Clupea_harengus   
XP_028972406.1 Esox_lucius   
XP_019132545.1 Larimichthys_crocea   
XP_008422369.1 Poecilia_reticulata   
XP_008322774.1 Cynoglossus_semilaevis csPjvk 
XP_008291779.1 Stegastes_partitus   
XP_007553767.1 Poecilia_formosa   
XP_022530820.1 Astyanax_mexicanus   
XP_006636618.1 Lepisosteus_oculatus   
XP_005920274.1 Haplochromis_burtoni   
XP_014325563.1 Xiphophorus_maculatus   
XP_005742320.1 Pundamilia_nyererei   
XP_023009232.1 Maylandia_zebra   
XP_023819485.1 Oryzias_latipes   
XP_003966800.1 Takifugu_rubripes   
XP_003459969.1 Oreochromis_niloticus   
XP_026157845.1 Mastacembelus_armatus   
XP_020470942.1 Monopterus_albus   
XP_007888272.1 Callorhinchus_milii cmPjvk 
XP_032879750.1 Amblyraja_radiata   
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